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Abstract 
Primary Biliary Cholangitis (PBC), formerly ‘Primary Biliary Cirrhosis’, is an 
autoimmune disease of the interhepatic bile ducts. Their damage leads to bile 
retention in the liver and subsequent damage to hepatocytes, leading to 
perpetuating injury and tissue damage, causing destruction of the normal liver 
architecture and eventual cirrhosis. 
The current therapy given to PBC patients, ursodeoxycholic acid (UDCA), is 
insufficient to prevent disease progression, and appears to only slow the natural 
history of the disease. Additionally, the drug is only effective in around 80% of 
patients with the remaining 20% showing no apparent benefit after a year of use. 
Breakthrough studies appear to suggest that there may be differences in clinical 
biochemical parameters between these patient groups which may explain their 
marked differences in response to the drug. These findings are leading to PBC being 
considered as an umbrella term encompassing two- or more separate disease 
subsets, broadly ‘responders’ and ‘non-responders’ referring to response to UDCA, 
with ‘non-responder’ categorisation requiring the inability of the drug to significantly 
lower a patient’s blood AST, ALP and bilirubin levels during the given time frame. 
Further elucidation of these subsets is crucial to identify patients and potentially 
allow the development of differential therapies which may benefit these “non-
responders”.  
The mechanism of action of UDCA has been investigated in this thesis with the aim 
to use this data to highlight key pathways of interest differentiating the 
responder/non-responder subgroups. This involved flow cytometric analysis and 
ELISpot analysis of the effect of UDCA on T cells and also xCELLigence and 
supernatant transfer assays to investigate an impact on the cholangiocytes.   
Further elucidation of the responder/non-responder subgroups came from 
comparing antibody profiles of these groups. Multiple indirect enzyme-linked 
immunosorbent assays (ELISAs) were carried out to measure antibody titre and 
therefore detect patterns of auto-antibody isotypes in serum from PBC patients 
known to be “responders” (62) or “non-responders” (15) to UDCA. Recombinant 
human PBC autoantigens E2, E2 inner lipoyl domain (E2ILD) and E3 binding protein 
(E3BP) were used to uncover statistically significant differences in antibody 
responses. Using cross-sectional analysis, it was found that results from patient 
data were able to replicate the proposed responder and non-responder grouping 
based on age and liver function criteria. It was found that compared to responders, 
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non-responders have higher levels of anti-E2 IgE (p=0.025), anti-E2ILD IgA 
(p=0.047) and anti-E2ILD IgG3 (p=0.01). The study also found that men with PBC, 
generally considered non-responders, have significantly lower levels of some 
antibodies, which are higher in non-responders, anti-E2IgE (p=0.003) and anti-
E2ILD IgG3 (p=0.05). This is further evidence that men with PBC may constitute 
their own sub group of non-responders. 
These findings provide further evidence that the disease includes biologically 
different subsets which should be treated differently.  Differences in antibody isotype 
to dominant autoantigens suggests that there may be significant functional 
differences in T helper cell subsets in each patient group.  Further investigation into 
the differences between these subsets could provide a diagnostic tool which could 
be used early on in diagnosis to categorise patients for stratified treatment. 
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1 Chapter 1 - Introduction 
1.1 Introduction to Immunity 
At its core, the immune system is a mechanism within the host to protect from pathogens 
and toxins. An essential requirement of this system is the ability to differentiate between 
self-molecules and foreign, potentially harmful antigens. 
The immune system has evolved over many millions of years to protect the body from 
pathogenic invasion. There is a pathway which has been in existence since before plants 
and animals diverged from each other in evolutionary history (Belvin and Anderson, 1996). 
This pathway, the Toll pathway, involves the release of the protein complex nuclear factor 
kappa-light-chain-enhancer of activated B cells, NFκB, by degradation of inhibitor κB, 
allowing NFκB to carry out its functions such as: DNA transcription; causing release of 
cytokines; protection from toxic, bacterial or viral compounds (Ruben et al. 1991). Genes 
for this pathway are conserved over millions of years of evolution and are found in 
organisms of invertebrates, vertebrates and plants (Belvin and Anderson, 1996). For 
millions of years, it has been crucial for an organism’s survival to have the ability to fight 
harmful pathogens and throughout human evolution the immune system has become the 
complex and intricate network that humans possess today.  
The understanding of the immune system has also evolved, with the first recorded 
acknowledgement of immunity dating back to 430 BC, when Athenian historian Thucydides 
wrote of the ability of those who had previously contracted the plague to be able to care for 
others infected during the plague of Athens without the risk of infection (Kousoulis et al., 
2012). By 1549, there was some acknowledgement of inoculation: in China, people would 
insert pus from the sores of smallpox sufferers into their nostrils in the knowledge that they 
could then only suffer a less severe form of the disease (Boylston 2012). 1796 saw the first 
vaccination against smallpox (Boylston 2012); 1890 saw the identification of substances in 
the blood, transferable between organisms, which could render some pathogens harmless 
(von Bhering, 1991); in the early 1900s came understanding of the nature by which 
antibodies bind to antigens (Marrack, 1976). Today exists the extensive and vast and 
expanding knowledge of the pathways, cells and proteins which make up the complex 
mechanism of the immune system. 
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1.2: The adaptive immune system 
 
There are several important cells important in the immune system, called the leucocytes, 
all of which differentiate from the common haematopoietic stem cells. The first differentiation 
from haematopoetic stem cells is to lymphoid and myeloid progenitor cells. Myeloid 
progenitor cells then differentiate into granulocytes, erythrocytes, monocytes or platelets 
whereas lymphoid progenitor cells differentiate to T cells, B cells and natural killer (NK) cells 
(Chaplin 2003).  
There are two strands to the immune system: the innate immune system and the adaptive 
immune system. The innate immune system acts as a crucial first line defence from 
pathogens with no memory or long-term immunity offered. The adaptive immune response 
is a second line, more specialised system which offers memory whereby the body is pre-
prepared on subsequent experiences of the antigen (Chaplin 2003).   
 
1.2.1: T cells 
T cells are lymphocytes which control cell mediated immune responses. They mature in the 
thymus where they acquire a T cell receptor (TCR) and other surface molecules, helping to 
define the T cell subsets. 
The T cell receptor is the most defining characteristic of the T cell. Made up of subunits α 
and β, or in much smaller abundances γ and δ, this is the molecule which recognises 
specific antigen as presented by MHC molecules on antigen presenting cells (APCs) (Attaf 
et al, 2015). Cellular development of TCR specificity is outlined in section 1.2.1.1.  
Importantly, T cells also require a CD4 or a CD8 molecule which determines the type of 
major histocompatibility complex molecule (MHC) it can recognise and therefore helping to 
determine its immune function. Antigens are processed by cells and expressed on the 
surface within an MHC molecule, which the T cells can recognise and respond to, if they 
encounter the antigen to which they respond as expressed by an MHC molecule. MHCI is 
expressed on all nucleated cells and usually presents intracellular proteins whereas MHCII 
is present usually only on professional antigen presenting cells (APCs), and presents 
extracellular antigens where an extracellular molecule has been phagocytosed by the APC, 
digested and processed then expressed on the surface within the MHCII molecule (Sadegh-
Nasseri, 2016). 
As all haemopoietic stem cells originate in the bone marrow, progenitor T cells must migrate 
from the bone marrow into the blood to reach the thymus, the site of T cell maturation. VDJ 
recombination, or somatic recombination, allows the progenitor T cell to obtain its own T 
cell receptor and become a naïve T cell. The naïve T cell will then leave the thymus and 
migrate to the lymph node. Here, it is determined whether the T cell should be allowed to 
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proliferate based on the antigen it recognises and how beneficial or possibly harmful 
proliferation of this T cell would be to the organism. Some are positively selected, if they 
are able to bind to the MHC molecule, ensuring it will only respond to antigen that is MHC-
bound. Some T cells are found to react when presented with a self-antigen, and so are 
selected for killing: they are negatively selected. The T cell will then undergo a permissive 
interaction with the APC causing it to proliferate and differentiate into either a CD8+ 
cytotoxic T cell or a CD4+ helper T cell (Takaba and Takayanagi, 2017). The development 
of these different types of T cells is outlined below. 
 
1.2.1.1: The generation of pre-T cells from Hematopoietic stem cells 
Well before its commitment down a T cell lineage, the cell begins as a haematopoietic 
precursor or haematopoietic stem cell (HSC), generated in the bone marrow. 
Haematopoeitic stem cells are able to self-renew, or differentiate into one of the many 
different leucocytes, shown in figure 1.2.1.1, (Luc et al., 2012). The early T cell precursor 
migrates from the bone marrow to the thymus. 
 
The lineage potential of cells at the point where they become thymic immigrants remains 
unclear. Some studies have shown that highly purified recent thymic immigrants maintain 
only T cell or granulocyte monocyte-restricted potential (Wada et al., 2008), whereas 
others have suggested that they may also maintain B cell lineage potential (Luc et al., 
2012). The latter would imply that thymic immigrants show a lymphoid progenitor 
phenotype, as shown in figure 1.2.1.1. Importantly, it is in the thymus where the T cell 
passes further lineage determining stages, rendering it committed to becoming a T cell, 
discussed in section 1.2.1.2.  
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Figure 1.2.1.1: Differentiation of haematopoietic stem cells. 
Adapted from Nelson and Roy 2015, this figure illustrates how haematopoietic stem cell 
can self renew or differentiate into the different leucocytes. Likely, new thymic immigrants 
exhibit a common lymphocyte progenitor phenotype (Luc et al., 2012). 
LT-HSC – long term haematopoietic stem cell; ST-HSC – short term haematopoietic stem 
cell. 
 
 
1.2.1.2: The T cell receptor; CD4+ T cells and CD8+ T cells. 
While a T cell is still developing in the thymus, it lacks both CD4 and CD8 surface receptors: 
it is ‘double negative’ (DN). The DN population of T cells can be further subdivided based 
on expression and/or lack thereof of 2 further surface receptors, CD44 and CD25, which is 
determined by its developmental stage. Importantly, at the DN3 stage, the cell is committed 
to becoming a T cell, when it is CD4-CD8-CD25+CD44-. This is when rearrangement of the 
T cell receptor β chain (TCRβ) may occur, and will eventually lead to the T cell developing 
its own specificity to an antigen. This leads to a transient CD4+CD8+ stage, and eventual 
loss of either CD4 or CD8 and commitment to being cytotoxic (CD8+) or helper (CD4+) 
(Abbey and O’Neill, 2008). Figure 1.2.1.2.1 shows an overview of the stage of commitment 
of a T cell progenitor down the T cell differentiation route. 
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Figure 1.2.1.2.1 T cell commitment down the eventual CD4+/CD8+ differentiation 
pathway 
Within the thymus lies a population of ‘double negative’ cells. These are at various stages 
down their commitment paths to become a mature lymphocyte. At stages DN1 and DN2, 
the cell has the potential to become a cell other than a T cell, but by stage DN3, when the 
cell expresses CD25 and CD44 expression has been downregulated, its path to become a 
T cell is confirmed. Selection of useful but non-self harming T cells occurs at the 
CD4+CD8+ stage. This figure is adapted from Abbey and O’Neill, 2008. 
 
The specificity of the T cell is reliant on recombination of genetic material directing the amino 
acid sequence which will eventually make up the variable region of the TCR. The diverse 
repertoire of antigens T cells will encounter demands a system for a diverse range of TCRs. 
The process is similar to recombination events involved in isotype switching, outlined in 
section 1.2.2. A series of irreversible genetic rearrangements occur, firstly to join a diversity 
(D) fragment to a joining (J) fragment within the β chain, then with a variable (V) region 
joined in front of the diverse fragment, and finally a constant, C, region added on the end, 
depicted in figure 1.2.1.2.2. Splicing of mRNA removes intervening sequences, leaving the 
completed protein transcript for the β chain. Α chain genetic rearrangements follow from β 
rearrangements and α and β chains combine to give the completed αβ TCR. A γδ TCR also 
exists but is of less importance for this thesis and these cells are in far less abundance than 
αβ TCR expressing T cells (Boyd et al. 2009). 
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Figure 1.2.1.2.2: Outline of beta-chain genetic recombination events. 
This diagram shows a schematic depiction of the pre-recombined TCR locus including 
joining of D to J and subsequent V joining which leads to eventual TCRβ construction 
after transcription, mRNA splicing and translation. This figure is taken from Murray et al. 
2012. 
 
 
1.2.1.2: CD4+ T cells 
CD4+ T cells, through the CD4+ molecule, recognise extracellular antigen on MHCII on the 
surface of professional APCs. There are several subsets of CD4+ T cells, including helper 
T cell subsets and regulatory T cell subsets.  
The CD4 molecule comprises IgG-like domains denoted D1, D2, D3 and D4. CD4 binds the 
antigen-presenting MHCII molecule of the APC, spatially distinct to TCR binding. CD4-
MHCII interaction increases T cell antigen sensitivity by order of 102-fold.  
Helper T cells include Th1, Th2, Th17 and Th1/17. They are involved in many strands of 
the immune system including helping to activate B cells, cytotoxic T cells and macrophages 
(Sadegh-Nasseri 2016). They can be identified by their surface receptors, the cytokines 
they release and the transcription factors they use. 
 
Th1 
Th1 CD4+ T cells are important in cell-mediated immunity and secrete interferon γ (IFN-γ), 
interleukin-2 (IL-2) and tumour necrosis factor β (TNF-β) (Romagnani, 2000). IFN-γ 
activates macrophages, which engulf pathogens, and stimulates expression of MHCII (Gray 
and Goeddel, 1982). IL-2 has many functions, including promoting the differentiation of T 
cells to regulatory T cells. TNF-β is involved in regulation of cell proliferation, differentiation 
and apoptosis (Nedwin et al., 1985). Their surface receptors include CD3, CD4, CXCR3. 
Th2 cells are primarily concerned with humoral immunity. They are essential in B cell class 
switching, described in section 1.2.2, but are also important for activation of cytotoxic T cells 
and phagocytic cells. Th2 cells release IL-4, IL-5, IL-6, IL-9 and IL-13, with individual 
functions including causing isotype switching in B cells; activation of B cells and secretion 
of immunoglobulins; cell proliferation and preventing of apoptosis (Sadegh-Nesseri, 2016). 
Extracellular markers include CD3, CD4, CXCR4, CCR3, CCR4. Th17 cells produce IL-17, 
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IL-21 and IL-22 and have functions which include maintenance of mucosal barriers and 
inhibition of Treg differentiation. Th17 cells have been known to interact with B cells and 
may be involved in antibody production and/or isotype switching (Takagi et al., 2008). 
Extracellular markers include CD3, CD4, CCR4, CCR6. Regulatory T cells have the primary 
function of suppressing the immune response such that excessive damage from excessive 
inflammation does not occur. Regulators T cells can also have an important function in 
preventing autoimmune diseases by suppressing the action of cells which could potentially 
recognise self-antigen (section 1.4.1) (Corthay 2009). Identifiers include intracellular FoxP3 
and extracellular CD25, CD4, CD3. Follicular T cells are found in germinal centres at the 
outside of B cell follicles within secondary lymphoid organs and are important in determining 
survival of B cells (Linterman et al. 2009). Th9 cells mature in the presence of TGF-β, 
released by many different cell types, and IL-4, released by Th2 cells and they release IL-
9. Only recently defined, they appear pleiotropic, functionally, but may help to ensure the 
survival of B cells (Linterman et al., 2009). 
 
1.2.1.3 : CD8+ T cells 
Most CD8+ T cells are cytotoxic T cells. Cytotoxic T cells secrete IFN-γ and also granules 
with cell-killing properties. These granules contain the enzyme granzyme B which causes 
permeablisation to the target cell and its eventual apoptosis (Catalfamo and Henkart 2003).  
Similarly to CD4+ T cells, cytotoxic T cells also have subset populations with similar 
cytokine-expressing profiles to their helper counterparts but are less well-defined. CD8+ T 
cells primarily target cells infected with intracellular pathogens such as bacteria and viruses 
(Gulzar and Copeland, 2004). 
 
 
 
1.2.2: B cells and antibody production 
B cells are lymphocytes which control the humoral immune responses. The humoral 
response protects the spaces in between cells which microorganisms use to transport from 
host cell to host cell. A B cell, upon activation which usually requires interaction with a CD4+ 
helper T cell, will become a plasma cell and secrete antibodies into these extracellular 
spaces to attach to these microorganisms, eventually rendering them unable to further 
infect host cells. 
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The progenitor B cell remains in the bone marrow where it undergoes VDJ (somatic) 
recombination to produce its own antibodies, usually initially of isotype IgM, and become 
an immature B cell. The immature B cell then migrates to the lymph node (Chaplin 2003). 
The mature B cell could then become activated upon interaction with a helper T cell which 
recognises the same antigen as it, or in some circumstances could be activated by the 
antigen directly. Upon activation, the B cell then enters the dark zone of the germinal centre 
where it undergoes somatic hypermutation, the process by which mutations in the DNA 
coding for the antibody undergoes mutations which can increase the affinity, diversity or 
specificity of the antibodies. The B cell then moves into the light zone of the germinal centre, 
where it becomes a centroblast and undergoes class switching and clonal expansion. The 
centroblast will differentiate into either a memory B cell or an antibody secreting plasma cell 
(Chaplin 2003). 
 
1.2.2.1: Immunoglobulins and their isotypes 
Often depicted as a Y-shape, the immunoglobulin contains four chains, two light and two 
heavy. Disulphide bonds link the heavy chains to the light chains. Each immunoglobulin has 
a variable region and a constant region. The variable region contains the paratope, which 
will bind its corresponding epitope of the antigen. The antigen is the protein to which the 
response is being made and the epitope is the specific region of this antigen to which the 
antibody binds. Immunoglobulins have different isotypes, covered more thoroughly further 
on. Figure 1.2.2.1 shows a detailed diagram of an immunoglobulin in monomeric form, the 
IgG isotype. The structure is divisible into 2 fragments. The crystallisable fragment is the 
region which interacts with surface receptors of cells and can also activate the compliment 
system, important in the innate immune system. The antigen-binding region binds to the 
target molecule: the antigen. (Flajnik 2002).    
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Figure 1.2.2.1: Diagram of the IgG immunoglobulin 
This figure outlines the regions of particular interest of the immunoglobulin, often denoted 
by their abbreviations: 
Antigen binding fragment - FAB 
Crystallisable fragment - FC 
Constant region - C 
Variable region - V 
 
B cells not only have the potential to produce antibodies against millions of antigens but 
also they can alter the type of antibody against the antigen to give a different response. 
There are five classes giving rise to nine types of antibody isotype: IgM, IgD, IgG(1-4), 
IgA(1, 2) and IgE, each of which having a different heavy chain, detonated µ, δ, γ, α, ε. The 
different isotypes of antibody are adapted to trigger different effector cell responses 
depending upon the antigen source (Flajnik 2002).  
Multiple gene rearrangements occur which lead to unique codes for unique antibodies to 
be produced. In the genome there are 2 light chain loci, λ and κ, and one heavy chain locus. 
Each light chain locus contains several L, V, J and C regions and the heavy chain locus 
contains regions L, V, D, J and a C, where L encodes a leader peptide, V a variable region, 
J a joining segment, D a diversity section and C a constant region of the eventual whole 
polypeptide chain. Somatic recombination in the DNA of the cell leads to most of these 
segments being removed. The light chain gene then eventually only consists of: one L exon, 
one V and J encoding exon and a C region exon. The heavy chain, similarly becomes: a 
leader exon, the complete VH exon (comprising V-D-J), then the C region exons including 
a hinge region. The order of heavy chain C region exclusion determines the isotype of the 
antibody. The first 2 are used initially, Cμ and Cδ, and differential splicing of the RNA 
transcript gives rise to IgM or IgD antibodies respectively. Subsequent C regions γ, α and ε 
lead to IgG, IgA and E. Further subsetting of isotypes occurs with there being 4 subsets of 
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IgG, labelled 1-4 corresponding to their relative abundance in the blood and IgA subtypes 
1 and 2 denoting whether it is in monomeric or dimeric form. Different C regions leading to 
different isotypes of antibody allow for a range of different functions and also means that 
different antibodies can occupy different areas. Further diversity of immunoglobulins is 
established by somatic hypermutation in the V region genomic sequences which can also 
lead to more specific binding of an antibody to its target over a period of days after the 
primary response. (Nemazee 2006). 
 
1.3: Cytokine induced cell signalling 
Differential responses of immune cells rely heavily on the release and interpretation of 
signals of many different proteins such as cytokines. Cytokines are released by a variety of 
cells in the immune system such as T and B cells and have a large variety of potential 
responses, necessary when there is such a diverse repertoire of pathogens with the 
potential to invade the human body and cause harm. Cytokines come in many different 
forms and often require assembly of 2 heterodimer molecules and corresponding assembly 
of heterodimer receptor molecules. Figure 1.3 depicts IL-12 signalling pathway which 
eventually leads to downstream binding of STAT4 to the IL-12 response element (Newport, 
2003).  
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Figure 1.3: Depiction of IL-12 and downstream signalling pathway 
This figure shows the combination of the sub-units of IL-12, p40 and p35, combining to 
form IL-12 and interacting with the heterodimer IL-12 receptor. The signalling pathway 
involves IL-12 binding to the dimerised receptor and subsequent phosphorylation of 
tyrosine kinase 2 (TYK2) and Janus kinase 2 (JAK2), causing docking of STAT4 which is 
then phosphorylated. STAT4 then forms a homodimer and translocates to the nucleus 
and binds with IL-12 response element (IL-12RE). This figure is taken from Newport, 
2003.  
 
Another layer of signal diversity can lie in that some cytokines share subunits with other 
cytokines, which may lead to competition of the most abundant combination winning out to 
confer a particular signal. This is further outlined in chapters 5 and 6. 
 
1.3.1: T and B cell interaction 
Some cytokines produced by T cells are B cell-acting and their binding to their receptor on 
the B cell activates downstream signalling pathways which have downstream effects of 
prompting isotype switching. Additionally, some cytokines, produced by cells such as T cells 
have the function of triggering regulatory networks which suppress isotype switching. In 
order for the B cell to receive these signals from the T cell, the CD40on the surface of the 
B cell must interact with the CD40L on the T cell surface. Engagement of the T cell receptor 
(TCR) with the recognised-peptide-expressing MHCII on the surface of the B cell is the 
primary event, followed by binding of CD40 and CD40L and the secretion of cytokines by 
the T cell which will enhance, modify or skew the response (Elgueta et al., 2009). 
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Many actions of T cell cytokines on B cell isotype switching have been well-documented for 
many years. IL-4, produced by Th2 cells, is known to induce switching to IgG1 and IgE and 
inhibit switching to IgG3. Th1-secreted IFN-γ has been shown to inhibit IL-4 mediated IgG3 
and IgE switching and enhance IgG2 switching. TGF-β, secreted by many cell types, can 
induce an increase in IgA, for example. More detail is in chapters 5 and 6.  
The type of antibody produced by a B cell also depends on whether it was activated in a T 
cell dependent or T cell independent manner. It has been shown in vitro that 
lipopolysaccharide (LPS), found in gram-negative bacterial membranes and commonly 
used in vitro to stimulate an inflammatory environment, stimulates IgG3 isotype switching, 
and this action is inhibited by IL-4 and IFN-γ, therefore this T cell independent pathway is 
blocked by T cell activity to favour a T cell dependent mechanism. Often, such situations 
do occur where a B cell will experience multiple signals all at once and must be able to cope 
with often conflicting signals and, as isotype switching involves gene rearrangement, only 
one type of antibody can be produced by a B cell at once. Additionally, other factors specific 
to the environment can influence the resulting antibody isotype secretion such as B cell 
survival or proliferation and the concentrations of the individual incoming cytokines. Further 
studies in the LPS-induced inflammatory environment in vitro have shown that, although 
IFN-γ is able to inhibit IL-4 mediated isotype switching signals, neither TGF-β nor IL-4 is 
able to inhibit the effects of IFN-γ but IL-4 is able to inhibit TGF-β signals (Deenick et 
al.,2005). This conflicted with previous studies which implied that TGF-β is able to inhibit 
IgG1, IgG2a, IgG3 and IgE production (McIntyre et al.,1993). These data together suggest 
that the antibody response produced to an antigen is dependent on many factors including 
the environment and direction from T cells.  
The type of immune response, even down to type of Th cell response, elicited towards a 
pathogen can, then, be extremely important. How successful the host is at fighting infection 
can rely on the correct response being elicited. For example, when a patient is infected by 
tuberculosis-causing bacteria Mycobacterium leprae, the type of disease they exhibit is 
largely dependent on the type of response to the antigen. If Th1 cells are activated, the 
cytokines released are IL-2, IFN-γ and TNF-β which together enhance macrophage activity. 
The resultant disease is tuberculoid leprosy with cell mediated immunity, involving low 
infectivity, low levels of infective organism, normal T cell responses with M. leprae specificity 
and normal serum immunoglobulin levels. In contrast, the exact same organism can cause 
lepromatous leprosy, when there is a Th2 response rather than Th1, and there is release 
of IL-4, IL-5 and IL-10 which together B cell activity. The type of immune response is 
humoral immunity which is far less effective against this particular pathogen. There is 
significant organism growth, high infectivity, low T cell responsiveness and 
hypergammaglobulinaemia (Pinheiro et al., 2011). Therefore, regulation of the correct type 
of immune response is extremely important and inappropriate or incorrect activation of the 
wrong pathway can have dire consequences for the host on infection. 
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Further studies have shown that other cytokines can influence B cell isotype switching, 
which is discussed in more detail in chapters 5 and 6.  
 
1.4: Concept of autoimmunity 
The immune system requires differentiation of self-molecules and foreign molecules in 
order to function effectively and without damage to the host. Pathogens have evolved with 
humans over millions of years and therefore have evolved to have molecules similar to 
those of humans, leading to the requirement for the immune system to adapt and become 
intricately capable of differentiating between these foreign molecules and those of its own 
body. There are several mechanisms in place to avoid an autoimmune attack despite 
remaining an effective system for killing invading pathogens. 
 
1.4.1: Tolerance and loss of tolerance 
There are tissues in the body which have a function of expressing self-molecules to T cells 
to determine if they will recognise these antigens and this will lead to their destruction. 
Developing T cells, in the thymus are challenged with self-peptide expressed by bone 
marrow-derived antigen-presenting cells, orchestrated by autoimmune regulator gene 
(AIRE). Those which respond to self-antigen with strong antigen binding will be sent This 
occurs while the cells are still CD4+CD8+, outlined in section 1.2.1.1 (Abbey and O’Neill, 
2008). 
Occasionally, a T cell recognising self-molecules will escape negative selection and 
become a circulating T cell with the potential to recognise a self-molecule, and therefore 
with the potential to perpetuate damage to self-tissues. This is not usually problematic 
because there are several peripheral tolerance-inducing mechanisms which will render the 
T cell unable to surmount an immune response even if it interacts with the antigen as 
presented by an MHC molecule: it will be ‘tolerant’ to the antigen it recognises. If this self-
reactive T cell recognises antigen on any cell other than a professional antigen presenting 
cell (APC) then it will not receive the essential costimulatory signal in order to be activated. 
Without this costimulatory signal, the T cell will become anergic and be unable to propagate 
an immune response. (Fabbri, Smart et al., 2003). 
Antibodies are not necessarily completely specific to a target epitope. 
Due to interactions between antibody and antigen being relatively weak and non-specific, 
an antibody may occasionally bind to, or cross react with, different antigens with different 
relative strengths. This promiscuity between peptide sequences and antibodies also gives 
rise to the theory of molecular mimicry, a process whereby pathogen-derived peptides can 
lead to the development of autoimmunity. If a pathogenic peptide shares structural 
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homology with a self-protein, antibody raised against this pathogenic epitope could also 
bind the self-protein leading to autoimmunity. (Elde and Malik, 2009). 
 
1.5: The function and structure of the liver 
1.5.1: Structure 
The macrostructure of the liver contains four lobes: the right, left, caudate and quadrate. 
These are separated by ligaments composed of the same double membranes which engulf 
the entire structure of the liver. The hepatic portal vein and the hepatic artery provide the 
blood supply to the liver. The hepatic portal vein provides approximately three quarters of 
the blood volume but only half of the liver’s oxygen supply, whereas around one quarter of 
blood volume and half of the oxygen supply come from the hepatic artery. Microscopically, 
the liver is composed of many lobules, roughly hexagonal in shape and through each corner 
of these is a triad of hepatic portal vein, hepatic artery and small bile duct and also lymphatic 
vessel and vagus nerve, shown in figure 1.5.1 (Ricken et al., 2015). There is a central vein 
through each lobule and hepatocyte plates spread from these. Running through these 
plates are the sinusoids which are large capillaries through which blood from the hepatic 
portal vein and hepatic artery enters and where exchange of materials between the liver 
and the blood occurs. This blood then collects in the central, or hepatic, vein before leaving 
the liver. (Elias and Bengelsdorf, 1952). 
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Figure 1.5.1: Diagram of liver lobule structure, taken from Ricken, et al., 2015. 
This figure shows the structure of a liver lobule as arranged around the central vein. The 
hepatic portal vein transports blood from the intestine. The hepatocytes are the main 
functional cells of the body of the liver. 
 
1.5.2: Functions 
As well as having major importance in the digestion of carbohydrates, fat and proteins, the 
liver also has many other functions such as detoxification of chemicals, metabolising drugs, 
breaking down red blood cells, producing proteins important in blood clotting, synthesising 
amino acids (Attili et al., 1986). Most relevant in PBC, the liver is responsible for 
synthesising bile which is required for breakdown of lipids in the diet. Bile is toxic to 
hepatocytes and in some liver diseases, bile is unable to leave the liver, causing death of 
hepatocytes and scar tissue formation, which can propagate to fibrosis or cirrhosis of the 
liver (Xia et al., 2006).  
Liver fibrosis occurs in response to liver injury and involves accumulation of extracellular 
matrix molecules produced by hepatic stellate cells (HSC) in response to fibrogenic 
cytokines, including TGF-β1, angiotensin II and leptin, released by activated hepatocytes 
and activated stellate cells. This accumulation of extracellular matrix molecules is scar 
tissue, which is a response to repeated liver injury. In large cases of repeated liver 
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damage and subsequent scar tissue formation, there can be serious disruption to the 
architecture and functional integrity of the liver (Batalla and Brenner, 2005).   
 
 
 
1.6: Primary Biliary Cholangitis (PBC) background 
 
The pathogenesis of PBC involves destruction of biliary epithelial cells which line 
intrahepatic bile ducts leading to bile retention. Hepatic portal inflammation exacerbates 
chronic liver fibrosis leading to eventual loss of liver function as the scar tissue interferes 
with bile duct activity(Jones, 2003a, Neuberger et al., 1997) . This cycle eventually leads to 
liver failure and a liver transplant is required(Poupon et al., 1997). The series of events 
involved in the aetiology of PBC is outlined in figure 1.6. Left completely untreated, mean 
survival time after diagnosis can range from 1-20 years(Kim and Jeong, 2011). The current 
therapy for PBC is ursodeoxycholic acid, a secondary bile acid which is usually 
endogenously obtained from intestinal bacteria(Lepercq et al., 2005). Clinically this is 
thought to increase biliary flow and replace more toxic bile acids in the bile acid pool. It is 
prescribed in concentrated form to those with PBC and some other diseases(Poupon et al., 
1991, Beuers et al., 1992). Although its exact mechanism of action in PBC is unknown, 
UDCA seems to attenuate the effects in most PBC patients and prolong the time before a 
transplant is required(Kim and Jeong, 2011).   
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Figure 1.6: Flow diagram of progression of PBC 
This flow chart illustrates the rough sequence of events involved in PBC. The disease is 
detectable before liver insufficiency and hence before the disease becomes symptomatic. 
Once liver fibrosis has begun, it is self-perpetuating by immune action through 
inflammation and hepatic stellate cell activation. At this stage, only UDCA may be of 
potential benefit, however does not prevent progression to cirrhosis of the liver and 
eventual liver failure. This is adapted from Addison’s other disease, DE Jones, 2003 
(Jones, 2003a). 
 
Symptoms can include chronic fatigue, pruritus, dry eyes and mouth, abdominal pain and 
diagnosis is based on increased IgM, raised aspartate aminotransferase/alanine 
aminotransferase (AST/ALT) levels, with a ratio between 1.0 and 2.0; raised alkaline 
phosphatase; the presence of anti-mitochondrial antibodies (AMAs) in over 95% of patients, 
notably against the E2 or E1α component of the pyruvate dehydrogenase (PDC) 
complex(Fussey et al., 1991a, Jones, 2000); Anti-nuclear antibodies (ANAs) are also seen 
in a significant proportion of PBC patients(Invernizzi et al., 2001). Although the 
pathogenesis involves a common series of events including bile duct loss, liver fibrosis, liver 
cirrhosis and eventual liver failure(Jones, 2003a), outlined in figure 1, the rate of decline 
and ultimate outcome can vary widely between patients(Carbone et al., 2013). 
 
The presence of self-reactive antibodies and PDC specific infiltrating T cells are indicative 
of the failure of immune tolerance(Yeaman et al., 2000). One postulated mechanism for the 
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loss of tolerance to self-antigen is cross-reactivity between responses generated against 
pathogen-derived PDC peptides and host PDC(Jones et al., 2002). Bacterial PDC, although 
not pathogenic, is immunogenic: the structural similarity between many of these peptides 
and their human counterparts could potentially lead to endogenous PDC being recognised 
by antibody, a mechanism known as molecular mimicry(Zavala-Cerna et al., 2014). 
Although, there is little evidence of the presence of relevant pathogens in patients, as 
tolerance breakdown occurs a significant time prior to diagnosis, presence of any initiating 
microorganism would be unlikely. Also, this theory does not explain the geographical 
clustering of the disease(Smyk et al., 2010). 
 
1.6.1: Environmental factors, clustering, infection and xenobiotics 
It has been reported that those living in certain geographic areas, for example those with 
high pollution, and potentially a specific type of xenobiotic exposure, are at a greater risk of 
contracting PBC(Koulentaki et al., 2014, Prince et al., 2001, Ala et al., 2006). Studies have 
suggested that exposure to certain xenobiotics could increase the likelihood of PBC 
incidence. Xenobiotics could potentially modify self-PDC into a form against which there is 
no immune tolerance, antibodies produced against this modified form may then also bind 
non-modified PDC, leading to breakdown of self-tolerance. Several animal models have 
demonstrated that tolerance to PBC can be broken by sensitisation with non-self or 
chemically modified PDC. A mechanism for inclusion of xenobiotics into PDC has been 
demonstrated which shows that 6-bromohexanoic acid can be processed by human 
lipoylation enzymes in the place of lipoic acid and could modify self-PDC-E2. This altered 
PDC binds more avidly than native PDC with patient antibodies and is likely to be sufficiently 
different to break tolerance in susceptible individuals(Walden et al., 2008). Although this 
evidence is compelling, there is still only a relatively small incidence of the disease in these 
areas, therefore there are likely other factors, both environmental and genetic, in 
determining the likelihood of contracting the disease. 
 
1.6.2: Dominant autoantigens 
There are two main recognised disease-specific autoantigens in PBC: E2 and E3 binding 
protein (E3BP), both of which are subunits of pyruvate dehydrogenase complex (PDC). 
PDC is a multi-subunit enzyme complex located in the mitochondrial matrix and has the 
function in respiration of splitting pyruvate to generate Acetyl Coenzyme A (Acetyl CoA) 
which can then enter the citric acid cycle. Other subunits of PDC include E1 and E3 
(Mooney et al., 1999). A complex of E1, E2 and E3 are depicted in figure 1.6.2. Many 
repeats of this complex and also structural subunits such as E3BP, make up PDC.  
 
 
 33 
 
Figure 1.6.2: E1, E2 and E3 of PDC 1 
This schematic diagram shows how the key functional subunits are bound for transfer of 
pryruate and its metabolites are transferred to the system, eventually leading to Acetyl 
CoA entry into the citric acid cycle. 
 
 
The initial and rate limiting stage involves binding of pyruvate to thiamine pyrophosphate 
(TPP) which is the cofactor of E1, a pyruvate dehydrogenase enzyme. TPP binds to 
pyruvate, removing CO2 and generating hydroxyethyl TPP (Marobbio et al., 2002). E2, a 
dihydrolipoyl transacetylase, contains the cofactor lipoic acid which contains a disulphide 
bond, to which the hydroxyethyl, or acetyl, group is then passed, creating a high energy 
thioester bond. This bond allows transfer of the acetyl group to CoA in solution, giving rise 
to acetyl CoA which can then enter the citric acid cycle (Chueh et al., 2011). The removal 
of the acetyl group leaves two reduced sulphurs on the lipoic acid of E2. The E3, a 
dihydrolipoyl dehydrogenase, contains FAD, which removes the two hydrogens from these 
sulphurs, regenerating the disulphide bond. NAD+ in solution then oxidises the FADH2 to 
FAD, forming NADH and H+. E3BP, a dihydrolipoyl dehydrogenase binding protein, binds 
E3 and maintains proximity of E3 to the core E2 subunit (Patel et al., 2014).  
 
The two disease specific autoantigens E2 and E3BP have a high similarity, with differences 
being that E3BP is without the outer lipoyl binding domain and a key discrepancy in the 
amino acid sequence of the inner lipoyl domain (Palmer et al., 1999).  
 
Despite antibodies against E3BP having been isolated from the blood of some PBC 
patients, it is not considered a dominant autoepitope. It has been suggested that these 
antibodies are a result of cross reactivity with E2 or epitope spreading. 
 
1.6.3: Subsets of PBC 
Until recently, studies into PBC have used only small study sizes due to relatively few 
patients treated at each centre. PBC was classed as one single disease with varying 
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degrees of severity. A UK-PBC cohort study was recently carried out which encompassed 
2353 patients and assessed and compared features such as: response to UDCA therapy, 
laboratory results and symptom impact as reported by the patient (Carbone et al., 2013). 
Relationships discovered between various characteristics suggest that there are different 
subtypes of the disease. Research into therapies for PBC should therefore accommodate 
each individual subtype. This would increase the overall capacity for patient response. This 
concept is explored more thoroughly in chapters 5 and 6. 
 
 
1.6.4: UDCA & its mechanism of action 
Ursodeoxycholic acid (UDCA) is the only current PDA approved therapy for PBC and its 
administration has long preceded research into its possible mechanisms of action(Bachrach 
and Hofmann, 1982). 
The discovery of the relevant mechanisms of action of UDCA in PBC could give insight into 
why some patients respond and others do not with the highlighting of key proteins and 
pathways affected by UDCA. This discovery would be unlikely to lead to the discovery of a 
cause of PBC, as UDCA cannot completely prevent disease progression, however may give 
insight into the differing phenotypes of the different disease subsets. 
Primary bile acids are generated in the liver and are transported into interhepatic bile ducts, 
drained into the left and right hepatic ducts and then collected in the common hepatic duct 
where it can be diverted to the cystic duct for storage in the gallbladder for later release into 
the duodenum of the intestine following food entry into the duodenum (Griffin et al., 2017). 
On release into the intestine, primary bile acids are metabolised to form secondary bile 
acids by intestinal bacteria to form secondary bile acids such as UDCA. UDCA is then 
reabsorbed into the bloodstream and then is drained directly to the liver through the hepatic 
portal vein (Griffin et al., 2017).  
UDCA is not itself generated in the liver although it does form tertiary bile acids 
tauroursodeoxycholic acid and glycoursodeoxycholic acids by conjugating with taurine and 
glycine respectively by gut bacterial enzyme activity.  
Bile duct loss in PBC can lead to bile retention in the hepatocyte which damages the tissue, 
preceding fibrosis. UDCA has been shown to stimulate bile flow by increasing the number 
of bile salt export pumps (Bsep) and conjugate export pumps (Mrp2) on the canalicular, or 
apical, membrane(Paumgartner and Beuers, 2002). This appears to be due to the 
hydrophilic UDCA conjugate Tauroursodeoxycholic acid (TUDCA) mediated increase in 
Bsep and Mrp2 insertion into the apical membrane(Beuers et al., 2001). The function of 
Bsep is to eliminate bile acids and salts into bile ducts from hepatocytes via cholangiocytes 
and Mrp2 is a multidrug resistance associated protein also involved in biliary 
transport(Nezasa et al., 2006). In this way, UDCA administration may increase bile 
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drainage, decreasing the damage caused by bile retention and increasing the time until 
significant bile duct damage shortly preceding liver failure. Additionally, if xenobiotics are 
having an effect in the pathology of the disease, UDCA may also help to excrete these 
reducing the potential of further self-antigen modification which may play a minor role in the 
further exacerbation of disease. 
 
It has been shown that UDCA can indirectly stimulate HCO3- secretion, likely by increasing 
intracellular Ca2+ in cholangiocytes(Beuers et al., 1993) causing stimulation of Ca2+-
dependent Cl- channels. The resultant increase in Cl- concentration in the bile duct causes 
an increased Cl-/HCO3- exchange via the exchanger protein anion exchanger 2, as shown 
in figure 1.6.4. HCO3- is a component in bile and so its stimulated release by UDCA may 
help bile formation thus reducing bile build up in hepatocytes. HCO3- release has been 
implicated in PBC due to attenuated anion exchanger 2 expression (Melero et al., 2002), 
therefore this is likely a mechanism in which UDCA helps responders to eliminate bile and 
anion exchanger 2 expression could be an example of a pathway implicated in only 
responders. 
 
 
Figure 1.6.4: This diagram of cholangiocytes forming a small bile duct illustrates 
some of the potential mechanisms by which UDCA may illicit a therapeutic 
response in PBC. 
1. UDCA has been shown to increase intracellular Ca2+ which can increase Cl- 
transport out of the cholangiocyte via the Ca2+ dependent Cl- channel. The 
increased extracellular Cl- concentration causes in increase in Cl-/HCO3- 
exchange via this exchanger. As HCO3- is a bile constituent, this process can help 
increase bile drainage from the liver. 
 
UDCA conjugate, tuaroursodeoxycholic acid, has been shown to increase the 
insertion of transport proteins Mrp2 and Bsep into the canalicular membrane of 
cholangiocytes, which is believed to help increase bile drainage from the liver. 
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1.6.4.1: Protection against bile acid induced apoptosis 
Build-up of bile acid in hepatocytes can lead to their apoptosis. UDCA may send a survival 
signal to hepatocytes that would otherwise apoptose.  
Bile build up in the hepatocyte can damage the mitochondria and cause mitochondrial 
swelling(Rodrigues et al., 1998a). Additionally, studies in rats have shown that increased 
hepatocyte exposure to glycochenodeoxycholic acid, a bile duct constituent, resulted in 
significantly increased enzyme cytolysis, indicating a large increase in cell apoptosis(Benz 
et al., 1998). This increased cytolysis was then significantly lowered with the co-incubation 
with TUDCA, at certain concentrations. The mechanism of action is thought to be an 
apparent  decrease in the uptake of toxic bile acid constituents into the mitochondrial 
membranes, caused by UDCA (Rodrigues et al., 1998b, Benz et al., 1998). This may reduce 
ATP depletion associated with mitochondrial damage (Krähenbühl et al., 1994). 
 
1.6.4.2: The immunosuppressant effect 
Many studies have shown that UDCA could have an immunosuppressive effect which could 
help slow disease progression in responding patients(Zhang et al., 2009). 
It has been investigated if UDCA can be used to help prevent graft rejection due to its 
potential anti-inflammatory effects(Zhang et al., 2009, Pageaux et al., 1995). There are 
conflicting studies: Zhang and colleagues found that mice given one intravenous 25mg/kg 
dose of UDCA on the day of transplant could survive indefinitely with a fully mismatched 
cardiac allograft(Zhang et al., 2009). However, Pageaux and colleagues report a failure of 
UDCA to prevent liver transplant rejection in humans given an oral dose of 600mg UDCA 
every day for 2 months commencing 3-5 days after surgery(Pageaux et al., 1995). There 
could be many reasons for this disparity, including: different organisms, different time 
transplant of administration, different method of drug delivery, different dose concentration. 
Further research into this area could investigate whether the success in mice could be made 
applicable to humans by experimenting with the delivery conditions, for example 
intravenous delivery the day after transplantation. 
 
These findings, coupled with the finding that UDCA only attenuates the symptoms in a 
certain range of patients, raise the question of what the difference in phenotype between 
responders and non-responders is which potentially allows UDCA to protect mitochondrial 
membranes in only some patients, which is an area for potential further study. 
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1.6.5: Other drugs: Farnesoid x receptor agonists 
Just as UDCA has been shown to increase the expression of transporter proteins such as 
Bsep on the canalicular membrane of the bile ducts, other bile acids can indirectly stimulate 
the expression of the same transporter by acting as ligands for Farnesoid X receptor (FXR). 
FXR, in a heterodimer with Retinoic X receptor α (RXRα), can bind hexamer response 
element targets to induce expression of bile export protein Bsep. Bsep is then transported 
to the canalucular membrane where it can increase clearance of bile acids into the small 
bile duct lumen. The endogenous bile acid chenodeoxycholic acid (CDCA) functions as an 
endogenous FXR agonist, however this action can be inhibited by lithocholic acid (LCA), 
another bile acid. Synthetic ligands for FXR have been identified. (Neuschwander-Tetri et 
al., 2014) 
 
1.6.6: Genetics 
1.6.6.1: GWAS 
Incidence of PBC increases from 0.002-0.04% to 1.33-9% when there is an affected first 
degree relative(Mells et al., 2013). Previous studies show that the class II MHC loci DR8, 
DQA1*0102 and DQ/_1*0402 appear to be associated with PBC(Zhang et al., 1994). 
Additionally, the incidence increases from 0.002-0.04% to 1.33-9%when there is an affected 
first degree relative, suggesting a genetic basis(Mells et al., 2013). Genome-wide 
association studies have characterised some coding and non-coding at risk loci which could 
predispose to PBC. 
 
Many genes relating to immune function were discovered to be significantly linked to 
PBC(Liu et al., 2012), displayed in table 1.6.6.1. These include: IRF5, with immune system 
activity(Krausgruber et al., 2011); ORMDL3, cytokine and chemokine inducible(Ha et al., 
2013); DENND1B, can be associated with asthma(Sleiman et al., 2010); NFKB1, activated 
by cytokines. Arguably, a more significant find in the GWAS study is a number of significant 
differences in genes important in T cell function being a relatively regular find. These are: 
STAT4 and IL-12, involved in Th1development and controlling the Th17:Treg ratio(Xu et al., 
2011); CD80, necessary for T cell T cell activation and survival; IL7R, essential for T cell 
development and also is involved in immunoglobulin class switching in B cells(Tani-ichi et 
al., 2013). This evidence implies that PBC may be largely a T cell disease. Research into 
the differing phenotypes of self-reactive T cells from UDCA responders and non-responders 
could give insight into the difference between UDCA responders and non-responders and 
also early and late onset patients. Given that not all patients respond and that disease 
progression continues, albeit at a slower pace in responders, drugs which target earlier 
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stages must be investigated and then administered early enough to have an effect, i.e. 
before irreversible liver damage.  
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Gene SNP At-risk  
Allele 
Chromosome 
position 
P-value 
MMEL1 rs10752747 T 1p36 2.65 × 10−3 
IL12RB2 rs17129789 C 1p31 9.48 × 10−20 
IL12A rs485499 T 3q25 2.29 × 10−16 
(MHCs) rs7774434 C 6p21 3.86 × 10−34 
IRF5 rs12531711 G 7q32 8.90 × 10−17 
ORMDL3 rs7208487 T 17q12 7.89 × 10−7 
SPIB rs3745516 A 19q13 1.63 × 10−13 
DENND1B rs12134279 T 1q31 1.07 × 10-9 
STAT4 rs10931468 A 2q32 2.55 × 10-12 
CD80 rs2293370 G 3q13 7.70 × 10-11 
NFKB1 rs7665090 C 4q24 5.33 × 10-7 
IL7R rs860413 A 5p13 3.09 × 10-10 
 -  rs6974491 A 7p14 3.39 × 10-6 
CXCR5 rs6421571 C 11q23 3.53 × 10-10 
TNFRSF1A rs1800693 C 12p13 5.51 × 10-8 
RAD51L1 rs911263 T 14q24 1.68 × 10-9 
CLEC16A rs12924729 G 16p13 7.68 × 10-11 
 -  rs11117432 G 16q24 1.20 × 10-6 
MAP3K7IP1 rs968451 T 22q13 4.31 × 10-7 
Table 1.6.6.1: GWAS genes of interest in PBC 
This figure shows the potential susceptible genes in PBC, as discovered in a whole 
genome analysis study. SNPs described in the table, in these genes, appear linked with 
an increased risk of PBC. The genes of particular interest are, arguably, STAT-4, IL-12, 
CD80 and IL7R as they implicate a T cell function, as prior studies also suggest. Much 
further study is required to elucidate the potential impact of each of these SNPs. 
Additional immune response genes of interest include: IRF5, ORMDL3, DENND1B, 
NFKB1. Adapted from Mells et al., 2013. 
 
1.6.6.2: X chromosome loss 
Enhanced X monosomy in PMBCs, especially T and B cells, is commonly found in women 
with PBC and also two other autoimmune diseases (Miozzo et al., 2007). X monosomy is 
also linked with older age (Russell et al., 2007). Haploinsufficiency of genes involved in 
tolerance maintenance and immune function due to loss of an X chromosome could play a 
role in autoimmune diseases such as PBC. Two such genes are CSF2RA and CD40. The 
CSF2RA protein is involved in control, differentiation and production of macrophages and 
granuloytes (Goldstein et al., 2011) and CD40 is involved in T cell dependent 
immunoglobulin class switching (Mohammadinejad et al., 2014). Notably, defects in CD40 
have been linked to hyper IgM syndrome(Hirbod-Mobarakeh et al., 2014). It is possible that 
insufficient CD40 due to X chromosome loss could lead to raised IgM in PBC. As this is 
more common in those of older age(Miozzo et al., 2007), it potentially could be a 
contributing factor for those with the later onset, less aggressive form of the disease. To 
validate this, an investigation into the extent of raised IgM and age of patient, or the extent 
of X chromosome loss, could be carried out. It is important to note, however, that the 
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mechanisms of the disease may be due to other genes on the X chromosome inactivation 
and not necessarily CD40.  
 
The possible involvement of X monosomy in PBC should be further investigated because 
X monosomy is related to age, which also seems to be related to the subset of disease a 
patient is presenting (Carbone et al., 2013), therefore could potentially be one key factor 
differentiating between aggressive and non-aggressive disease. X chromosome loss must, 
then, also be investigated in younger patients, to determine whether it could be impacting 
PBC as a whole or just the older patients. Additionally, the possible involvement of other 
genes escaping X inactivation must also be studied, such as CSF2RA, which, if involved, 
indicates a granulocyte or macrophage involvement in the disease as well as the 
established T cell involvement, thus potentially further helping to elucidate the cause of 
disease. 
 
 
1.7: Conclusion 
 
Typically, removal of the stimulus is important for reversal of fibrosis(Pellicoro et al., 2012), 
an impossibility in PBC where the antigenic stimulus is endogenous. The chronic 
inflammatory response leads to further tissue damage and a cascade of fibrosis eventually 
precluding correct tissue function(Pellicoro et al., 2012), illustrated in figure 1. Ideally, 
therapies which target T cells must be administered at the earliest possible stage in order 
to give maximum effect, before the cycle of chronic inflammation is fully established. 
Therefore, once fibrosis has begun, the stage has passed whereby T cell therapies could 
give maximum effect. 
 
Given the variable effects of UDCA treatment, considerable recent research has been 
focussed on the development of novel treatments (Jones et al. 2011, Levy et al. 2011). 
However, positive results from the latest trials have yet to be presented, and several trials 
have been halted due to insufficient efficacy at phase II. Given the potential spectrum of 
pathogenicities involved, it may be that not all recruited patients were likely to respond to 
specific immunotherapy, a factor which may have contributed to the failure of recent clinical 
trials.  
 
If the differing underlying pathologies were better understood it may be possible to identify 
which patients will not respond to standard treatment early following diagnosis, rather than 
when fibrosis is established, as displayed in figure 1. This would give the potential to stratify 
both clinical trials and anti-inflammatory treatment and therefore lead to promising novel 
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drugs being assessed more appropriately and potentially more effective treatment in patient 
subsets. 
 
The study carried out by Carbone and colleagues which identified the sub-classification of 
PBC was statistical and symptomatic, based on phenotype alone. It has been well 
established in the literature that the dominant autoantigen in PBC is the E2 component, 
particularly the inner lipoyl domain, however other regions of the E2 protein and also the 
E3BP have also been shown to be autoreactive in PBC (Palmer et al., 1999). It could be 
that there are different levels of diseased severity relating to different autoantigens in the 
disease. As the key determining factors in the Carbone study were age, response and sex, 
this would, then, imply that there could be a link between the particular autoantigen against 
which the patient develops an immune response and their age, likelihood to respond and 
blood biochemistry. It is unlikely that the autoantigen alone could determine these factors, 
however differences in antibody isotype could help explain these differences.  
This example highlights the importance of the type of immune response. PBC could involve 
a crossroads whereby the type of immunological response could determine the severity of 
the disease. This could be related to responsiveness to the drug because it is well known 
that UDCA does not completely halt disease progression, only slows it down. The 
effectiveness of UDCA could be less important than type of response, such that if a patient 
is giving the ineffective immune response then any effect by UDCA will be negligible.  
 
1.8: The future 
All types of PBC lead to a similar phenotype (Carbone et al., 2013). However the journey 
towards this outcome may be significantly different in terms of the affected 
pathways(Carbone et al., 2013). There may be differing triggers of the disease in 
individuals, be they genetic, xenobiotic, biological or a combination of these(Jones, 2003b). 
Their effects on the general population and how they correspond to disease incidence are 
unknown. We believe a paradigm shift in the understanding of the pathogenicity of PBC is 
taking place, and that by fully elucidating mechanisms of disease within different patient 
groups we can devise more effective treatments. 
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1.9: Aims of this thesis 
 
This thesis aims to further clarify the subgroups of PBC patients to help bring the disease 
into the era of stratified medicine whereby patients can receive a therapy which is tailored 
to their type of disease. This thesis aims to bring new evidence to light to characterise these 
subgroups biologically such that in the future there may be a diagnostic tool which can 
distinguish patients in the different subgroups at diagnosis to avoid ineffective therapy from 
being given inappropriately and unnecessarily to the non-responders. In attempt to achieve 
this, the impact of UDCA was investigated including both its impact on immune cells and 
on cholangiocytes. The subgrouping was discovered in its most broad sense in the light of 
UDCA response, therefore further elucidating the mechanisms of action of this drug may 
highlight key pathways of interest which may differ from responder to non-responder. 
Furthermore, biological differences were investigated between the subgroups of PBC 
patients. This was done by quantifying the autoantibody titres in patients and comparing the 
different groups of patients. Together these data begin to underpin biological reasoning 
behind the discovered phenotypic discrepancies between different patients all currently 
denoted ‘PBC patients’ under what is likely an umbrella term.  
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Chapter 2 – General Methods 
2.1: Laboratory procedure  
All work was conducted under the safety policy of Northumbria University with relevant risk 
assessments having been undertaken by the PhD student and signed off by one of the 
supervisory team and checked by technical staff. All work was in compliance with Control 
Of Substances Hazardous to Health (COSHH) and Control Of Biological Substances 
Hazardous to Health (BioCOSHH) records, written by the PhD student using relevant 
chemical information sheets and other product guidance from the supplier, and which were 
then checked by a member of the supervision team and checked by technical staff. All 
potentially harmful biological material, such as unscreened healthy volunteer blood, was 
treated as potentially infected and category II+ containment facilities were used.  
 
2.2: Common reagents 
Non-sterile phosphate buffered saline (PBS) was used for all work not carried out under the 
containment hood or not for flow cytometric analysis. To make 10x working concentration 
of non-sterile PBS: 80g NaCl, 2.0g KCl, 14.4g Na2HPO4, 2.4g KH2PO4 were dissolved in 
800ml distilled water in a 1l Duran. pH was then adjusted to 7.4 and the volume adjusted to 
1l, then the PBS was autoclaved. PBS was diluted in distilled water 1 in 10 for working 
concentration use. Sterile PBS was purchased from Sigma Aldrich. 
Rosewell Park Memorial Institute culture medium (RPMI) was used for cell culture of non-
adherent cell lines. Unsubstituted RPMI (R0) was used where specified but for all culturing 
purposes RPMI was substituted with 10% FBS, 1% L-Glutathione and 1% Penicillin and 
streptomycin antibiotic cocktail to make complete RPMI media (R10).  
 
2.3: Isolation and culture of PBMCs and cell lines 
2.3.1: Phlebotomy 
Blood was taken from consenting healthy volunteers who had read and signed full consent 
forms. Phlebotomy was carried out by a fully trained phlebotomist with certificate and signed 
off as per Northumbria University procedures. 5 x 10ml lithium heparin-containing 
vacutainers were used per patient at one time and blood was taken using a 21-gauge 
butterfly needle. The lithium heparin inactivates thrombin and thromboplastin to prevent 
blood clotting within the glass container. 
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2.3.2: PBMC isolation 
15ml of lymphoprep was first added to each filter-containing Falcon tube and then pulse 
centrifuged. Up to 30ml of whole blood was then added on top of each filter within the tube 
and the tubes were spun at 2100rpm for 12 minutes with brake set to 0. The blood would 
then be separated into a large serum fraction containing the buffy PBMC-containing 
fraction. Serum would then be removed and frozen at -20OC. The PBMC-containing buffy 
layer would then be carefully removed, washed in R10 and resuspended and counted for 
use.  
 
2.3.3: Culture of PBMCs 
PBMCs are cultured at 1x106/ml in R10 unless otherwise stated in individual methods. This 
same method was applied to the Jurkat cell line.  
 
2.3.4: Culture and splitting of adherent cell lines 
Adherent cell line H69 was cultured and allowed to grow until 70-80% confluent, then split 
1:5 or otherwise stated. Culture medium used was Dulbecco’s Modified Eagle Medium 
(DMEM) low glucose and F12 Ham (2:1), supplemented with FBS (10% of total media 
volume), penicillin and streptomycin antibiotic mixture (1% of total media volume), L-
glutamate (1% total media volume), Adenine (120µl per l media of 0.2mg/ml working 
solution), Triiodothyronine (135µl per l total media volume of 10ng/ml working solution), 
epinephrine (20µl per l total media volume of 50mg/ml stock solution made up in 0.5N HCl), 
ITS-X (10ml per l total media volume), Hydrocortisone (20ml per l total media volume).  The 
H69 cell line is an immortalised cell line originally isolated from intrahepatic bile ducts 
(Tabibian et al., 2014). Cells were obtained from Dr Ben Millar, Institute for Cellular and 
Molecular Biosciences, Newcastle University, in culture form in 10ml of full media in a cell 
culture flask. Cells had been checked and confirmed negative for mycoplasma 
contamination immediately before their release to Northumbria University for this study. 
Splitting of these cells was carried out by checking cell health microscopically, decanting 
culture medium, washing with PBS 3 times then adding pre-warmed trypsin solution and 
incubating at 37OC for ten minutes or as long as it took for cells to be visibly dissociated by 
microscopic visualisation, then collected, centrifuged at 400 x g for 5 minutes and 
resuspended in their culture medium for counting. Cells were then plated either by 1:5 or to 
the required number of cells/ml.  
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2.3.5: Freezing and thawing of cells 
Cells were frozen by centrifuging and resuspending at 1 x 107/ml in 50% culture medium, 
40% FCS and 10% dimethyl sulphoxide (DMSO) in 1ml vials and quickly placed in the ‘Mr 
Frosty’ freezing container (ThermoFisher) which contained a sponge and isopropanol layer 
for slow freezing. This was then placed at -80OC overnight, then vials were transferred to 
liquid nitrogen for long term storage. Cells needed to be quickly transferred into the ‘Mr 
Frosty’ as DMSO is potentially toxic to cells at above 0.3% volume of culture media, outlined 
in chapter 3. The ‘Mr Frosty’ ensures that cells are frozen at 1OC per minute. Slow freezing 
helps prevent cells from bursting due to rapidly expanding liquids and DMSO renders the 
cells porous to allow diffusion of large quantities of liquid, again to prevent bursting (Angel 
et al., 2016). 
Cells were thawed rapidly at 37OC and diluted drop-wise to avoid both DMSO toxicity and 
osmotic shock. Once diluted 15-fold, cells were rested in media for 30mins then centrifuged 
to remove DMSO and resuspended to required cell concentration. 
 
2.4: Flow Cytometry 
2.4.1: Background 
4’,6-diamidino-2-phenylindole (DAPI) is a fluorescent dye which strongly binds A-T regions. 
Live cells are impermeable to DAPI whereas porous dead cells are not. Therefore, live cells 
can be differentiated from dead cells by the presence of DAPI in only dead cells. DAPI is 
read in the BV421 channel (Gomes et al., 2013). 
Carboxyfluorescein succinimidyl ester (CFSE) is a cell permeable molecule which 
covalently binds to intracellular molecules, particularly the lysine residues of proteins. Due 
to the covalent nature of the binding, CFSE can stably remain inside the cell for a long 
period of time. When the stained cell divides, the dye is divided between the two daughter 
cells and so is diluted down each generation. Because of this effect, the proliferation of the 
cells can be studied using flow cytometry over time based on the relative intensity of the 
dye within each generation of cells (Banks et al., 2012). 
 
2.4.2: Washing cells 
Unless otherwise stated, washing of cells entailed adding 2ml of FACS buffer and spinning 
at 400 x g for 5 minutes and then removing the supernatant and resuspending in FACS 
buffer for the subsequent wash. 
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2.4.3: Staining 
For staining for flow cytometry, cells were first washed 3 times in FACS buffer, made up of 
sterile 1 x phosphate-buffered saline solution (PBS) containing 5mM 
ethylenediaminetetraacetic acid (EDTA) and 2% fetal bovine serum (FCS). Cells were then, 
if applicable to the panel tube, stained with 4’,6-diamidino-2-phenylindole which involved 
first washing with sterile PBS 3 times and then incubating in the dark on ice in sterile PBS 
containing 3μM DAPI at 1x 106 cells/ml for 30mins. Cells were then washed and 
resuspended in FACS buffer. Extracellular identifiers such as surface receptors were than 
stained for by resuspending cells at 1 x 107/ml in FACS buffer and the titrated concentration 
for each antibody based on stain index (usually equivalent to 1/200 dilution of raw antibody). 
Staining took place over an incubation of 30mins at room temperature in the dark then 
washed 3 times and resuspended in FACS buffer. 
The Treg tube required intracellular staining which was performed after extracellular 
staining. The kit used for intracellular staining of Foxp3 was the eBiosciences 
FoxP3/Transcription factor staining buffer set. Solutions were firstly made up as per 
manufacturing guidelines: fixation/permeablisation concentrate was diluted 1 in 4 with 
fixation/permeablisation diluent and permeablisation buffer concentrate was diluted 1 in 10 
in distilled water. 1 x 106 cells were spun at 400 x g and then supernatants discarded. Cells 
were then resuspended and then 1ml of fixation/permeablisation working solution was 
added and the tube was vortexed. Cells were incubated for 30-60 minutes at room 
temperature in the dark. 2ml permeablisation buffer was then added per tube and spun at 
400 x g for 5 minutes and the pellet resuspended in residual permeablisation buffer after 
decanting the supernatant. Cells were then blocked with 2μl of FCS added directly to the 
residual solution and mixed, then incubated for 15 minutes at room temperature. The titrated 
volume of FoxP3 antibody is then added and cells are incubated for 30minutes at room 
temperature. Cells were then washed in working concentration permeablisation buffer and 
spun at 400 x g for 5 minutes before being resuspended in FACS buffer for flow cytometric 
analysis.  
For proliferation experiments, cells were stained with CFSE prior to culture where specified 
to measure numbers of proliferation cycles. For CFSE staining, 2µl of the 5mM CFSE stock 
solution was diluted 1/100 in PBS to give 200µl 0.05mM CFSE solution, 2ml of which was 
then diluted 1/25 in PBS to give a 2µM CFSE solution. 10% FBS RPMI was kept on ice. 
Cells to be stained were counted, then washed twice in 0.1% FBS PBS then resuspended 
in 0.1% FBS PBS at 1X107/ml. This was mixed with an equal volume of 2µM CFSE solution 
and incubated at 37oC for 5 minutes. Cold 10%FBS RPMI was then added to terminate the 
reaction at a volume equal to the cell solution and CFSE solution mixture. The sample was 
then placed on ice for five minutes. The tube was then topped up with 10% FBS RPMI and 
centrifuged at 800 g for ten minutes and resuspended in 10% FBS RPMI, then rewashed 
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before final resuspension in 10% FBS RPMI. Antibodies and clones used for staining are 
listed in the appendix, table 8.6. 
 
2.5: Enzyme-linked immunospot (ELISpot) 
The ELISpot uses enzymes with cleavage properties such that the cleaved product is 
visible, so that the release of a cytokine by a cell in response to antigenic encounter can be 
visualised in the form of a spot. The number of spots visible relates to the number of 
antigenic encounters in the well. The ELISpot was carried out to determine if UDCA was 
having an effect on T cells to recognise antigen (Todryk et al., 2009). 50µl of diluted capture 
antibody, diluted in bicarbonate buffer, at the pre-determined best concentration for that 
antibody was added to each well, ensuring thorough covering of the bottom of every well. 
This was incubated at 4OC overnight (8-48 hours is acceptable). Excess capture antibody 
was removed and the plates washed 3 times with PBS. The plates were then blocked with 
RPMI containing 10% FCS for 1-8 hours at room temperature to minimise non-specific 
binding. Blocking solution was then removed to virkon solution. 
 
2.6: xCELLigence 
The xCELLigence assay was used to determine if UDCA was having an impact on 
cholangiocyte cell line proliferation. The proliferation of cells is proportional to the electrical 
impedance detected on the gold plate, transferred to the software. As a cell makes contact 
with the golden plate at the bottom of the well, there is increased electrical impedance 
whereby he greater cell density causes current opposition, which is used as a measure for 
proliferation. 
Microelectrodes cover 80% of the well surface and throughout the duration of the 
experiment, there is a voltage applied across these electrodes and impedance is measured 
every 15 minutes throughout the experiment. Impedance is the overall opposition to current 
flow, given resistance, reactance and capacitance of the elements in the circuit. As cells 
proliferate, they provide additional impedance to the circuit as the microelectrodes are 
positioned such that their presence obstructs the flow of electrons. Therefore, the 
impedance relates to the number of cells present in the well and so gives a representation 
of proliferation (Martinez-Serra et al., 2014). 
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2.7: Enzyme-linked immunosorbent assay (ELISA) 
 
2.7.1: Background 
The ELISA assay was used to quantify the titres of autoantibody found in patient and 
volunteer serum. Each well was coated with the protein of interest to allow adherence of 
the antibody. A secondary antibody conjugated to an enzyme attached. The enzyme had 
cleavage properties such that the substrate produced has a colour which has a measurable 
intensity, proportional to the titre of antibody in the serum sample (Engvall and Perlmann, 
1971). 
 
 
2.7.2: Reagents 
Tween 20-substituted PBS (PBST) was used in ELISA assays to wash plates between 
stages. This was made up of 0.05% tween 20 mixed slowly in PBS, slowly to avoid bubbling. 
ELISA blocking solution was made up of 5% skimmed milk powder dissolved in PBST.  
Diluent solution used as the blank and to dilute patient and volunteer samples was made 
up of blocking solution diluted 1 in 10 in PBST.  
Patient serum samples were kindly donated by Prof Dave EJ Jones and Dr Vinod Hegade, 
Freeman Hospital, provided in raw serum form and immediately transferred to -20oC 
storage until use.  
Citrate phosphate buffer was made by adding 9.149g dibasic sodium phosphate and 4.668g 
citric acid to 800ml of distilled water then adjusting the pH to 5.0 before adjusting the volume 
to 1l with distilled water. 
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Chapter 3 – Design of an assay which can 
distinguish between different subsets of T cell 
for use in categorising patient subgroup T cell 
populations and to investigate any skewing 
ability of UDCA on T cell populations. 
Abstract 
There is convincing evidence in the literature that PBC may be a T cell mediated disease 
with many autoantigen specific T cells, in particular CD4+ T cells, detected around the 
damaged sites in PBC. Increasing evidence suggests the importance of many signalling 
pathways in PBC, including IL-12/IL-23 p40, IL-17A and IL-22, IFN-γ and others which does 
not satisfy the cytokine release profile of just one subset of CD4+ T cells, indicating that 
there may be several different T cell subsets involved in the pathogenesis of PBC. This 
chapter describes the design of a flow cytometric assay which can distinguish between cells 
of different T cell subsets within a population. This involves design of a panel of antigens, 
establishing the ideal voltage for each channel, titration of each dye, establishing of the 
negative gate and compensation of all dyes together. This assay was designed to 
investigate skewing of the normal ratios of T cell subsets by action of UDCA, and to 
investigate any proliferation inhibition activity that may be specific to one or more types of 
T cell. Healthy controls were used, with the aim to also use patient cells in the future to 
determine if responder and non-responder patients have similar responses. 
 
3.1: Introduction 
CD4+ T cells recognise extracellular antigen displayed by MHCII molecules which are 
usually only present on professional antigen presenting cells (APCs) (Mosmann et al. 
1986). Some types of APCs are macrophages, B cells, dendritic cells and biliary epithelial 
cells (BEC). BEC are the cholangiocytes that make up the small bile ducts. Their primary 
role is not thought to be as APCs but they do possess the ability to regulate T cell activation. 
Although they do highly express MHCII for antigen presentation, BEC do not express 
essential costimulatory molecules CD80 or CD86, however T cell activation can occur in an 
alternative way using programmed death ligand 1 (PD-L1) and prostaglangin E2 production 
(Kamihira et al.2005). APCs take up extracellular antigen, process it internally, then present 
it on the cell surface within an MHCII molecule which can then be recognised by a CD4+ T 
cell (Trinchieri and Sher, 2007). CD8+ T cells recognise processed antigen displayed on 
MHCI, which is present on all nucleated cells in the body. Another mechanism by which 
antigen can be presented is by APCs using MHCI to CD8+ T cells, a process called cross-
presentation. The common autoantigens in PBC are those from oxo-acid dehydrogenase 
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complexes, predominantly PDC, and are known to be intracellular antigens, however both 
autoreactive CD4+ and CD8+ T cells have been isolated from PBC patient blood and also 
shown to be enriched in the liver of PBC patients (Palmer et al., 1999). This suggests that 
the autoantigens are being recognised and processed as both intracellular and extracellular 
antigen. 
Aberrant surface expression of PDC-E2 has been shown in BECs of PBC patients, however 
studies have shown that this is insufficient to cause disease on its own (Inamura et al, 2006), 
therefore BECs are unlikely to be the primary APC in PBC. Additionally, presence of AMAs 
alone does not seem to be pathogenic, as some post-liver transplant patients have been 
shown to have high AMA levels for years post-transplantation without disease recurrence 
(Neuberger and Thompson, 1999). Additionally, AMA level is not predictive of disease 
progression (Van Norstrand et al., 1997). Another mechanism must exist for the recognition 
of PDC subunits as extracellular antigen. Some studies have suggested a B cell origin for 
CD4+ T cell recognition, whereby the B cells take up and express PDC subunits on the 
surface which are then recognised by autoreactive CD4+ T cells (Zhang et al., 2014), more 
of which is discussed in Chapter 1: Introduction. A recent study has brought to light the 
possible importance of CD4+ Th1 and Th17 cells in PBC (Kawata et al. 2013), outlined 
below.   
In response to some antigens and also the inflammatory environment, APCs can release 
IL-12, which causes differentiation of naïve T cells to Th1. Additionally, macrophages and 
dendritic cells may release IL-23, which causes differentiation of naïve T cells to Th17. IL-
12 and IL-23 share a subunit of IL-12B, also known as p40. When p40 is bound with p19, 
this forms IL-23 and when p40 is bound with p35, this forms IL-12. Therefore, the relative 
ratio of IL-12 and IL-23, and therefore possibly also the relative levels of Th1 and Th17 
cells, could be being governed by the relative levels of p35 and p19 (Kawata et al, 2013). 
Similarly, the IL-12 receptor subunit IL-12Rβ1 forms a heterodimer with both IL-23R and IL-
12Rβ2 to form the IL-23 and IL-12 receptors, respectively. A recent study used mice with a 
deletion of p40, p35 or p19 with2-octynoic acid conjugated to bovine serum albumin (2OA-
BSA) immunisation-induced cholangitis, to investigate the potential role of these subunits 
in PBC. They found that there was less portal inflammation and cholangiocyte damage in 
the p35 and p19-deleted mice than wild type mice, when there were downregulated levels 
of either Th1 or Th17, however the p40 deleted mice showed no detectable lymphocytic 
infiltration (Kawata et al., 2013). They concluded that when there is no IL-12 or IL-23 to 
cause differentiation to Th1 or Th17 respectively, there is less overall portal inflammation 
than without any deletion, however when there is no IL-12 and no IL-23 together, there is 
no detectable portal inflammation (Kawata et al. 2013). This data is suggestive that Th1 and 
Th17 cells are important in the initiation of inflammation in PBC, giving some evidence to 
suggest an early importance of CD4+ Th1 and Th17 cells. 
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Regulatory T cells (Tregs, CD4+CD25+FoxP3+) are also of interest in PBC because their 
levels are lower in PBC patients than in the healthy population (Lan et al. 2006). Tregs are 
known to be of importance in preventing breakdown of self-tolerance and are implicated in 
many autoimmune diseases (explained in detail in the main introduction). Specifically to 
PBC, it has been found that there are significantly fewer circulating CD4+CD25+Tregs in 
PBC patients compared to the healthy population (Lan et al., 2006). It has not been 
investigated if Tregs could play a role in determining whether a patient is a ‘responder’ or 
‘non-responder’ to UDCA (response and non-response are discussed more in chapters 5 
and 6). 
One study indicated an early abundance of Th2 cells, followed by an eventual decline in 
Th2 levels, and the prevalence of Th1 cells into late stage disease (Sekiya et al., 1999). 
The group stained T cells isolated from patient blood for intracellular cytokines, using 
patients at different disease stages and determined that there was a prevalence of Th1 cells 
into late stage disease and a decline of Th2 cells (Sekiya et al., 1999). The study was not 
carried out in the context of PBC responders and non-responders, however does indicate 
a potential early importance of Th2 cells and a potential importance of Th1 cells for disease 
progression.  
These data together suggest that there is evidence to suggest importance of CD4+ T cell 
subsets but how, why and when the differences in T cell differentiation are orchestrated is 
poorly understood.  
Chapter 1, section 1.6.6, outlines how there could be different genetic variants within 
different groups of PBC patients, and this may have a consequential impact on the levels 
and ratios of different T cell subsets. This chapter aims to develop an assay which can take 
a population of patient PBMCs and analyse the relevant quantities of Tregs, Th1 cells, Th2 
cells and Th17 cells. This can be used to provide further evidence on the peripheral T cell 
population in PBC. This assay can furthermore be used to distinguish any differences in T 
cell populations between patient sub groups which have been shown to be phenotypically 
different (Carbone et al., 2013). The subgrouping of PBC patients identified in this study is 
further explained in chapters 1, 5 and 6.  
 
3.1.1: Flow Cytometry 
The flow cytometer can be used to analyse a solution of cells based on their physical 
properties and the light properties of antibodies attached to them based on the biomarker 
profiles of the cells in question. Cells are placed into the machine which draws them up and 
they undergo pressure from sheath fluid which forces the cells into single file so that they 
can be analysed individually (Bandura et al., 2009). The cell is subject to a laser to measure 
forward scatter and side scatter of the laser beam based on properties of the cell. For cells 
in the size range of lymphocytes, forward scatter can be used to predict the approximate 
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size of the cell and also side scatter can indicate internal complexity or density of organelles. 
When the initial laser comes into contact with the cell, some of the laser’s signal is scattered 
due to the change in relative refractive index (Bandura et al. 2009). Some scatter is 
determined by the cell as a whole and the size of the cell governs the degree of this scatter 
whereas some light enters the cell and is scattered by organelles. The scatter caused by 
the cell, forward scatter, is measured as is that caused by organelles, side scatter, and this 
data is represented in a forward/side scatter scatter graph (Cossarizza et al. 2017).  
Based on prior knowledge or a reference graph, it can be estimated where the lymphocytes 
are on a graph of forward scatter against side scatter, which will later be checked based on 
other identification markers. Cells are usually stained with fluorescent antibodies targeting 
surface markers, intracellular markers and/or other dyes. Further lasers challenge these 
markers and electrons in the fluorescent conjugates can be excited to higher energy states, 
and then energy of a discrete wavelength is emitted when electrons fall back to a lower 
energy state, allowing determination of which colours are present (Nicholas et al. 2016). 
Antibodies are chosen based on their fluorochrome and also the epitope to which they bind, 
therefore presence of a pulse of light in a particular channel is indicative of presence of that 
particular epitope. Other fluorescent dyes attach other proteins, for example CFSE binds to 
cytoplasmic proteins and its concentration indicates the number of divisions carried out by 
that cell (Banks et al. 2011) as explained in General Methods. The presence of DAPI 
indicates that a cell is dead because its presence inside a cell indicates a porous membrane 
which has allowed the dye to enter the cell, which is characteristic of a dead cell. 
Manipulation of biomarkers and properties of cells in this way allows cells to be examined 
so that conclusions can be drawn about the cell population (Zhao et al., 2010). 
 
3.1.1.1: Distinguishing between different types of T cell based on extra- and 
intra-cellular markers 
The population of T cells in a given sample can be determined by examining the specific 
surface markers or intracellular markers of the cells within the sample. CD3, CD4, CD8, 
CD25, CXCR3, CCR6, CD45RO and FoxP3 can be used to identify the relative numbers of 
T cells, divided T cells, CD4+ helper1 or helper 2 T cells, CD8+ cytotoxic T cells and memory 
or naïve memory T cells (Okado et al. 2008). All T cells have the CD3 marker, therefore will 
stain positively for CD3, and within the T cell population: helper T cells stain CD4+CD8-, 
cytotoxic T cells stain CD4-CD8+ and regulatory T cells stain positively for FoxP3 and CD25 
(Owen et al. 2003).  
 
 
3.1.1.1.1: CD3 
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Cluster of differentiation 3 (CD3) functions as the T cell receptor co-receptor. Chains within 
this complex bind the TCR when it recognises antigen to help in T cell activation upon 
recognition of an antigen by the TCR, as presented by the MHC molecule on the presenting 
cell. CD3 contains extracellular regions made up of heterodimers of polypeptide chains γ, 
δ and ε in the conformation of εγ and εδ (Saito et al., 1987). CD3 also contains an 
intracellular homodimer ζζ. The γ, δ and ε each contain an intracellular region the ζ subunits 
are fully intracellular. The intracellular regions of these subunits contain the intracellular 
signal transducing immunoreceptor tyrosine activation motifs (ITAMs), with each of γ, δ and 
ε having one ITAM and each ζ having3 ITAMs, totalling ten ITAMs per CD3 molecule 
(Neumeister et al., 1995). 
3.1.1.1.2: CD4 
 
CD4 is on the surface of helper T cells and functions as a co-receptor of the T cell receptor 
(TCR). The TCR binds to the MHCII of the antigen presenting cell (APC) during interaction 
with the APC and functions to amplify downstream signalling eventually leading to activation 
of NF-κB transcription factors and activation of the T cell (Voll et al., 2000). CD4 is also 
found on the surface of monocytes, macrophages and dendritic cells. It has subunits which 
include extracellular immunoglobulin domains. These include D1 and D3 which are similar 
to IgV domains, and D2 and D4 which are similar to IgC domains. It is the D1, which is not 
present in CD8, which binds MHCII (Silva et al., 2007).  
3.1.1.1.3: CD8 
 
CD8, present on the surface of cytotoxic T cells, is a co-receptor for the TCR which binds 
the MHCI of the APC and causes downstream signalling eventually leading to the activation 
of transcription factors such as NF-κB, NFAT and AP-1 (Masuda et al., 1993). CD8 contains 
subunits CD8-α and CD8-β which each contain an extracellular domain similar to IgV. It is 
the CD8-α, not present in CD4, which binds the α3 subunit of MHCI, leading to the specificity 
of cytotoxic T cells binding MHCI, not MHCII (Willemsen et al., 2006).  
3.1.1.1.4: FoxP3 
 
FoxP3 is a nuclear receptor known as the master regulator of T cells. It is a protein in a 
large family of transcription factors called the forkhead transcription factor family. Expressed 
in CD4+ regulators T cells, it acts to supress NFAT and NFκB which are transcription factors 
for many inflammation-generating and immune-response genes such as IL-2 and effector 
cytokines in T cells. Along with CD25 and CD4, it can be used to identify CD4+ regulatory 
T cells by flow cytometry (Tzang et al., 2017). 
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3.1.1.1.5: CD25 
 
CD25, or IL2RA, functions as the α chain for receptor for interleukin 2 (IL2), which is a 
heterotrimer made up of an α, β and a γ chain, αβγ. Other combinations include ααγ and 
ββγ, which give lower affinity receptors with the lowest affinity receptor being ααγ. The β 
and γ chains span the cellular membrane and include intracellular tyrosine kinase- bound 
domains which are involved in signal transduction. CD25 is associated with CD4+ Tregs 
and is one marker which can be used to identify these cells, alongside CD4+ and FoxP3 
(Tzang et al., 2017). 
3.1.1.1.6: CXCR3 
 
CXCR3 is a Gαi protein coupled receptor which acts as a chemokine receptor which 
regulates leucocyte trafficking. CXCR3 is expressed on Th1 cells and promotes Th1 
maturation. CXCR3 is involved in T cell migration. In activated T cells, it binds chemokines 
CXCL9, CXCL10 and CXCL11, related to migration. Where Th1 T cells express CXCR3, it 
is not expressed in Th2 and Th17 cells (Groom and Luster, 2011a). 
3.1.1.1.7: CCR6 
 
An important Th17 cell marker, CCR6, is a G protein coupled receptor important for B cell 
lineage maturation, specifically antigen driven B cell differentiation. Its ligand is MIP-3, an 
inflammatory protein released by macrophages. Th1 cells are CXCR3+CCR6-, Th17 cells 
are CXCR3-CCR6+ and Th2 cells are CXCR3-CCR6-, allowing flow cytometric 
distinguishing of Th1, Th17 and Th2 cells (Gosselin et al.).  
3.1.1.1.8: CD45RO  
 
CD45RO is one of many isotypes of CD45. Also known as Protein Tyrosine Phosphatase 
Receptor Type C, PTPRTC, CD45 is involved in cell growth and differentiation but 
negatively impacts cytokine production. If a cell expresses CD45RA, this is indicative of a 
naïve T cell, whereas a memory T cell will express CD45RO, therefore CD45RO and 
CD45RA can be used to differentiate memory from naïve T cells. CD45RO presence, 
alongside CD4, CD25 and FoxP3 can indicate memory T cells where 
CD4+CD25+FoxP3+CD45RO- Tregs are likely naïve (Thiel et al., 2015). CD45RO has had 
exons RA, RB and RC removed and so can essentially be thought of as ‘CD45 R naught’.  
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3.1.2: Jurkat cell line 
The Jurkat cell line is an immortalised T lymphocyte cell line originally isolated form a 14-
year old leukaemia patient. This is a potentially suitable cell line for proliferation studies 
because it expresses the CD3 antigen therefore addition of an anti-CD3 mitogen can 
stimulate proliferation of this cell line just as with primary human T cells. The Jurkat cell line 
will be tested for use in the assay being developed in this chapter. If these cells are suitable 
for flow cytometric, including proliferation, experiments, this will be far more convenient than 
using primary cells because Jurkat cells have the capacity to grow to 20 passages for 
reliable use in experiments whereas primary T cells cannot be passaged and require a 
healthy volunteer for each new experiment (Schneider et al., 1977).  
 
3.1.3: Aims of the chapter 
The primary aim of this chapter was to design of an assay which can distinguish between 
different subsets of T cell for use in categorising patient subgroup T cell populations and to 
investigate any skewing ability of UDCA on T cell populations. 
There are many stages involved with designing a multicolour flow cytometry assay. These 
include: design of a panel of antigens, establishing the ideal voltage for each channel, 
titration of each dye, establishing of the negative gate and compensation of all dyes 
together.  
The development of a robust protocol to categorise the populations of T cell subsets in PBC 
patients is important as it may allow further categorisation of the responder/non-responder 
subgroups and possibly may eventually lead to directed therapeutic intervention (Hardie et 
al., 2016). Initially this assay will be used on healthy volunteer cells having been incubated 
with different concentrations of UDCA to investigate any skewing of T cell ratios by UDCA 
or any proliferation inhibition activity that may be specific to one or more types of T cell. 
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3.2: Methods 
3.2.1: Enrichment of T cells for the determination of the best T 
cell enrichment kit assay 
PBMCs were isolated from whole blood as described in Chapter 2: General Methods, and 
counted using a haemocytometer. They were then separated into 5 groups: PBMCs, 
Easysep, Rosettesep, Miltenyi and plastic. All groups of cells except for the PBMC group 
were subject to one of the T cell isolation methods, described below, and stained with 
antibodies APC-anti-CD4, FITC-anti-CD8 and PerCP-anti-CD3 antibodies as per the flow 
cytometry preparation staining protocol in Chapter 2: General methods. DAPI staining and 
CFSE staining are also described in General Methods. Cells were then run through the flow 
cytometer as described in General methods and data analysed using FACSDiva software 
to determine the most effective T cell proliferation kit.  
 
3.2.1.1: Easysep: 
The STEMCELL technologies Easysep negative selection kit contains a cocktail of 
antibodies which attach to all cells other than the desired cells and then attaches those 
unwanted cells to magnetic particles which can be separated by magnetism with a large 
magnet and pouring the desired cells away from those bound to the beads. 
A negative selection kit was chosen rather than a positive selection kit which would include 
a cocktail and bead combination that would cause the T cells to be bound to the magnetic 
beads and leaving the rest of the PBMCs in solution. Although the positive selection method 
would be effective, the negative selection kit was selected in order to leave the cells of 
interest as undisturbed as possible. These T cells were then used in proliferation 
experiments, in which it is important to activate T cells only at the desired time, therefore 
the negative selection kit was most appropriate.  
PBMCs were isolated from whole blood as per the method in chapter 2, General Methods. 
Cells were counted, then transferred to a sterile 5ml polystyrene round bottom tube with 
cap and centrifuged at 1400rpm for 5mins then resuspended in PBS with 2% FCS and 1mM 
EDTA to a concentration of 5 x 107 cells/ml with a maximum of 2ml in each tube. Easysep 
Human T cell Enrichment cocktail was then added at 50µl per ml volume of cell suspension, 
mixed thoroughly and incubated at room temperature for 10 mins. Easysep D Magnetic 
Particles were then vortexed for 30 seconds and then added at 50µl per ml cell suspension 
volume. The solution was mixed well then incubated at room temperature for 5 minutes. 
PBS with 2% FCS and 1mM EDTA was then added to bring the total volume to 5ml and 
gently mixed. The cap was removed from the tube and placed into the magnet and left for 
5min. Without disturbing the nature of the beads, the magnet and tube were picked up 
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together and inverted, pouring the remaining solution fraction which contains the purified T 
cells into a fresh collecting tube.  
 
3.2.1.2: Rosettesep: 
The STEMCELL technologies Rosettesep assay used is a negative selection kit similar to 
Easysep but is designed to eliminate the need for a second stage with magnetic beads and 
instead incorporates isolating the T cells with removing the red blood cells from the whole 
blood. The Rosettesep kit includes a cocktail which cross links PBMCs not of interest to the 
red blood cells so that they are pelleted with red blood cells in a density gradient 
centrifugation.  
Rosettesep Human T cell Enrichment cocktail was added to the whole blood at 50µl per ml 
of blood and then the blood was mixed well. The blood was incubated at room temperature 
for 20 mins and then diluted 1:1 with PBS containing 2% FCS and 1mM EDTA. Blood was 
then layered carefully to prevent mixing over a density medium such as lymphoprep in a 
50ml falcon tube and the sample was spun as per blood separation method, general 
methods. The lymphocyte fraction contained only T cells. This fraction was collected and 
the rest discarded.  
 
3.2.1.3: Miltenyi 
The Miltenyi T cell isolation kit, like the Easysep kit, utilises magnetic beads although, rather 
than having to tip off the cells of interest, the Miltenyi kit passes the bead-containing mixture 
through a column of similar magnetic beads which allowing only unbound cells to pass 
through. 
Cells were counted and prepared such that there were 107 cells in 40µl PBS with 2% FCS 
and 1mM EDTA. 10µl Pan T cell Biotin-Antibody Cocktail was added per 107 cells and mixed 
well then the mixture was refrigerated at 2-8OC for 5 min. 30µl of PBS with 2% FCS and 
1mM EDTA and 20µl Pan T cell MicroBead Cocktail were then added per 107 cells. The 
mixture was incubated for 10mins at 2-8 OC. The MACS magnetic column was then 
assembled and washed with 3ml of PBS containing 2% FCS and 1mM EDTA. A suitable 
collecting tube was placed underneath the column and the cell suspension was added to 
the column. Another 3ml of PBS containing 2% FCS and 1mM EDTA was then added to 
the column and the run-off was added to the initial collection. This stage is in place to collect 
any T cells stuck in the column.  
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3.2.1.4: Plastic: 
Incubating the PBMCs in a culture flask overnight takes advantage of the nature of some 
PBMCs to adhere to the plastic surface, for example monocytes, such that a more enriched 
T cell suspension can be poured off.  
PBMCs were suspended at 1x106 in their culture medium and incubated overnight at 37OC 
in a culture flask. All remaining PBMCs in solution were then poured into a suitable 
collecting container and kept as this was the T cell-containing fraction. 
 
3.2.2: Fresh and frozen cell comparison 
As the main aim of this study was to establish a flow cytometry panel assay which could be 
used to determine differences in patient cells, it needed to be established if patient cells 
may be frozen prior to their use in the assay or if they must be used fresh. Logistically, using 
frozen cells would be far more feasible as many samples could then be collected and 
processed at the same time.  
Blood was collected from 3 healthy volunteers and PBMCs were isolated as per the protocol 
outlined in Chapter 2: General methods. T cells were then isolated from the blood using the 
Easysep T cell enrichment kit, protocol described in section 3.2.1.1. Half of these cells from 
each volunteer were then frozen using the cell freezing method outlined in Chapter 2: 
General methods. The other half were stained with CFSE dye and incubated in their media 
their substituted RPMI containing 10µl Dynabeads and 50U/ml IL-2 to induce proliferation. 
Cells were extracted each day including day 0, the day the experiment was set up, until 
media discolouration occurred, which implied that the cells had depleted their media 
nutrients and begun to die, and also until proliferation peaks could be seen on analysis with 
the flow cytometer. For flow cytometer analysis, cells were stained with APC-anti-CD3 to 
allow gating round all T cells.  
 
3.2.3: Jurkat cells 
Jurkat cells (ATCC® TIB-152™) were kindly provided by Dr K. Padgett, Faculty of Health 
and Life Sciences, Northumbria University.  
It was initially intended to use Jurkat cells in T cell proliferation experiments to monitor the 
effects of proliferation in different conditions and to optimise assays. This would theoretically 
be more convenient than using primary T cells which would involve the need for a healthy 
volunteer and isolation of the PBMCs every time. Jurkat cells survive in culture for a number 
of passages, giving an advantage over using primary cells.  
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3.2.3.1: Jurkat growth curve 
Firstly, the optimal conditions and concentrations for optimal growth were established. Cells 
were allowed to grow to 80% confluency in a flask then plated in triplicate in a 24-well plate 
at 1x105 cells/ml. Every 24 hours, cells were counted using a haemocytometer and trypan 
blue staining. These are displayed on a graph so that the optimal growth period can be 
established from the steepest positive gradient straight line portion of the graph and the 
number of days until cells die off without a media change or splitting can also be established, 
and the concentration of cells at which this happens.  
 
3.2.3.2: Jurkat healthy cells bead titration 
To establish the concentration of Dynabeads which is most appropriate for 
proliferation of Jurkat cells, a titration experiment was carried out to compare the 
effect of different concentrations of Dynabeads on Jurkat cells with the same 
concentration on healthy control cells. Cells were stained with CFSE dye and 
incubated for 3 days in the presence of 50U/ml IL-2 and every 24 hours including 
the set up day, day 0, cell samples were harvested for staining with APC-anti-CD3 
for analysis by flow cytometry.  
 
3.2.4: Priliminary proliferaton experiment 
T cells were isolated from whole blood of 3 volunteers by first using the PBMC isolation 
method and then purifying the T cells using the easysep method described in section 
3.2.1.1. T cells were then CFSE-stained and set up for proliferation in the presence of 10µl 
Dynabeads T cell proliferation beads and 50U/ml at different concentrations of UDCA in a 
24-well tissue culture plate for 3 days. Samples were extracted from culture every 24 hours 
and prepared for flow cytometric analysis by method and stained with anti-CD3APC. CD3+ 
T cells are gated around and then analysed on a FITC-channel histogram to view 
proliferation peaks and compared to 0µM UDCA. The zero-UDCA contains the ethanol 
carrier at 0.3%, the same volume of ethanol as in all other wells. 
 
3.2.5: T cell proliferation methods 
Several proliferation methods were trialled, (anti-CD3 mitogen; IL-2; IL-2 plus Dynabead T 
cell proliferation beads; phytohaemagglutinin (PHA); phorbol 12-myristate 13-acetate 
(PMA) at different concentrations with ionomycin) to establish the most suitable for future 
assays. 
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Factors considered included: if the number of divisions could easily be counted based on 
the peak patterning and which cytokines are likely to be produced on activation by each 
method. If the cytokines give too much of a skew towards a particular T cell sub-type, then 
it may be difficult to observe a pattern in different T cells produced by different PBC 
populations.  
Section 2.2.5 of this chapter details optimising strategy in detail. Briefly, PBMCs were 
isolated from whole blood by the method in Chapter 2: General Methods and stained with 
CFSE. Each of the assays for testing was set up with PBMCs at 1 x 106/ml across 5 x sterile 
5ml flow cytometry tubes and incubated for up to 7 days, with a tube used at days 3, 4, 5, 
6 and 7 and stained with dead/alive comparison dye DAPI for flow cytometric analysis for 
proliferation.  
 
3.2.5.1: Anti-CD3 mitogen 
The αCD3 mitogen is a monoclonal antibody that binds to the ε-chain of CD3. CD3 is the T 
cell antigen receptor and the ε-chain is non-antigen related. The αCD3 mitogen binds and 
crosslinks the TCR, mimicking the effect of binding an antigen and related MHC. Although 
unable to cause a response in the T cell due to lack of a surface the T cell can be cross-
linked to, αCD3 is sufficient to cause proliferation of the T cell in the presence of IL-2, which 
is provided by other PBMCs when it is a PBMC cell suspension (Jason and Inge, 1996). 
The αCD3is diluted 1/200 from 1mg/ml to 5μg/ml in complete RPMI for working 
concentration use.  
 
3.2.5.2: IL-2+beads 
Dynabeads Human T-Activator beads can be used to stimulate proliferation of T cells. They 
consist of metal beads bound with anti-CD3, anti-CD28 and anti-CD137 (glossary ref here). 
IL-2 is also added to the culture to induce proliferation at a concentration of 50 U/ml. 
The beads are magnetic so that they can be removed prior to flow cytometry if necessary.  
The required volume of Dynabeads is first calculated using the guide provided in the 
information pack with the kit and these are placed in a vial and mixed 1:1 with PBS 
containing 2% FCS and 1mM EDTA. The vial is placed in the magnet and left for 5min. All 
liquid is poured into waste and then the beads are resuspended in their initial volume, of 
PBS with 2% FCS and 1mM EDTA. Beads are required to be added at a ratio of 1:1 beads 
to cells, therefore, according to the manufacturer guidelines, a final cell concentration of 1 
x 106 will require 25µl per ml of cells. However, in this study a titration was carried out which 
showed adequate T cell proliferation using only 10µl of beads, as shown in the results 
section of this chapter, figure 3.3.3.2, therefore 10µl of beads would be used in further 
experiments. 
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3.2.5.3: IL-2 alone 
IL-2 is added to the cells at a concentration of 50 U/ml to see compare with IL-2 and 
Dynabeads to see what difference adding the beads makes compared with just IL-2.  
IL-2 is a cytokine which targets T cells, B cells, NK cells, monocytes and macrophages. 
Downstream mechanisms of IL-2 include inducing proliferation in and inducing expression 
of more IL-2 and IL-2R in CD3+ T cells. In theory, IL-2 is insufficient to induce proliferation 
alone in the absence of antigenic response, however some groups have recorded increased 
T cell proliferation in vitro even without adding antigen (Kennell et al., 2014). Therefore, IL-
2 will be tested for its ability to proliferate T cells in the PBMC population and compared to 
other T cell proliferating methods. 
 
3.2.5.4: Phytohaemagglutanin (PHA) 
The poorly-defined mechanism by which PHA causes T cell expansion is thought to involve 
the alternative activation pathway of CD2. CD2 offers an alternative proliferation pathway 
for T cells to CD3, and potentially gives a larger response with more IL-2 released and 
stronger Th cell responses. A lectin, PHA binds to glycoproteins on the cell surface, 
including the TCR, and cross links them, inducing metabolic activity and cell division 
(O'Flynn et al., 1986). It can be predicted that this method will not give reliable proliferation 
results by way of a predictable peak patterning on CFSE staining as the alternative pathway 
can induce apoptosis and is generally a more sporadic pathway (Wesselborg et al., 1993).  
 
3.2.5.5: Phorbol 12-myristate 13-acetate (PMA) + ionomycin 
PMA, a small organic compound, diffuses through the cell membrane and into the cell, 
directly activating protein kinase C, thus bypassing the need for cell surface glycoprotein 
cross linking.  
Ionomycin is used in conjunction to raise intracellular IL-2, IL-4, IFN-γ and perforin and the 
intracellular Ca2+ level, which is required for intracellular signal transduction (Heit et al., 
2006). 
The concentration of PMA to use depends on the cell type, therefore it is necessary to titrate 
the concentration to obtain optimal concentration of PMA to proliferate T cells. The standard 
1µg/ml of ionomycin is used along with 0.5, 5.0 or 50ng/ml PMA, depending on the result 
of the titration, therefore all of these concentrations are used in this assay. 
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3.2.6: Flow Cytometry preparation 
3.2.6.1: Antibody titration 
It is necessary to find the optimal staining concentration for antibodies before their use in a 
major flow cytometry experiment. The antibody is diluted 1 in 10 with PBS such that very 
small volumes of antibody can be added accurately, avoiding pipetting tiny volumes of 
undiluted antibody. Cells are stained as per flow cytometry staining method outlined in 
Chapter 2: General methods, but taking into account the different volumes and the dilution 
of the antibody, and run on the flow cytometer. The ideal stain concentration range is taken 
from a graph of concentration of antibody in cell suspension during staining against the 
standard index, calculated by the below formula: 
Standard Index, SI = (medianpos – medianneg) / 2xSDneg 
The ideal range of antibody concentrations is the upper-most portion of the curve, as shown 
in figure 3.3.5.2. 
 
3.2.6.2: Voltages 
Voltages for each antibody need to be adjusted to ensure that both the negative and positive 
peaks are visible in the displayed range. There is a method to determining the optimal 
voltage range for each dye (Maecker and Trotter, 2006), however in practise the most 
important aspect is that the positive and negative peak are clearly visible and fully between 
0 and 105 on the x axis such that no extremely low or high values are cut off by the limitations 
of the graph. Voltage adjustment is carried out for every dye to ensure they satisfy this 
criterion using the voltage menu in the FACSDiva software. Figure 3.3.5.2 shows the 
maximum range of voltages permissible. In this dye, anti-CD8 PE-Cy7, ideally the voltage 
would be decreased to move the positive peak below the 105 mark on the x axis, however 
doing this would move the negative peak to below the zero. Adjusting the voltage for each 
dye is important for before compensating the dyes. 
 
3.2.6.3: Fluorescence Minus One, FMO 
Fluorescence Minus One, FMO, analyses must be carried out for each antibody to ensure 
that the gates for positive and negatives are in fact in the correct places. The FMO uses 
every dye except the dye in question to help place the negative gate for that dye. The 
negative gate cannot be placed based on unstained cells because this is not indicative of 
how the other dyes interact with that channel, which for the demonstrative figure is the 
BV510 channel. Figure 3.3.5.4 shows the difference between unstained cells and the FMO. 
The FMO gives a more accurate negative because it allows ruling out of spill-over 
fluorescence from other dyes.  
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3.2.6.4: Isotype negatives 
Using an isotype negative for an antibody is a way of determining how inclined the cell is to 
randomly bind antibodies of this isotype despite non-specificity, or how inadequate the 
blocking stage of the staining protocol is. The isotype negative is used in place of the 
antibody to test how many positives there are. The isotype negative is an antibody of the 
same isotype as that in question and with the same conjugate but is raised against a random 
antigen, not present on the cell. Therefore, any positive readings in the channel in question 
are likely due to not all non-specific binding sites being blocked effectively (Baksh et al. 
2007).  
 
3.2.6.5: Doublet and clump discrimination 
When 2 or more cells stick together, then 2 cells may be unintentionally read as one cell, 
therefore a dye can appear twice as bright as it actually is. To ensure only singlet cells are 
examined, a graph of forward scatter height against forward scatter area. Forward scatter 
can be indicative of cell size. ‘Height’ describes a cell’s total maximum signal, ‘Width’ 
describes the time the cell spends passing through the laser beam and ‘Area’ is a total of 
all of the ‘H’ readings made during time ‘W’. Cells that show a smaller ‘Height’ per unit ‘Area’ 
are likely clumps or doublets because they also then give more ‘Area’ per unit ‘Height’, so 
more readings per unit cell size, implying there are more scatter readings than expected for 
something which should only be one cell. These cells are gated out so that those cells 
analysed are likely only singlets. This is important because if analysing doublets, it may 
appear as though there are twice as many biomarkers in one cell than there actually are. 
Gating out the doublets and clumps is illustrated in figure 3.3.7.2.1.  
 
3.3: Results 
3.3.1: Method of T cell isolation 
Four methods of T cell enrichment were compared for their efficiency at producing a pure 
enriched T cell population. Easysep was chosen based on giving a greater percentage of 
CD3+ cells and also more total CD4+ T cells plus CD8+ T cells.  
Figure 3.1 shows the gating flow cytometric analysis for how these results were obtained 
and table 3.1 shows the tabularised results from the gating in figure 3.3.1, as counted using 
FACSDiva software.  Table 3.3.1 shows that there are 95.51% T cells in culture isolated by 
the Easysep method when gated by CD4+ and CD8+ presence and 98.58% T cells in 
culture when gated by CD3+ presence, higher values in both criteria than any other method.  
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Figure 3.3.1: Flow Cytometry counting of T cell sub sets for isolation kit 
comparison 
This figure shows how the cells are gated and analysed for their surface markers. The top 
graphs in black show gating around the lymphocyte fraction based on side scatter and 
forward scatter separation. The bottom graphs show gating to discriminate the different 
cell populations. The number of cells within a gate or quadrant are counted by the 
software. 
a: The graph is separated into quadrants where Q1 gates around CD4+CD8- cells, Q2 
gates around CD4+CD8+ cells, Q3 gates around CD4-CD8- cells and Q4 gates around 
CD4-CD8+ cells. Quadrants Q1, Q2 and Q4 are totalled. 
b: The histogram feature is used to quantify all anti-CD3 PerCPvio700 positive cells (P4). 
 
 
 
a 
 65 
 
Table 3.3.1: Table to compare T cell isolation methods. 
This table shows the percentages of CD4+, CD8+, CD4+CD8+ and CD3+ T cells within 
the lymphocyte gate shown in figure 3.3.1, isolated using each of the different methods 
outlined in section 3.2.1: Methods.  
 
3.3.2: Fresh and frozen primary T cell comparison 
T cells isolated from the whole blood of 3 healthy volunteers were proliferated using IL-2 
and proliferation beads where one sample from each patient was frozen and reanimated 
and the other sample was freshly isolated and not frozen. Fresh and frozen proliferation 
results were compared by t testing by counting the populations of 1 and 2+ shown in figure 
3.3.2 and no significant results were found, therefore it was determined that frozen cells 
could be used if inconvenient to use fresh cells, particularly in incidences of receiving large 
numbers of patient blood samples. However, in order to ensure experimental parity any 
experiment using patient cells would use frozen cells. 
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Figure 3.3.2: Fresh and frozen proliferation comparison 
This is a comparison between cells frozen to -150oC then reanimated and cells isolated 
from fresh whole blood and used immediately. Stimulated samples have IL-2 and 
proliferation beads added to induce proliferation. There was no significant difference 
found between divided frozen cells and divided fresh cells. Unstimulated cells are 
included to illustrate that the right-most peak on proliferation graphs is likely 
representative of cell proliferation without any stimulant. 
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3.3.3: Jurkat cells 
3.3.3.1: Jurkat cells growth curve 
Figures 3.3.3.1 a and b show the growth of Jurkat cells and healthy volunteer cells over 
time. This graph suggests that Jurkat cells appear to proliferate uniformly until day 8 when 
they begin to die, as shown by the drop off in the lines. Healthy T cells proliferate more 
sporadically, not closely following the average line.  
 
3.3.3.2: Jurkat cell proliferation assay 
Figure 3.3.3.2 shows Jurkat cell proliferation using Dynabeads, mechanism of action 
outlined in section 3.2.2, compared with proliferation of healthy volunteer T cells using 
Dynabeads. With the healthy controls, there are clear fractions of T cells which have 
proliferated a discrete and measurable number of times relative to the right-most peak. The 
area under the curve of each peak is indicative of the number of cells in this fraction and 
can be counted using the software. Regarding the Jurkat cells, for all concentrations of 
Dynabeads there is only one peak from which no proliferation data can be inferred, 
suggesting that Jurkat cells are inappropriate for further cell proliferation experiments.  
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a.  
b.  
Figure 3.3.3.1: Growth curve of cells of the JURKAT cell line. 
a: The graph shows the number of cells counted per ml over time, encompassing lag 
phase, exponential phase, plateau and death phase. 
b: This graph shows a growth curve of healthy volunteer T cells isolated from PBMC 
culture, isolated from whole blood of a healthy volunteer.  
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Figure 3.3.3.2: Proliferation bead titration for healthy T cells and JURKAT cells.  
JURKAT cells are compared by their proliferation pattern to healthy T cells isolated form a 
volunteer to assess their use as an adequate model cell line in T cell proliferation studies. 
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3.3.4: Flow cytometry preliminary data 
A preliminary experiment was carried out to determine if there was an effect on T cell 
proliferation of isolated T cells by UDCA which could then direct further investigation into if 
different subtypes were affected differently. Figure 3.3.4.1 shows the pattern of proliferation 
peaks visible when cells have divided by different numbers of divisions within the 
population. The far-right and most CFSE-intense peak is representative of cells which have 
not proliferated or cells which have proliferated the minimum number of times among the 
population, and this peak is used as the ‘undivided’ reference, which is possible when the 
far-right peaks line up across different concentrations including zero, which was the case. 
It was found that there was a significant difference in divided cells between cells incubated 
with 300µM UDCA and 0µM UDCA, as shown in figure 3.3.4.2 where t-testing proliferation 
of T cells in 300µM UDCA with proliferation of T cells in 0µM UDCA gives a p value of 0.039, 
which is significantly different. 
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Figure 3.3.4.1: Flow cytometric acquisition of counts of cells at different 
proliferation numbers. 
Individual peaks in the histogram indicate number of divisions past the far-right peak of 
either zero divisions or the minimum number of divisions observed across the experiment. 
The fewer divisions the less dilution of the dye has occurred and the higher the intensity of 
CFSE. The table shows counting of cells in each group with cells in peaks 1, 2 and 2+ 
added to give total proliferated.  
 
 
 
 72 
 
Figure 3.3.4.2: Graph displaying average percentages of proliferated T cells of the 3 
volunteers. 
The graph includes error bars as the standard error of the data. There is a significant 
difference between cells divided at 300µM and 0µM UDCA (p=0.039).  
 
3.3.5: Flow Cytometry Optimisation 
Antibodies for use in flow cytometry were titrated to optimise the ideal concentration for their 
use. Figure 3.5.1 shows how populations of positively stained and negatively stained dyes 
are gated using FACSDiva software. The software can be used to give mean values, 
median values and standard deviations from the mean for the points within a gate in terms 
of their x and y axis readings.  Figure 3.3.5.2 shows the graph plotted to infer ideal 
concentration and table 3.5.1 shows the calculated values used to plot this graph. Figure 
3.3.5.2 shows that 30ng/ml of antibody is within the ideal range and table 3.3.5.1 indicates 
that this is obtained by adding 2μl of raw antibody. 
Optimisation of voltages is carried out using FACSDiva software. Figure 3.3.5.3 shows an 
example of optimised voltage peaks. The negative peak, labelled, needs to be readable 
above 0 intensity and the positive peak, labelled, must be ideally below 105. This is so that 
both positively and negatively stained cells are comparable on the same graph. The 
voltages for each dye were adjusted using commands in the FACSDiva software to position 
the peaks for each dye to satisfy these criteria. 
Negative gates for dyes are calculated using FMOs. Finding one FMO is depicted in figure 
3.3.5.4. This is important because, as figure 3.3.5.4 shows, gating on the unstained alone 
does not accurately allow for negative gating in the context of all other dyes added together 
as there is an element of background into a channel from dyes for other channels. 
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Throughout this study, isotype negatives were used to assess the ‘stickiness’ of the cells in 
question. Use of isotype negatives was incorporated into the FMO experiment, where 
isotype negatives were used instead of unstained. 
After gating out lymphocytes, singlets were discriminated from doublets or clusters using 
the criteria outlined in section 3.2.6.5. Figure 3.3.7.2.1 shows the lymphocytes selected, 
and then applied to a FSC-H vs FSC-A graph and the singlets gated around for further 
counting. The singlet gate determines cells examined in the following graph, which selects 
for live and dead cells. 
In addition, all dyes were compensated for spectral overlap by adjusting the voltage 
parameters. This is carried out using scatter plots of all dyes against each other, selecting 
statistical view and then adjusting the voltage parameter for each dye such that for one 
particular dye, the positive mean and negative mean are the read at close to the same value 
on the other dye (not shown). This is important because it standardises positive and 
negative measures for each dye against the other, controlling for low level noise spilling into 
one channel from another. 
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Figure 3.3.5.1: Images copied directly from FACSDiva software showing the 
acquisition of numeric data for the antibody titration of anti-CD3 BV421. 
a shows the histogram peaks where the positive and negative peaks are discernible.  
b shows the scatter plot and gating of the positive and negative populations. 
c shows the results from counting of the numbers of cells in each gate from b. The 
software can be manipulated to also calculate the mean, median and standard deviation 
within the populations. 
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Volume 
added 
(µl) 
Mass 
antibody 
(ng) 
Final 
conc. 
(ng/ml) 
Medianpos Medianneg SDneg 2xSDneg SI 
20 60 300 2143 657 151 302 4.92 
10 30 150 2173 861 148 296 4.43 
7.5 22.5 112.5 2073 786 154 308 4.18 
5 15 75 1762 509 117 234 5.35 
2 6 30 916 176 51 102 7.25 
1 3 15 521 96 34 68 6.25 
0.5 1.5 7.5 446 96 35 70 5 
Table 3.3.5.1: Table of values used to plot the graph of 3.3.5.2.  
This graph shows the values established as per figure 3.5.2 for all of the different 
concentrations of antibody used in the antibody titration for this particular dye. The 
Standard Index (SI) is calculated using the formula: 
Standard Index, SI = (medianpos – medianneg) / 2xSDneg 
The volume added is from a dilution of 1 in 10 of the original antibody concentration in 
order to allow the antibody to be titrated to very small concentrations avoiding a high error 
from the pipette. The mass of antibody and final concentration are calculated from the 
manufacturer stated concentration of undiluted antibody. 
 
 
Figure 3.3.5.2: Graph of final concentration of antibody against standard index of 
dye for antibody titration assay. 
Values in table 3.3.5.1 were plotted to give this graph to establish the ideal concentration, 
labelled here as ‘Ideal antibody range’. Concentrations in this range, shown as giving the 
highest SI values, whereby the concentrations are readable on the x axis, give the largest 
distance between the positive and negative values per unit standard deviation, therefore 
the values are the best distance apart while including values with less variance which can 
make values difficult to distinguish. 
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Figure 3.3.5.3: Voltage optimisation for anti-CD8 PECy7 dye. 
This histogram shows the number of counts per unit intensity of fluorescence for voltage 
optimisation for the anti-CD8 PECy7 fluorescent antibody. The negative peak, labelled, 
needs to be readable above 0 intensity and the positive peak, labelled, must be ideally 
below 105. This is so that both positively and negatively stained cells are comparable on 
the same graph. 
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Figure 3.3.5.4: Figure illustrating the difference between using the unstained 
population for the negative gate and using the FMO 
The unstained graph would suggest that the negative gate can be applied at around the 
5x102 mark on the x axis, whereas the FMO, which takes into account spill-over from 
other channels and is more accurate, shows the truer negative to be gated at 
approximately 9x102. This illustrates the discrepancy between the unstained and the 
FMO and highlights the importance of using the FMO, not the unstained, for reference 
when plotting the negative gate.  
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3.3.6: Determination of method of proliferation to be used 
There are many different T cell proliferation methods accepted in the literature for use in T 
cell expansion studies, outlined in section 3.2.5.1. In order to decide which would be the 
most appropriate for further studies, examining and quantifying T cell subsets in the 
presence of different concentrations of UDCA, some available T cell proliferation methods 
were tested and compared by methods outlined in section 3.2.5.1. The normal ration of 
CD4/CD8 T cells is usually approximately 2.0 (Bogner et al., 1989), so methods were 
examined for their ability to maintain this ratio and not give to much of a CD4 or CD8 bias. 
Also, proliferation needed to be approximately uniform across divisions such that divided 
cells could be discriminated from undivided cells for their accurate quantification. Figures 
3.3.6.1 show bar charts depicting the relative levels of cells within gates at each gating 
stage and allows visual comparison of CD4+ and CD8+ divided cells between days and 
methods. For example, comparing IL-2 with IL-2 and beads can show that by adding 
Dynabeads there is much greater proliferation of T cells, but the ratio of CD4/CD8 looks like 
it is roughly maintained where the CD4 bar is larger than the CD8 bar throughout all days.  
Table 3.3.6.1 shows the quantified amounts of cells within each gate by percentage of 
parent gate, where lymphocyte number shows percentage of all input that are lymphocytes. 
‘Singlets’ shows the estimated percentage of lymphocytes not in doublets or clumped due 
to sticking together which can happen during cytometry preparation as cells are centrifuged 
a number of times. ‘Live’ indicates the percentage of singlet cells which did not absorb the 
DAPI stain, therefore are likely alive. Cells within this live gate are examined on CFSE 
graphs to discriminate divided and undivided. All divided cells are counted and also CD4+ 
and CD8+, as shown by the CFSE scatter graphs coming from the live cell graph.  
The quadrant graph shows all CD4+ cells as those right of the vertical division line and all 
CD8+ cells as all of those above the horizontal division line. The upper right quadrant shows 
that some cells are CD4+/CD8+, however these were a negligible percentage (<0.1% total 
divided cells) so were unlikely to interfere with the overall CD4/CD8 ratio. 
Table 3.3.6.1 and figures 3.3.6.1 show that anti-CD3 gives a sudden increase in CD8 T 
cells dividing at day 5, with CD4:CD8 being 16.8:37.5 on day 5 after 14.1 to 0.5 on day 4. 
CD8 cells. This low CD4/CD8 ratio is maintained through to day 7 with 25.1:41.9. PHA gives 
relatively low CD4+ and CD8+ proliferation compared to the other methods, with the 
maximum proliferation occurring at day 7 with 9.6% and 2.6% of divided cells making up 
CD4+ and CD8+ T cells respectively. IL-2 alone gave similarly low results of 4.4% and 2.0% 
at day 7. PMA methods with 5.0 and 50ng/ml ionomycin giving a very low CD4/CD8 ratio 
referring to percentage of divided cells, most apparent with 5.0ng/ml ionomycin with 2.5% 
divided cells CD4 and 57.5% divided cells CD8 at day 7. Figure 3.3.6.1 displays the trend 
for CD8 to be higher than CD4 for PMA with 5.0 and 50ng/ml ionomycin throughout the 
experiment. PMA with 0.5ng/ml ionomycin gives relatively low levels of proliferated CD4+ 
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and CD8+ T cells compared to other methods, with the day with the highest percentages of 
CD4+ and CD8+ T cells in the divided population being day 7, with 4.5% of divided cells 
CD4+ and 3.0% of divided cells CD8+.  
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Figures 3.3.6.1:Cell counts for various proliferation methods, days 3-5.  These bar 
charts display the % of divided cells at days 3. 4 and 5, proliferated by the different 
methods. The series names indicate the criteria by which cells were gated, displayed in 
figure 3.6.2. ‘Lymphs’ refers to lymphocytes gated based on forward and side scatter 
criteria described in section 3.1.1. 
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Figure 3.3.6.1 cont.:  
Cell counts for various proliferation methods, days 3-5. 
These bar charts display the % of divided cells at days 3. 4 and 5, proliferated by the 
different methods. The series names indicate the criteria by which cells were gated, 
displayed in figure 3.6.2. ‘Lymphs’ refers to lymphocytes gated based on forward and side 
scatter criteria described in section 3.1.1. 
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Percentages of cells: 
   Method Lymphs Singlets Live DividedCD4 DividedCD8 
Day 3 
Unstim 85.1 99.3 98.0 0.5 0.7 
αCD3 91.1 98.7 98.5 14.1 0.5 
PHA 83.6 99.5 98.6 0.7 0.5 
PMA50% 54.1 78.3 96.2 2.6 20.7 
PMA5% 31.2 84.1 98.9 0.5 37.5 
PMA0.5% 71.4 99.1 94.5 0.7 0.6 
IL2+beads 76.3 98.3 93.9 18.7 8.3 
IL2 79.3 99.2 97.3 0.7 0.6 
Day 4 
Unstim 81.9 84.0 99.7 0 0.7 
αCD3 84.6 90.7 99.4 16.8 37.5 
PHA 81.0 85.7 99.7 0.6 0.8 
PMA50% 46.1 66.8 93.4 5.9 26.1 
PMA5% 66.7 68.4 98.6 6.3 44.1 
PMA0.5% 74.4 87.5 100 1.4 1.3 
IL2+beads 78.6 87.0 88.6 26.7 18.5 
IL2 83.3 85.3 99.9 0.7 0.7 
Day 5 
Unstim 73.8 88.6 99.9 2.8 1.9 
αCD3 68.0 89.5 100 21.5 36.4 
PHA 74.5 89.0 99.9 2.5 1.6 
PMA50% 8.2 46.0 66.9 9.4 28.7 
PMA5% 45.1 42.4 93.6 8.6 60.0 
PMA0.5% 60.5 86.5 99.5 2.2 1.8 
IL2+beads 65.4 89.4 99.8 27.1 21.9 
IL2 72.2 88.4 99.9 2.3 1.5 
Day 6 
Unstim 64.2 78.9 99.9 4.6 2.3 
αCD3 74.6 90.9 99.8 22.3 38.9 
PHA 80.0 86.3 99.9 5.6 2.2 
PMA50% 10.4 43.9 89.5 4.1 22.4 
PMA5% 60.6 29.6 94.5 1.5 55.2 
PMA0.5% 61.8 86.8 99.9 2.3 1.6 
IL2+beads 59.4 87.1 96.2 32.5 25.6 
IL2 79.9 88.4 98.4 3.0 1.9 
Day 7 
Unstim 79.6 78.5 99.9 6.1 3.0 
αCD3 66.1 79.4 99.8 25.1 41.9 
PHA 73.8 80.7 100 9.6 2.6 
PMA50% 2.7 34 76.2 4.1 28.2 
PMA5% 51.9 17.7 93.9 2.5 57.7 
PMA0.5% 54.9 78.4 97.9 4.5 3.0 
IL2+beads 64.6 81.2 99.3 33.0 28.7 
IL2 78.7 79.5 100 4.4 2.0 
Table 3.3.6.1: Percentages of cells within the gating criteria for the proliferation 
method comparison experiment.  
The table shows percentages of cells within a gate of the whole parent population, for 
example ‘Lymphs’ (referring to lymphocytes) shows the percentages of cells within the 
lymphocyte gate of all cells registering on the forward/side scatter graph; ‘Singlets’ 
readings indicate the percentage of cells that are considered singlets from the lymphocyte 
population. Gating of populations is depicted in figure 3.3.6.2. 
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Figure 3.3.6.2: Gating of populations from their parent populations using FACS-
Diva software 
This figure shows the gates used in communicating with the FACS-Diva software which groups of 
cells to count, based on decided parameters. From a population, the sub-population of interest is 
isolated and gated around. The lymphocyte population is selected based on known side and 
forward scatter criteria; the singlets are gated based on height-area forward scatter proportionality, 
explained more in section 1.1; live cells are selected based on being DAPI-stain negative; divided 
cells are selected based on being less CFSE positive than the most CFSE-rich (least divided) 
population; CD4+ and CD8+ are selected based on presence of the relevant dye. Gating criteria is 
outlined in further detail in section 2.6.  
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3.3.7: Finalisation of flow cytometric assay 
There were 2 fluorescent antibody panels for consideration. One, shown in figure 3.3.7a, 
uses only one tube, whereas the other, shown in figure 3.3.7b and c (used in conjunction) 
uses 2 tubes.  
Figure 3.3.7a shows a panel, Panel 1, with the potential of differentiating Tregs, Th1, Th2 
and Th17 T cells: CFSE identifies and allows quantification of number of proliferation cycles 
of cells; CD3+ identifies T cells; CD4 discriminates CD4+ T cells such as helper T cells from 
other T cell subsets (such as cytotoxic T cells); CD4, CD25 and FoxP3 in conjunction 
identify Tregs and further along with CD45RO identify memory Tregs; CD4+ and presence 
of CXCR3 but absence of CCR6 identifies Th1 cells; CD4 and presence of CCR6 but 
absence of CXCR3 identifies Th17 cells and CD4 and absence of CXCR3 and CCR6 
identifies Th2 cells, as explained in section 3.1.1.1  
Figure 3.3.7b and c shows a panel, Panel 2, of 2 tubes used in conjunction where the above 
parameters apply over 2 tubes with the addition of CD8 to identify cytotoxic T cells in 
conjunction with CD3 and DAPI to allow discrimination of live cells from dead cells.  
Panel 1 is advantageous over Panel 2 whereby more data can be obtained from fewer cells, 
whereas Panel 2 has the potential to obtain more data overall, but more cells are required. 
 
a: 
Channel: FITC PE 
PerCP-
Cy5.5 
PE-
Cy7 APC 
APC-
CY7 BV421 BV510 
Dye: CFSE CD25 CD45RO FoxP3 CCR6 CD4 CXCR3 CD3 
b: 
Channel: FITC BV510 
PE-
Cy7 APC 
PerCP-
Cy5.5 
BV421 
Dye: CFSE CD4 CD8 CCR6 CXCR3 DAPI 
c: 
Channel: FITC APC PE 
PE-
Cy7 
PerCP-
Cy5.5 
Dye: CFSE CD4 CD25 FoxP3 CD45RO 
Figure 3.3.7: Tables showing fluorescent antibody panels for identifying different 
subsets of T cells.  
These tables depict different antibody panels for flow cytometry use to analyse the 
quantities of different T cells of different patterns. ‘a’ was the initial designed panel which 
could envision Treg and T cell subsets using just one tube where ‘b’ and ‘c’ would 
separately investigate helper/cytotoxic T cells and Tregs, to be used in conjunction with 
each other.  
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Figures 3.3.7.1.1 and 3.3.7.2.1 show Panel 2 cell gating which leads to data gathering 
shown in figures 3.3.7.1.2 and 3.3.7.2.2. Lymphocytes are gated based on known forward 
and side scatter criteria and, from those, the further sub-populations are gated. The actual 
cell counts and percentage parent populations are displayed by the software in table form, 
shown in figures 3.3.7.1.2 and 3.3.7.2.2. This data was then tabularised and analysed in 
chapter 4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 86 
 
Figure 3.3.7.1.1: Gating criteria for Treg results  
This figure shows how each population is gated from its ‘parent’. Lymphocytes are gated 
based on known side and forward scatter properties; CD4+(APC+) cells are then gated 
and divided CD4+(CFSElow) cells are gated from these; Treg cells are then gated based 
on FoxP3+ and CD45RO-/+ are then discriminated (where PercpCy5.5+ is CD45RO+) 
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Figure 3.3.7.2.1: Gating criteria for typing helper and cytotoxic T cells 
This figure shows how each population is gated from its ‘parent’ population. Lymphocytes 
are gated based on side/forward properties, singlets are gated based on proportionality 
between proportionality between forward scatter ‘height’ and ‘area’; live cells are gated by 
those that are DAPI-negative; divided CD4+ and 8+ cells are then gated (CFSElow) and 
then subsets are gated based on their CXCR3+/- and CCR6+/- criteria. 
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Figure 3.3.7.1.2: Quantification of numbers of cells within the gates depicted in 
figure 3.3.7.1.1 for proliferation of different types of CD4+ T cell analysis. 
All events indicates the total number of particles examined within the parameters of the 
set forward and side scatter voltages. Percentage parent indicates the percentage of cells 
within the previous population that satisfy the gating criteria of this population. The parent 
population is the population of cells shown in a scatter graph that were used to select this 
population from. 
 
 
 
Figure 3.3.7.2.2: Quantification of numbers of cells within the gates depicted in 
figure 3.3.7.2.1 for proliferation of Treg analysis. 
All events indicates the total number of particles examined within the parameters of the 
set forward and side scatter voltages. Percentage parent indicates the percentage of cells 
within the previous population that satisfy the gating criteria of this population. The parent 
population is the population of cells shown in a scatter graph that were used to select this 
population from. 
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3.4: Discussion  
3.4.1: Aims 
The primary aim for this chapter was designing a flow cytometry assay with the ability of 
differentiating T cell sub sets. This assay would be able to detect an effect of UDCA on 
proliferation of T cells but also differentiate the T cell subsets to see if UDCA is causing a 
particular skew toward a certain subtype of T cell. The most impactful use of this assay 
would be in comparing the T cell profiles of UDCA responders and UDCA non-responders 
to assess if there is the potential for a more aggressive disease state to be related to a 
different T cell response to the relevant autoantigen.  
 
3.4.2: Method of T cell isolation 
Four T cell isolation methods were tested for their ability to produce a pure sample of 
isolated T cells. Easysep was chosen as the method for further experimental analysis of 
purified T cells as it gave the most pure culture compared with other methods, so culture is 
likely less influenced by remaining PBMCs than in any other. Table 3.3.1 and section 3.3.1 
show and outline that Easysep gives 95.51% or 98.58% T cell purity depending on 
quantification criteria.  
 
3.4.3: T cell proliferation fresh and frozen comparison 
It was determined that frozen cells were acceptable for use as they did not show significantly 
different proliferation to fresh T cells and the proliferation peaks looked similar across fresh 
and frozen groups. Figure 3.3.2 shows that sample 1 appeared to show decreased 
proliferation into the 2+ division from fresh to frozen, whereas sample 2 shows the opposite. 
Sample 3 shows similar-looking proliferation peaks from fresh to frozen. Also, there was no 
statistically significant difference in average numbers of divided cells comparing fresh and 
frozen groups. 
 
3.4.5.1: Jurkat growth curve 
A Jurkat growth curve was plotted after a counting assay to display how Jurkat cells grow 
in terms of their proliferation and eventual death. This growth curve is shown in figure 3.3.1 
and can be compared with the growth curve of healthy volunteers in figure 3.3.3.1. The 
Jurkat cells show a more predictable and traditional growth pattern than the healthy cells. 
The Jurkat cells appear to proliferate in uniform until day 8, then plateau in number and 
then enter death phase in day 9, as per the pattern shown in figure 3.3.3.1. Primary T cells, 
growth curve depicted in figure 3.3.3.1, have a less uniform growth, roughly following a 
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pattern of number decline until day 4, then rising in number into day 5 before declining 
again. Unlike the jurkat growth curve, cells do not closely follow the average line. This data 
is not T tested because it was intended only to gain an idea of the growth of Jurkat cells 
compared with primary T cells to decide if it would be worth testing their proliferation with 
proliferation beads. As their growth appears predictable and uniform, it was decided to test 
them with proliferation beads to see if they can be used in proliferation experiments. 
3.4.5.2: Jurkat bead titration 
The recommended volume of proliferation beads (DynabeadsTM) to add for healthy cells is 
20µl per ml of cells at 1 x 106/ml. This is for primary human T cells, not Jurkat cells, therefore 
it is important to titrate the volume of proliferation beads to be added to Jurkat cells to give 
adequate proliferation.  
As shown in figure 3.3.2, the Jurkat cells do not proliferate in a distinct pattern as the healthy 
volunteer purified T cells do. The healthy T cells, when stained with CFSE, divide giving a 
distinct pattern when analysed by flow cytometry as the dye is diluted 50:50 between 
daughter cells and is therefore visible as a peak closer to the y axis with every subsequent 
division, as explained in section 3.2.3.2. The Jurkat cells proliferate in a manner that is not 
trackable. There are no series of distinct peaks, therefore, it is not possible to compare 
proliferated cells with unproliferated cells.  As the pattern of proliferation appeared to be 
different from that seen when using primary T cells it was decided to use only primary cells 
from healthy volunteers to develop the assay as these are expected to more closely 
resemble primary patient cells.  
In addition, it was decided to use only 10µl of proliferation beads despite the manufacturing 
guidelines suggesting twice this volume. Data in this chapter shows better proliferation with 
10µl where more cells enter each division fraction, including the 2+ divisions fraction where 
the peak is higher in comparison with other peaks in within the same graph in this band 
than with more beads, as apparent in figure 3.3.2. 
In figure 3.3.2, if the graph for 0 beads is compared to all other Jurkat graphs, there appears 
to be no difference. Figure 3.3.1, showing the growth curve for Jurkat cells, would indicate 
some growth after day 3, if the day 3 point is read at the y axis. It may be that the Jurkat 
cells need more time in culture before they begin dividing, or that they do not absorb the 
CFSE dye as readily as healthy T cells. 
The literature suggests that it is possible to obtain trackable proliferation with Jurkat cells 
and CFSE (Begum et al., 2013), however proliferation is slower than that shown in healthy 
volunteers in this study. Future experiments could incubate Jurkat cells for 3+ days before 
proliferation, however if healthy volunteers are available they should be prioritised over 
Jurkat cells as they do show fast proliferation by the methods in this study. Another limitation 
of using Jurkat cells is that using Jurkat cells cannot mimic T cell sub set variance within 
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the population and only faux t tests can be carried out, that is several measurements of 
essentially the same sample.  
 
3.4.6: Optimising the proliferation method  
Further to titrating the volume of proliferation beads to be added to cell culture, it was 
decided to experiment with other proliferation methods and determine the most effective 
that would not skew the T cell subsets too much from that expected in accordance with the 
literature. These methods were using an anti-CD3 mitogen; IL-2 and proliferation beads; IL-
2 alone; PHA; PMA at various concentrations with ionomycin.  
It was decided to use Dynabeads with IL-2 for further experiments using proliferation of T 
cells as the peaks were clearly discernible, such that it was easy to distinguish divided cells 
from undivided cells. Proliferation was consistently high, with some of the highest 
percentages of divided cells being CD4+ and CD8+, with 1.87% divided being CD4+ and 
8.3% divided being CD8+ on day 3 to 33.0% and 28.7% on day 7; conservative of the 
CD4/CD8 ratio, maintaining higher CD4+ than CD8+. 
Anti-CD3 giving a high CD8+ T cell percentage may be congruent with the literature in that 
one of the mechanisms is in causing increased IL-10, which, in some tumour environments, 
has been shown to cause expansion of tumour-resistant CD8+ T cells (Emmerich et al., 
2012). In addition, using anti-CD3 would come with the limitation of being unable to stain 
for cell surface CD3, as this may lead to competition for CD3 between the anti-CD3 mitogen 
and the anti-CD3 fluorescent antibody and therefore may produce a weaker signal for the 
fluorescent marker (Green, 2014). 
 
3.4.7: T cell subset identification panel 
As panel 2 has the potential to provide more information about the cell population than 
panel 1 as outlined in section 3.3.7, this panel was chosen over panel 1 despite the need 
for an extra tube of cells. It was noted that should cell abundance be inadequate, then panel 
1 would instead be used. For each experiment, the number of available cells will be counted 
and the number of cells required for planned experiments will be calculated to assess if 
there are sufficient available cells for panel 2, otherwise panel 1 will be used at the cost of 
additional information available in using panel 2. The number of available cells becomes 
important in patient blood studies where samples available are controlled by the Freeman 
hospital. 
One limitation using Panel 2 is in that cells are different shapes across panels under 
acquisition so voltages must be altered for side and forward scatter between tubes. The 
reason for this is because to stain for intracellular marker FoxP3 in the Treg tube, cells must 
be made permeable with an intracellular stain kit to allow the antibody against FoxP3 to 
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enter the cell causing the cells to be smaller in size. In addition, staining for FoxP3 is 
incompatible with DAPI staining because DAPI staining relies on live cells being 
impermeable to dyes, but the stain kit for FoxP3 renders cells permeable to DAPI as well 
as fluorescent antibodies, meaning all cells would stain positively with DAPI and appear 
dead.  
 
3.4.8: Limitations 
One limitation of the flow cytometric assay for analysis of helper T cell subsets is that there 
is no positive identifier specifically for Th2 cells: they are identified by being CD4+CXCR3-
CCR6-. This is acceptable in the literature as a Th2 identifying combination (Lubberts, 
2015), a more accurate Th2 identifying combination would be CD4+CCR6-CXCR3-CCR4+, 
as this eliminates the risk of falsely identifying a Th2 when either CCR6 or CXCR3 has been 
lost (De Jager et al., 2008). Due to there being a limited number of channels on the flow 
cytometric equipment used, this panel was designed to be a tester panel for if there were 
any measurable differences in T cell subsets, which could then be more further investigated 
with a more thorough panel which would include CCR4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 93 
Chapter 4: Further elucidating the mechanism of 
action of UDCA in PBC: investigating a direct 
effect on T cells in the cholangiocytes 
Abstract 
Although heavily studied, the precise mechanism of action of Ursodeoxycholic acid, UDCA, 
in PBC patients has not been fully elucidated. Most research into the mechanism of action 
of UDCA has thus far focussed on protection of the cholangiocytes and aiding movement 
of bile out of the liver but little research has been carried out to determine if the drug is 
having a direct effect on the damage-causing cells in the disease, particularly the T cells. 
Recent studies have suggested that there is more than one different type of disease under 
an apparent umbrella term of PBC and these differences have been discovered under the 
context of response or lack thereof to the drug UDCA. There is likely to be an underlying 
cause to this large disparity, possibly immunological. In this chapter, apoptosis assays, 
ELISpot assays, flow cytometric analyses and xCELLigence are used to investigate a direct 
mechanism of action of UDCA on immunological cells, in particular the T cells, which have 
been shown to be present in abundance around the cholangiocytes, at the site of 
inflammation in PBC. It was found that increasing concentrations of UDCA can have a 
negative impact on T cell proliferation and ability to react to antigens and may also have an 
indirect effect on T cell proliferation by cholangiocyte action. Elucidating a function of UDCA 
which impacts the T cells could direct future research into the underlying differences 
causing PBC patients to fit the newly-discovered grouping system and could direct further 
research into therapies for PBC. 
 
4.1: Introduction 
4.1.1: UDCA Background 
4.1.1.1: A history of UDCA usage 
Oral use of Ursodeoxycholic acid, UDCA, for the treatment of liver ailments was initiated as 
far back as 618-907AD because it was thought to help flush out toxic bile acids from the 
liver but also it was thought to replace toxic endogenous bile acids with non-toxic bile acids 
(Al-Harthy et al, 2012). Its value has long been appreciated, however it has only been in the 
past 30 years that its mechanism of action in such ailments have been able to be explored 
(Trauner et al., 1998). The majority of studies have focussed on its mechanical properties 
or its potential ability to protect the damaged cholangiocytes.  
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4.1.1.2: UDCA formation and conjugation 
UDCA is a secondary bile acid. Bile acids aid digestion of hydrophobic lipids by causing a 
decrease in liquid surface tension which causes the compounds to more readily form 
micelles (Trauner et al., 1998). UDCA is formed endogenously by action of bacteria in the 
gut microbiome. It is thought that certain bile acids are harmful to bacteria in the gut in that 
they prevent bacterial proliferation, therefore these bacteria have evolved mechanisms to 
transform these bile acids into less harmful forms: secondary and tertiary bile acids such as 
UDCA, a secondary bile acid, then TUDCA and GUDCA, tertiary bile acids (Invernizzi et al., 
1999).  
 
4.1.2: Contextualising UDCA and its conjugates 
An estimate for the concentration of UDCA in the blood can be calculated to be a maximum 
of 250µM. The dose given to a patient is 13-15mg/kg/day (mg drug/kg their weight/day) 
given over 2-4 doses per day, therefore a maximum dose is 7.5mg drug per kg their weight. 
Average human blood volume is 77ml/kg which would be 0.097mg/ml or 97µg/ml (Lindor et 
al., 2009). The molecular weight of UDCA is 392.57 therefore the highest possible 
concentration given 100% bioavailability of the drug is approximately 250µM. 100% 
bioavailability is unlikely, therefore circulating blood levels are likely to be lower than this 
estimated maximum. However, it is likely and widely reported that there is enrichment of 
bile acids in the liver (Beuers, 2006) therefore cells in the liver and bile duct regions may 
realistically experience concentrations much higher than this of bile acids including UDCA. 
Unfortunately, it is difficult to accurately estimate the concentration of UDCA and other bile 
acids experienced by immunological cells and cholangiocytes in patients. A study was 
carried out which measured the levels of bile acids in the interhepatic region of the liver 
which studied the concentration of UDCA in duodenal biopsy before UDCA administration 
and after 15mg/kg/day was taken for 3 weeks in 11 PBC patients and 11 healthy matched 
controls. Although levels of UDCA remained virtually unchanged in patients and volunteers 
(0±0µM pre-treatment and 3±3µM post-treatment in both groups), there were raised levels 
of other tertiary bile acids, GUDCA (patients 95±143µM to 3902±4545µM; healthy controls 
208±274µM to 3461±6814µM) and TUDCA in both patients and healthy controls in post-
treatment samples compared with pre-treatment samples. This is highly suggestive of liver 
enrichment of tertiary bile acids, as the bile leaves the liver and directly enters the 
duodenum with no other likely potential source of these bile acids (Dilger et al., 2012). For 
the purpose of experiments in this study, UDCA is used because it is the therapy prescribed 
to PBC patients, not TUDCA or GUDCA, and it is not certain the impact of the conjugation 
with glycine or taurine. It is entirely likely that the UDCA is having the impact of interest in 
the liver and then when passed into the duodenum is conjugated to glycine or taurine, 
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rendering TUDCA and GUDCA clinically less interesting than UDCA (Wahlstrom et al., 
2016). Some studies have attempted to compare TUDCA with UDCA to determine if 
TUDCA is therapeutically similar to UDCA. One study has shown that UDCA may 
preferentially conjugate with glycine over taurine in vivo (Rudolph G et al. 2002) and another 
compared bile secretion of patients given TUDCA with those given UDCA, and found similar 
levels of bile secretion (Ma et al., 2016) but so far it remains unclear if TUDCA can replace 
UDCA as a therapy or precisely when and where UDCA is conjugated with UDCA in vivo.  
One study examined the bile acid content of the liver and blood of normal rats compared 
with germ-free rats, who lacked the gut microbiome required to convert primary bile acids 
to secondary bile acids including UDCA (Swann et al., 2011). They found that in the germ-
free rat, rendered ‘germ-free’ by administration of antibiotics, there was little difference to 
the bile acid levels in blood serum compared with the microbiome containing rat in terms of 
bile acid content (Swann et al., 2011). This suggests that the drug, rather than remaining in 
the blood serum, is quickly absorbed into tissues and therefore is heavily enriched in organs 
and tissues, for example the liver. Therefore, the estimation of UDCA concentration in 
human blood in the previous paragraph should not necessarily be used as a limiting factor 
for usable concentrations of UDCA in in vitro experiments in this study. 
 
4.1.3: Mechanism of action of UDCA 
UDCA has been the primary therapy for PBC for many years although only recently has 
research begun to elucidate its mechanism of action. It was long believed that UDCA served 
only to mechanically aid flushing of bile and other toxic compounds out of the liver. Recent 
and current studies are discovering more and more biochemical functions of UDCA, 
suggesting it serves many more purposes than as a physical aid.  
One such mechanism of action of UDCA is its potential to increase export pumps on the 
canalicular membrane of the small bile ducts. Studies in mice have shown post-
transcriptional effects of UDCA on the amount of Bsep, a cholate conjugate transporter, in 
cholangiocytes isolated from mice. Those fed UDCA had significantly more positive staining 
for Bsep on the canalicular membrane of tissue stained by immunohistochemistry than that 
of those fed no UDCA and a similar trend was also reported for Mrp2, a multidrug resistance 
protein (Fickert et al., 2001). The impact of more Bsep and Mrp2 at the canalicular surface 
is an increase in transport of bile constituents and other toxic compounds from the 
hepatocytes, through the cholangiocytes and into the bile duct lumen. In PBC, 
cholangiocytes are broken down, therefore more of these export pump proteins in the 
remaining functional cells could attenuate the impact of cholangiocyte damage by rendering 
those surviving cholangiocytes as more efficient at bile transport. 
Cholangiocytes, in the past thought of as passive cells, have been shown to secrete HCO3- 
into the small bile duct lumen to contribute towards bile secretion. This HC03- secretion is 
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Cl- dependent. HC03- is formed from CO2 from the interstitial fluid diffusing into the 
cholangiocyte and H20 in the plasma, producing HC03- and H+, catalysed by carbonic 
anhydrase. Cl- passively diffuses out of the cell through the CFTR ATP binding ion channel 
and the Cl- is then moved back into the cell by secondary active transport for the exchange 
of an HCO3- by the anion exchanger 2 protein (Hwang and Kirk, 2013). It is thought that 
UDCA may raise cellular Ca2+ levels which can enhance Cl- movement back into the cell, 
increasing HCO3- output (Shimokura et al., 1995). 
There are many other potential mechanisms of action of UDCA, however, there is very little 
being carried out to investigate a direct impact of UDCA on lymphocytes such as T cells. 
One study in mice has shown that UDCA may cause preferential differentiation to the Treg 
phenotype by suppression of CD4+ T cell cytokines IL-2, IL-6 and IFN-γ and an increase in 
IL-10 which can suppress Th1 and Th17 differentiation and favour Treg differentiation 
(Zhang et al., 2009). The study was carried out to investigate an effective of UDCA to help 
prevent allograft rejection. As the study used mice not humans, it is currently unknown if 
UDCA could be affecting T cell differentiation or proliferation in humans. 
It is well documented in the literature there is much evidence to indicate T cell importance 
in PBC (Hiromi et al., 2003). One key mechanism of action of UDCA could be in decreasing 
proliferation of T cells. Investigating this could also offer some explanation as to why there 
are different subtypes of PBC. Differences in T cell subset patterns between these PBC 
subgroups and an added preferential effect of UDCA on some T cell subtypes over others 
could lead to different overall effects on the immune cell population and its effectiveness 
between different PBC populations. This idea is covered in more detail in chapters 5 and 6. 
 
4.1.4: Aims and Introduction Summary 
The effect of UDCA is potentially of key importance because of recent research which 
suggests there are divisions of patients with PBC based on phenotypic data (Carbone et 
al., 2013). One large area for research is into whether there is an immunological basis for 
the differences in disease subtypes. If UDCA is having an effect on certain immune cells 
and not others then differential immune responses in patient groups could be the reason 
why a subset of patients do not respond to UDCA. Therefore, this chapter will aim to 
examine any effects on immunological cells of UDCA, with a particular focus on T cells and 
their proliferation.  
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4.2: Methods 
4.2.1: Apoptosis assay 
PBMCs isolated from whole blood, method described in Chapter 2: General Methods, were 
then purified using the Easysep T cell enrichment kit, method described in chapter 3. 
 
Enriched T cells were then plated in a 24 well plate, 1ml per well of cells at a concentration 
of 1 x 106 cells/ml. Cells were incubated at different concentrations of UDCA in triplicate, 
and in 2 separate assays whereby one used the carrier ethanol as the UDCA solvent and 
the other used DMSO. Concentrations of UDCA, obtained from Sigma Aldrich, catalogue 
number U5127, were used in triplicate for each carrier: carrier only (no UDCA), 10µM, 
100µM and 300µM. Because ethanol and DMSO can be toxic to cells at certain 
concentrations, the carrier solvent was kept to 0.3% total volume. UDCA was initially 
dissolved at 333.3x the final concentration in the carrier, then 3µl was added to the well. 
The cells were incubated at 37oC for 4 days. Every 24 hours the cells were resuspended 
and a 10ul sample taken.  Each sample was mixed 1:1 with trypan blue dye which allows 
discrimination of live and dead cells as it is excluded by non-porous healthy cell 
membranes. The cells were counted using a haemocytometer and the number of live and 
dead cells/ml of the cultures were calculated. 
 
Once the carrier least damaging to cells was established and chosen, the experiment was 
repeated using only this carrier but without the T cell enrichment stage, to give apoptosis 
assay results for non-purified PBMCs. 
Further experiments were then carried out on enriched T cells exploring greater UDCA 
concentrations and at different increments and for a longer period of time: extending to 8 
days. 
 
4.2.2: ELISpot method 
The plate required for ELISpot is the Millipore multiscreen flat-bottomed 96-well assay plate 
for ELISpot. 
The ELISpot sandwich assay is illustrated in figure 2.2.1. 50µl of diluted capture antibody, 
diluted in bicarbonate buffer, at the pre-determined best concentration for that antibody was 
added to each well, ensuring thorough covering of the bottom of every well. This was 
incubated at 4OC overnight (8-48 hours is acceptable). Excess capture antibody was 
removed and the plates washed 3 times with PBS. The plates were then blocked with RPMI 
containing 10% FCS for 1-8 hours at room temperature to minimise non-specific binding. 
Blocking solution was then removed to virkon solution. PBMCs isolated from blood by the 
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method described in General Methods, were then diluted to the optimised concentration for 
the cytokine of interest (usually 8x106 or a dilution of 1 in 5, 1 in 10 or 1 in 20 of this) and 
added to each well at 50µl per well and 50µl of stimulus then also added. The plates were 
then incubated at 37OC (in a 5% CO2 incubator) for 18-20h. Cell suspension was then 
removed to virkon solution and the plates washed 6 times with PBS. The biotinylated 
antibody was then diluted in PBS to the required concentration of 1µg/ml and 50µl added 
to each well. The plates were then incubated at room temperature for 2-4h. The detector 
antibody was then removed to waste and the plate washed 6 times in PBS. Alkaline 
phosphatase conjugated streptavidin (SA-ALP) was then added at a 1 in 1000 dilution in 
PBS at 50µl per well and incubated for 1-2h at room temperature. SA-ALP was then flicked 
off and the plate washed 6 times with PBS. 50µl of substrate, assembled per manufacturer’s 
guidelines (Bio-Rad AP conjugate kit, 170-6432), was then added to each well. The plate 
was then allowed to develop at room temperature for 5 minutes and then tap water was 
added to terminate the reaction and wash off excess substrate. The plate was allowed to 
dry for 1-2 days at room temperature and then read using the ELISpot reader. The number 
of spots read from a given well is directly related to the number of reactive cells per million 
total cells. The number of reactive cells per million (106) was calculated as outlined below. 
50µl, the volume of cell suspension added per well = 0.05ml. The initial concentration of 
cells in cells/ml can be multiplied by 0.05ml to find number of cells added. The concentration 
of cells initially was, for e.g., 8x106 cells/ml, therefore 8x106 x 0.05ml = 0.4x106 cells. This 
is 0.4 x 1 million cells, therefore this was multiplied by 2.5 in order to make 1 million cells. 
Therefore to find the number of reactive cells per million total cells, if the concentration 
initially was 8x106 cells/ml then the number of reactive cells per million is the spot count 
multipled by 2.5. If the concentration of cells added was further diluted from 8x106 cells/ml, 
the multiplication factor was adjusted accordingly so that it reflected what the concentration 
of cells would need to be multiplied by to make 106. Control wells were also included 
containing medium and cells but no stimulus to account for any background response, for 
example any response to anything which may have been in the media alone causing a 
response. 
A panel of common antigens were run on 4 volunteers for an idea of the antigens they 
respond to so that the effect of UDCA on their response to a true antigen, rather than a 
mitogen, could be investigated. Once a particular antigen was established for each 
individual which gave a high response, ELISpots were carried out which investigated 
different concentrations of UDCA on the reactivity against the chosen antigen for each 
individual patient under different concentrations of UDCA.  The cells at different patient were 
plated in triplicate in a series of UDCA concentrations. The same assay was carried out 
using the αCD3 mitogen in parallel. 
The αCD3 mitogen is a monoclonal antibody that binds to a non-antigen related region of 
CD3, which is the T cell antigen receptor. Although unable to cause a response in the T cell 
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due to lack of a surface the T cell can be cross-linked to, αCD3 is sufficient to cause 
proliferation of the T cell in the presence of IL-2, which is provided by other PBMCs when it 
is a PBMC cell suspension (Jason and Inge, 1996). 
Stimuli used were either an anti-CD3 mitogen or an antigen of interest. Antigens of 
interest used included those test common antigens used in the initial screen, 
described below, and PBC antigens, which were named PDC 1-4, or respectively: 
rhE2, rhE2ILD, rhE3BP and rhE3BPILD, all of which are described in chapter 1: 
Introduction, and with sequences in table 4.2.2.1. 
Healthy volunteers were all screened with a panel of antigens to determine an 
antigen that they respond highly to, which could be used to stimulate their cells 
in later experiments assessing the effect of UDCA on their reactivity to an antigen. 
The screening panel contained the following antigens: pokeweed mitogen (PWM), 
cancer cell line (K), Adenovirus (Adeno), Salmonella, cytomegalovirus (CMV), 
Epstein-Barr virus (EBV), Haemophilus influenza (Hib), pseudomonas antigen 
(PSA). The pokeweed mitogen is a positive control to ensure that cells will react 
and are alive and undamaged. Derived from the Phytolacca americana plant, the 
pokeweed mitogen binds to sugar residues on surface glycoproteins and causes 
their cross linking. This includes molecules associated with cell expansion (De 
Vries et al. 1980). Therefore, this mitogen has large proliferative properties and 
is an ideal positive control.  
 
 
Figure 4.2.2.1: Diagram of the ELISpot sandwich assay whereby the secreted 
cytokine is sandwiched between antibodies. 
This diagram illustrates the arrangement of the added components of the ELISpot assay. 
The secreted protein becomes sandwiched between a capture and a detector antibody. 
The detector antibody is the biotinylated antibody. The biotin conjugate mediates spot 
formation when it reacts with the streptavidin conjugate and forms a visible precipitate. 
 
 
 
 
 100 
Pep.No. Name of 
polypeptide 
Sequence Length of 
sequence 
(no. amino 
acids) 
1 E2pdh163 GDLLAEIETDKATI 14 
2 E3BP34 GDALCEIETDKAVV 14 
4 E2ogdc EQSLITVEGDKASM 14 
5 E2pdh159 KLSEGDLLA 9 
6 Psaer1 ALAEGDLLA 9 
12 SclTop586 AKVFRTYNASITLQQQL 17 
Table 4.2.2.1: Table of PBC antigen peptides 
This table shows a selection of peptides used which are thought to be of interest in PBC, 
used to screen healthy volunteer blood for reactivity so that these results can be 
compared to results from patient blood.  
 
4.2.3: ELISpot cell viability Flow Cytometry Experiment 
In order to test that the cells were still viable within the assay the ELISpot was carried out 
as per the method in section 4.2.2, but cells were then extracted after completion of the 
experiment, stained with DAPI and other cell surface markers and put through the flow 
cytometer to analyse the alive/dead status and subtypes of T cells.  
This ELISpot was carried out to test if UDCA was having a direct effect on the immune cells 
such that if by increasing the effect of the drug there is a decrease in number of spots 
formed, which would be a direct indicator of number of cells which have responded to the 
test antigen. However, if there were a toxic effect of UDCA on these immune cells, then a 
toxic effect could be masquerading as a direct effect on the immune activity of these cells. 
There have been assays carried out in this study which have shown that UDCA is likely not 
toxic at concentrations up to 300µM for up to 72h and longer, the apoptosis assay studies 
cells at rest likely undergoing no significant activity. The context of the ELISpot, although 
occupying under 24h of time, is entirely different in that cells are being stimulated and may 
begin to prepare for proliferation in response to the antigen. This test was carried out to 
monitor if cells were apoptosing in response to the raised drug concentration in the ELISpot 
context.  
The ELISpot was set up as per the panel in figure 4.2.3.1. Purified protein derivative, ppd, 
is an antigen which mimics tuberculosis, specifically Mycobacterium tuberculosis. It is 
diagnostically used to test for tuberculosis reaction to determine if a patient needs the 
vaccination or not, but can be used scientifically to cause a reaction in T cells in assays 
such as the ELISpot assay (Stavri et al., 2012) if the individual has encountered this antigen 
before and responds strongly, as is determined beforehand in a screen assay like that 
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described in section 2.2. The individual used for this assay gave a strong response to the 
ppd antigen as determined by a screen (data not shown). For the ELISpot mitogen, the anti-
CD3 mitogen used was the Purified NA/LE Mouse Anti-Human 
CD3 Clone HIT3a from BD Boisciences. This is diluted 1/200 from 1mg/ml to 
5µg/ml. αCD3 is normally used at cell concentrations of 4x105 for spot counting, however 
this does not give sufficient total cells per well to use for flow cytometry, therefore this same 
set up was repeated for an additional 3 columns with a higher cell count, 8x106, these wells 
contain too many cells to give readable spots: the well shows a ‘blackout’. The different 
concentrations were required to give countable spots but also enough cells for a flow 
cytometry analysis. Medium alone (no stimulus) was used alone so that the death of cells 
when there is the stimulus and without could be assessed.  
 
 
Figure 4.2.3.1: Diagram of layout of ELISpot plate for the ELISpot alive/dead assay 
The above shows the layout of the ELISpot designed to assess whether UDCA may be 
having a toxic effect in the context of the ELISpot at certain concentrations. Samples are 
plated in triplicate. Concentration of UDCA for a given row is shown to the far left and the 
stimulus for a given column along with cell concentration is shown above. 
 
4.2.4: Flow cytometry proliferation experiments 
4.2.4.1: Preliminary experiment 
In order to detect any effect on proliferation of T cells of UDCA, a preliminary experiment 
was carried out which used the method outlined in chapter 3, and involved isolated T cells 
from 3 healthy volunteers. They were stained with CFSE as per the protocol in Chapter 2:  
General Methods, and separated into 3 different wells, each with different concentrations of 
UDCA in 0.3% ethanol carrier, including a control with 0µM UDCA but still including the 
ethanol carrier. Concentrations of UDCA used were 100µM UDCA and 300µM UDCA. Cells 
were proliferated with 10µl CD3/CD28 T cell proliferation Dynabeads and IL-2 (method 
outlined in chapter 3), incubated for 4 days and then samples taken for flow cytometric 
analysis after staining with anti-CD3-APC conjugated antibody, as per flow cytometric 
preparation and staining protocol. Cell samples were analysed by flow cytometry, using 
 102 
FACSDiva software to count cells based on their proliferation and presence of CD3+, further 
explained in chapter 3.  
 
4.2.4.2: T cell proliferation assay analysing different T cell subsets and the 
effect on proliferation of UDCA 
An assay was also designed that could investigate an effect on proliferation on individual T 
cell subsets. The design of this assay is described in chapter 3. PBMCs of 3 volunteers 
were incubated by criteria outlined in chapter 3, in different conditions: unstimulated and no 
UDCA, no UDCA or carrier, 0.25mM UDCA in carrier, 0.1mM UDCA in carrier, 0.3% carrier 
alone and 1% carrier alone. Cells were processed for flow cytometric analysis, following 
Panel 2 criteria, outlined in chapter 3, including DAPI stain for CD4+ helper T cell subsets 
and analysed using FACS-Diva software. 
 
4.2.5: H69 Cholangiocyte cell line experiments 
4.2.5.1: H69 cholangiocyte media 
H69 cells were cultured in media which is 2:1 DMEM low glucose and F12 Ham, 
supplemented with FBS (10% of total media volume), penicillin and streptomycin antibiotic 
mixture (1% of total media volume), L-glutamate (1% total media volume), Adenine (120µl 
per l media of 0.2mg/ml working solution), Triiodothyronine (135µl per l total media volume 
of 10ng/ml working solution), epinephrine (20µl per l total media volume of 50mg/ml stock 
solution made up in 0.5N HCl), ITS-X (10ml per l total media volume), Hydrocortisone (20ml 
per l total media volume).  The H69 cell line is an immortalised cell line originally isolated 
from intrahepatic bile ducts. Cells were obtained from Dr Ben Millar, Institute for Cellular 
and Molecular Biosciences, Newcastle University, in culture form in 10ml of full media in a 
cell culture flask. Cells had been checked and confirmed negative for mycoplasma 
contamination immediately before their release to Northumbria University for this study. All 
media and additives were obtained from Sigma Aldrich. 
 
4.2.5.2: Supernatant transfer assay 
H69 cells were incubated in their medium until approximately 60-80% confluent. Some 
medium of H69 was harvested and frozen prior to its use on cells and frozen, alongside 
some media harvested from the cell culture at 60-80% confluent. UDCA was added to the 
H69 cells to a final concentration of 250µM in an ethanol carrier not allowing ethanol 
concentration to exceed 0.3%. H69 culture was then incubated for a further 24 hours to 
allow the cells to respond to the drug, then some more media was harvested from the H69 
culture and frozen. Cells were then washed 3x by centrifugation and resuspension in their 
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media to ensure that all UDCA had been washed from the H69 cells. The H69 cells were 
then re-suspended in media and incubated for 24h and another sample of media was then 
harvested. Cells were cultured for a further 4 days with media harvested at days 2, 3 and 5 
from addition of UDCA. A lysate of H69 was prepared by rapid freeze/thaw cycles followed 
by manual disruption and topped up to a concentration of 10% cells in their media.  
PBMCs from the blood of 3 healthy controls are extracted as per method in General 
Methods. Cells were stained with CFSE dye as per the method in chapter 3, then cultured 
at 1x106 per ml in a 24 well plate with 50% their own media with 1 in 200 αCD3 mitogen to 
stimulate proliferation and 50% one of 8 additive preparations as per table 4.2.5.2.  
 
Tube 
number: Additive making up 50% total culture media: 
1 Unused H69 media 
2 Harvested media from confluent H69 cells 
3 
Harvested media from H69 cells after 1 day of incubation with 
UDCA. 
4 Media from 3x washed H69 cells, 24h after UDCA addition. 
5 Media from 2 days after wash. 
6 Media from 3 days after wash. 
7 Media from 5 days after wash. 
8 Media containing H69 cell lysate. 
 
Table 4.2.5.2: Table of additives used in supernatant transfer assay 
The above figure shows the additives used in the supernatant transfer assay which would 
make up 50% of the total media in this sample. This experiment investigates the effect of 
any substance released by H69 cells in response to UDCA on the T cells. 
 
4.2.5.3: xCELLigence 
Prior to an xCELLigence, is it usually a requirement to carry out a prior experiment which 
involves plating cells at different numbers per well and running the experiment to determine 
the ideal number of cells to use per well. This would require 2 E-plates in total to use, one 
for the cell number titration experiment and another for the proliferation experiment itself. 
Acquisition of 2 plates was unfeasible due to budget constraints, therefore only one E-plate 
was available. Therefore, cells were seeded at 2000 per well as this is the number generally 
used in the literature and has been shown to give ideal results with the H69 cholangiocyte 
cell line (Chaiyadet et al., 2015a). 
Cells were seeded into each well at 2000 cells per well, with each well containing a total 
volume of 100µl of cells and their normal media, made up as per section 2.2.4.1. Cells had 
been kept at 0.05% FCS overnight to serum-synchronise them prior to the experiment. This 
arrests the cells in the same stage of proliferation so that they proliferate in synchronisation 
with each other once FCS levels resume to normal. The experiment was run for 97 hours, 
with readings taken every 15 minutes to test for their adherence and proliferation. UDCA 
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was added 24 hours into the recorded experiment. As a cell makes contact with the golden 
plate at the bottom of the well, there is increased electrical impedance detected in the gold 
plate and transmitted to the computer. Every 15 minutes readings of electrical impedance 
were measured and the results plotted in a graph by the software provided. This provides 
a graph of electrical impedance, which is proportional to cell number, against time. The 
resulting curve gives an indication of the proliferation of the cells, comparable to each other. 
The area under each curve gives a numerical value which can be directly compared to the 
others.  
 
4.2.6: Large Flow Cytometry assay  
Methodology for this section is not outlined in this chapter as the previous chapter is 
concerned with design of the assay used for this section. Methodology can be found in 
chapter 3. 
 
 
4.3: Results 
4.3.1: Trypan Blue apoptosis assay on isolated T cells 
Numbers of cells counted, corrected to x105/ml, are represented graphically in figure 4.3.1 
for the ethanol carrier and 4.3.1.2 for the DMSO carrier. Relevant p values are tabularised 
in table 4.3.1.1 for ethanol carrier; 4.3.1.2 for DMSO carrier. P values refer to comparison 
with carrier only at the stated concentration. Significantly different results when ethanol is 
used occur at 0h, 100µM (p=0.037) UDCA but at all other counts there is no significant 
difference from the carrier only. Significantly different results when DMSO is used occur at 
24h, 100µM (p=0.042); 120h, 100µM (p=0.004). 
A further apoptosis assay was then carried out using smaller increments of UDCA and also 
comparing the ethanol carrier to no carrier, to see if there is a toxic effect of the carrier alone 
compared to no carrier. All other comparisons were made to the carrier control. There are 
no significantly different results between the carrier (Control 1 or no carrier, figure 4.3.1.3 
and table 4.3.1.3).  
A further apoptosis assay was carried out to see if higher concentrations of UDCA could be 
used and also if the cells could be incubated in UDCA for longer periods of time with no 
significant decrease in alive cells. This used concentrations of UDCA up to 3mM and was 
carried out for 8 days of counting. The graph showing live counts is shown in figure 4.3.1.4 
with relevant p values in table 4.3.1.4. As can be seen in table 4.3.1.4, there appears to be 
significantly fewer live cells for concentrations of 0.5mM and above, at day 4 onward. The 
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p values are consistently significant above these values of time and concentration (shown 
in bold in table 4.3.1.4). 
A further apoptosis assay was carried out to see if the effect of live cell number on T cells 
also applies to PBMCs, as some further experiments were planned to use the PBMC 
population. This was a direct replication of the assays for figure 4.3.1.1 only used PBMCs. 
The only significantly different results, shown in bold in table 4.3.1.5, were for 0h, possibly 
due to non-uniformity of cells due to their possible stickiness from culture which led to cell 
plating.  
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Figure 4.3.1.1: Graph of alive T cells against time using ethanol as carrier 
This graph shows the counts of alive cells using trypan blue staining and the 
haemocytometer. Cells were counted at 24hour intervals. Different concentrations, shown 
in µM, were used in order to asses a toxic effect of UDCA. 
 
 
 
  p values for ethanol 
  UDCA conc. (µM) 
  10 100 300 
Ti
m
e 
el
ap
se
d 
(h
) 0 0.717 0.037 0.254 
24 0.594 0.999 0.373 
48 0.998 0.470 0.958 
72 0.933 0.999 0.963 
120 0.966 0.548 0.994 
Table 4.3.1.1: p values for data from live cell count against time at different UDCA 
concentrations using an ethanol carrier 
P values are from one way ANOVA with Dunnett’s correction for multiple comparison.  
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Figure 4.3.1.2: Graph of alive cells against time using DMSO as carrier 
This graph shows the counts of alive cells using trypan blue staining and the 
haemocytometer. Cells were counted at 24hour intervals. Different concentrations, shown 
in µM, were used in order to asses a toxic effect of UDCA. 
 
  p values for DMSO 
  UDCA conc. (µM) 
  10 100 300 
Ti
m
e 
el
ap
se
d 
(h
) 0 0.543 0.332 0.176 
24 0.129 0.042 0.113 
48 0.408 0.946 0.977 
72 0.498 0.634 0.999 
120 0.910 0.004 0.401 
Table 4.3.1.2: p values for data from live cell count against time at different UDCA 
concentrations using an DMSO carrier 
P values are from one way ANOVA with Dunnett’s correction for multiple comparison. 
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Figure 4.3.1.3: Graph of live T cell counts over time  
This graph shows the counts of alive cells using trypan blue staining and the 
haemocytometer. Cells were counted at 24hour intervals. Different concentrations, shown 
in µM, were used in order to asses a toxic effect of UDCA. Ethanol was used as the 
carrier. Control 1 is where no carrier is used and control 2 is where the ethanol carrier 
alone is used at 0.3% total volume, as per previous experiments and as per wells with 
UDCA. 
 
 
 Carrier:        
  10 50 100 150 200 250 300 
0h 0.423 0.999 0.284 0.185 0.144 0.451 0.560 0.451 
24h 0.189 0.245 0.171 0.581 0.806 0.430 0.394 0.171 
48h 0.230 0.602 0.986 0.999 0.869 0.999 0.828 0.783 
72h 0.264 0.398 0.999 0.995 0.939 0.466 0.872 0.781 
Table 4.3.1.3: p values for data from live cell count against time at different UDCA 
concentrations (μM) using an ethanol carrier 
P values for carrier vs media from 2 tailed students’ t tests; p values for concentrations vs 
carrier from ANOVA corrected with Dunnett’s correction. 
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Figure 4.3.1.4: Graph of live T cell counts over time  
This graph shows the counts of alive cells using trypan blue staining and the 
haemocytometer. Cells were counted at 24hour intervals. Different concentrations, shown 
in mM, were used in order to asses a toxic effect of UDCA. Ethanol was used as the 
carrier. Control 1 is where no carrier is used and control 2 is where the ethanol carrier 
alone is used at 0.3% total volume, as per previous experiments and as per wells with 
UDCA. This assay is a repeat of previous assays however extends the concentrations of 
UDCA used and also the number of days. 
 
 
 
Table of P values 
 
 
      
  UDCA concentration (mM) 
  0.1 0.5 1.0 1.5 3.0 
Da
y 
0 0.514 0.249 0.514 0.412 0.143 
1 0.328 0.810 0.937 0.937 0.328 
2 0.988 0.975 0.887 0.791 0.14 
3 0.999 0.986 0.703 0.789 0.083 
4 0.411 0.001 <0.0001 0.0013 <0.0001 
5 0.941 0.001 <0.0001 0.0013 <0.0001 
6 0.999 0.014 0.0065 0.0020 0.0007 
7 0.874 0.0010 0.0010 <0.0001 <0.0001 
8 0.068 0.002 0.003 <0.0001 <0,0001 
 
Table 4.3.1.4: p values for data from live cell count against time at different UDCA 
concentrations using an ethanol carrier 
P values are from ANOVA with Drummett’s correction assuming unequal variances 
comparing the corrected number of cells/ml for each UDCA concentration stated to carrier 
only for the stated time point. 
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Figure 4.3.1.5: Graph of alive cells against time using ethanol as carrier 
This graph shows the counts of alive PBMCs using trypan blue staining and the 
haemocytometer. Cells were counted at 24hour intervals. Different concentrations, shown 
in µM, were used in order to asses a toxic effect of UDCA. 
 
 
 
  Concentration UDCA (µM) 
  10 100 200 300 
Ti
m
e 
(h
) 0 0.043 0.107 0.024 0.107 
24 >0.999 0.971 0.872 0.770 
48 0.687 0.591 0.275 0.687 
72 0.811 0.725 0.725 0.811 
Table 4.3.1.5: p values for data from live cell count against time at different UDCA 
concentrations using an ethanol carrier 
P values are from ANOVA with Drummett’s correction assuming unequal variances 
comparing the corrected number of cells/ml for each UDCA concentration stated to carrier 
only for the stated time point. 
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4.3.2: ELISpot Results 
4.3.2.1: ELISpot cell viability Flow Cytometry assay 
The results described here refer to the experiment outlined in section 4.2.3.  
Figure 4.3.2.1 shows how the cells for flow cytometry, set-up of wells depicted in figure 
4.2.3.1, were gated and counted by the software. Results for the ELISpot portion are shown 
in figure 4.3.2.1.2. This is the number of corrected spot forming cells per million established 
from the ELISpot portion of this assay, depicted in figure 4.2.3.1. Results for the Flow 
Cytometry portion are shown in 4.3.2.1.3. This is the number of dead cells, or the number 
of cells positively stained for the DAPI dye, counted by the FACSDiva software and depicted 
in figure 4.2.3.1. 
Figure 4.2.3.1 shows that everything was carried out in triplicate. ‘m’ shows medium alone 
without carrier. T tests were carried out to compare values at all concentrations including 
no carrier to carrier alone. P values for the number of spot forming cells are shown in table 
4.3.2.1.2 and p values for numbers of dead cells from flow cytometric analysis are 
tabularised and shown in table 4.3.2.1.3. Cells unstimulated appear to only have 
significantly more death at 1mM UDCA, p=0.012. Cells stimulated with a realistic antigen 
but weaker than the αCD3 mitogen have significantly fewer cells reacting to the stimulus 
only when UDCA concentration reaches approximately 1mM, p=0.027. 
When cells are stimulated with the αCD3 mitogen, there appears to be, according to the 
data in this study, no significant increased cell death even at UDCA concentration of 1mM 
but decreased response to stimulus at concentrations 0.5mM and 1mM (p values = 0.007 
and 0.0002 respectively). 
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Figure 4.3.2.1.1: Gating of lymphocytes and graphs to show DAPI staining for dead 
and alive cells. 
a – Lymphocytes are gated based on their known estimated forward and side scatter 
properties. 
b – This histogram illustrates the relative proportions of DAPI + and – cells from the 
lymphocyte gate.  
c – Unviable cells are gated based on established DAPI negative gate, using Flow 
Cytometry optimisation criteria in chapter [FACS set up]. 
d – Software counts the cells within set gates and displays the values in a tabularised 
format. 
 113 
a  
b  
Figures 4.3.2.1.2 a and b: Graphs of spot forming cells per million at different 
concentrations of UDCA in ELISpot assays using the αCD3 mitogen and the ppd 
antigen.  
The graph shows the effect of UDCA on the average number of spot forming cells per 
million at different concentrations of UDCA using the αCD3 mitogen and also a ppd 
antigen.  
 
 
 
 
 
 
 
0
1000
2000
3000
4000
5000
6000
m e 0.01 0.05 0.1 0.25 0.5 1
Sp
ot
 fo
rm
in
g 
ce
lls
 /1
06
Concentration of UDCA (mM)
Spot forming cells per million in ELISpot using 
αCD3 mitogen as antigen
0
50
100
150
200
250
300
350
m e 0.01 0.05 0.1 0.25 0.5 1
Sp
ot
 fo
rm
in
g 
ce
lls
/1
06
Concentration of UDCA (mM)
Spot forming cells per million in ELISpot using 
ppd antigen
 114 
a  
b  
Figures 4.3.2.1.3 a and b: Graphs showing percentages of dead cells from flow 
cytometric analysis of cells from the ELISpot assay, a - using αCD3 mitogen and b – 
using no stimulus, at different concentrations of UDCA.  
The graphs show the effect of UDCA on the average percentage of cells that are dead at 
different concentrations of UDCA using the αCD3 mitogen and also no stimulus.  
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ELISpot p values 
Conc. 
UDCA 
(mM) 
Antigen 
αCD3 ppd 
m 0.541 0.602 
0.01 0.299 0.918 
0.05 0.518 0.868 
0.1 0.385 0.37 
0.25 0.092 0.687 
0.5 0.007 0.524 
1 0.0002 0.027 
Table 4.3.2.1.2: p values corresponding to figure 3.2.1.2. 
Significant values include comparison of 0.5mM UDCA against carrier alone (p=0.007) 
and 1mM and carrier alone (p=0.0002) for αCD3; 1mM against carrier alone (p=0.027) for 
ppd. 
 
Flow cytometry p values 
Conc. 
UDCA 
(mM) 
Antigen 
αCD3 Medium 
m 0.141 0.4 
0.01 0.183 0.309 
0.05 0.086 0.167 
0.1 0.259 0.286 
0.25 0.196 0.225 
0.5 0.343 0.088 
1 0.053 0.012 
Table 4.3.2.1.3: p values corresponding to figure 4.3.2.1.3. 
Significant values are for comparison between 1mM UDCA and carrier alone, p=0.012, in 
the unstimulated lane. 
 
4.3.2.2: ELISpot results 
Figures 4.3.2.2.1 a and b show the spot forming cells per 106 when 4 healthy non-PBC 
volunteers are challenged in the ELISpot context with a panel of common antigens to 
establish an antigen for each volunteer which produces a strong response for future 
experiments. The strongest response antigens for each individual are: EBV for 1 and 2, 
CMV for 3 and Salmonella for 4. 
Figures 4.3.2.2.2 show similar data to 4.3.2.2.1 only using 7 volunteers and PBC antigens 
rather than common antigens. This was intended for comparison with PBC patients. 
Figures 4.3.2.2.3 and 4.3.2.2.5 show results from ELISpot assays where serum from 4 
volunteers is challenged for response to a stimulus where in 4.3.2.2.3, the stimulus is an 
αCD3 mitogen and in 4.3.2.2.5, the stimulus is the antigen established to be that which 
each individual responds strongly from figure 4.3.2.2.1. Figures 4.3.2.2.4 and 4.3.2.2.6 
show the averages, respectively, of these, and tables 4.3.2.2.4 and 4.3.2.2.6 show the 
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relevant p values. These figures show a significant difference in spot forming cells per 106 
when an αCD3 mitogen is used at concentrations 0.5mM and 1mM, p values 0.0027 and 
0.00064 respectively, but no significant difference in spot forming cells per 106 when a 
common antigen each individual is known to respond strongly to is used. 
a  
b  
Figure 4.3.2.2.1 a and b: Graphs of number of spot forming cells per million when 
the PBMCs of 4 volunteers are challenged with a panel of common antigens.  
a shows a panel of antigens that 4 healthy volunteers were challenged with to determine 
one antigen each individual will respond to strongly for use in further experiments. 
b shows the same data as a but with the controls removed in order to better visualise the 
antigen counts, as they are small relative to the positive control. Numbers 1-4 refer to the 
assigned numbers of the different healthy volunteers. 
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Figure 4.3.2.2.3: Graph of number of spot forming cells per million at different 
UDCA concentrations with αCD3 mitogen. 
The above figure shows data for 4 healthy individuals. The graph shows the effect of 
UDCA on the average number of spot forming cells per million at different concentrations 
of UDCA where m denotes medium alone used instead of UDCA and e denotes where 
the carrier, ethanol, alone is used with no UDCA. Comparing e to m shows any response 
from the carrier alone, not attributable to UDCA. The stimulus used is the αCD3 mitogen. 
Different colours of bars are used for different volunteers, with one colour assigned to 
each volunteer. 
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Figure 4.3.2.2.4: Graph of Average number of spot forming cells per million at 
different UDCA concentrations with αCD3 mitogen. 
The above figure shows pooled data, averaged for 4 healthy individuals. The graph shows 
the effect of UDCA on the average number of spot forming cells per million at different 
concentrations of UDCA where m denotes medium alone used instead of UDCA and e 
denotes where the carrier, ethanol, alone is used with no UDCA. Comparing e to m shows 
any response from the carrier alone, not attributable to UDCA. 
 
 
 
  p 
UD
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co
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tra
tio
n 
(m
M
) 0 0.106 
0.01 0.136 
0.05 0.537 
0.1 0.282 
0.25 0.081 
0.5 0.002 
1 0.0006 
   
Table 4.3.2.2.4: p values for Graph of Average number of spot forming cells per 
million at different UDCA concentrations with αCD3 mitogen, figure 3.2.2.4. 
Significant comparisons are between carrier alone and: 0.5mM (p=0.002) and 1mM 
(p=0.0006). 
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Figure 4.3.2.2.5: Graph of number of spot forming cells per million at different 
UDCA concentrations using antigen specific to the individual. 
The above figure shows data for 4 healthy individuals. The graph shows the effect of 
UDCA on the average number of spot forming cells per million at different concentrations 
of UDCA where m denotes medium alone used instead of UDCA and e denotes where 
the carrier, ethanol, alone is used with no UDCA. Comparing e to m shows any response 
from the carrier alone, not attributable to UDCA. Antigens used vary between the 
individuals and were decided on by use of a panel of antigens to determine an antigen 
each individual will respond highly to. Different colours of bars are used for different 
volunteers, with one colour assigned to each volunteer. 
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Figure 4.3.2.2.6: Graph of average number of spot forming cells per million at 
different UDCA concentrations using antigen specific to the individual. 
The above figure shows pooled average data for 4 healthy individuals. The graph shows 
the effect of UDCA on the average number of spot forming cells per million at different 
concentrations of UDCA where m denotes medium alone used instead of UDCA and e 
denotes where the carrier, ethanol, alone is used with no UDCA. Comparing e to m shows 
any response from the carrier alone, not attributable to UDCA. Antigens used vary 
between the individuals and were decided on by use of a panel of antigens to determine 
an antigen each individual will respond highly to. 
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m 0.838 
0.01 0.684 
0.05 0.56 
0.1 0.45 
0.25 0.201 
0.5 0.07 
1 0.063 
Table 4.3.2.2.6: p values for Graph of average number of spot forming cells per 
million at different UDCA concentrations using antigen specific to the individual, 
figure 4.3.2.2.6. 
These p values are from t tests comparing spot forming cells per million at different UDCA 
concentrations (or no UDCA and no carrier – m) to the carrier alone (e, ethanol). 
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Figure 4.3.3.1.1 is a graphical depiction of preliminary data which shows that proliferation 
of T cells becomes ever more restricted as the concentration of UDCA rises. Each 
histogram is from cells gated for αCD3-APC staining, having been incubated for 3 days with 
IL-2 and Dynabeads T cell proliferation beads. At 300µM, the peak for cells having entered 
a third extra division relative to the highest staining peak, labelled 3+, looks visibly smaller 
than that for no UDCA. Visibly, there appears to be more of a skew towards the 0 relative 
divisions peak for 300µM compared to 0 UDCA. At 100µM, the peaks appear similar to 
those for 0 UDCA. As it cannot be discerned whether those cells in the right-most peak 
have divided or not, those cells counted in peaks representing further divisions are 
discussed in terms of how many more divisions they have incurred relative to the right-most 
peak. 
Figure 4.3.3.1.2 is a bar chart displaying the average proliferation of T cells at different 
concentrations of UDCA. Proliferated cells are counted as those whose CFSE intensity has 
decreased to less than those cells making up the right most and most CFSE-intense peak. 
At 300µM UDCA, there is significantly less proliferation than with ethanol alone (0µM UDCA 
– contains 0.3% ethoanol, used as the UDCA carrier), p=0.039. 
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Figure 4.3.3.1: Graph to show the effect of increase in drug concentration on T cell 
proliferation 
The graph shows proliferation, visualised by CFSE dye in cell cytoplasm, which is diluted 
down the daughter cells. The peaks are smaller in the 2 and 3+ columns the more UDCA 
is present.  Unstimulated cells are shown to illustrate the effect of the proliferation beads 
and IL-2. This result is obtained after 3 days of incubation at 37oC. 
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Table 4.3.3.1.2: Graph of quantified proliferation of T cells at different 
concentrations of UDCA.  
This graph shows the average proliferation of T cells across 3 samples from different 
volunteers along with ‘standard error’ error bars and showing the significant difference 
between 300µM UDCA and carrier alone. 
 
4.3.3.2: The effect of UDCA on T cell subset proliferation 
Cells were set up in the assay described in chapter 3 and gated as per figures 3.3.7.1.1 and 
3.3.7.1.2. Figures 4.3.3.2.1-4.3.3.2.3 show graphical representation of average numbers 
across 3 volunteers of proliferated cells of Th1, Th1/Th17, Th2 and Th17 subsets and also 
the corresponding Tc subsets and CD4+ Tregs and CD45RO+ Tregs. Percentages of T 
cells are based on percentage of the parent population, which is why ‘Divided CD4+’ T cell 
bars are smaller than other bars. Gating criteria are outlined in chapter 3, figures 3.3.7.1.1 
and 3.3.7.1.2. 
Table 4.3.3.2 shows the p values where proportions of T cell subsets within the T cell 
population were compared with the 0.3% carrier (vehicle). Significant results are at 0.25mM 
UDCA, CD4+ T cells in the Treg tube (p=0.008) and CD8+ T cells (all p=0.02; Tc2 p=0.03).  
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Figure 4.3.3.2.1: CD4+ T cell proliferation under different conditions, after 
incubation for 4 days with IL-2 and CD3/CD28 Dynabeads. 
This figure depicts the different levels of divided CD4+ T cells and CD4+ T cell subsets 
based on percentage of parent gate or quadrant count, outlined in chapter 3. ‘Standard 
error’ error bars are also included.  
 
0
10
20
30
40
50
60
70
80
90
Pe
rc
en
ta
ge
 o
f c
el
ls
 (%
)
Conditions of cells
Average percentages of different subsets 
of T cells at different UDCA 
concentrations
Divided CD4+
Divided CD4+ Th1
Divided CD4+ Th1/Th17
Divided CD4+ Th2
Divided CD4+ Th17
 125 
 
Figure 4.3.3.2.2: CD8+ T cell proliferation under different conditions, after 
incubation for 4 days with IL-2 and CD3/CD28 Dynabeads. 
This figure depicts the different levels of divided CD8+ T cells and CD8+ T cell subsets 
based on percentage of parent gate or quadrant count, outlined in chapter 3. ‘Standard 
error’ error bars are also included.  
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Figure 4.3.3.2.3: Treg cell proliferation under different conditions, after incubation 
for 4 days with IL-2 and CD3/CD28 Dynabeads. 
This figure depicts the different levels of divided regulatory T cells and regulatory T cell 
subsets based on percentage of parent gate, depicted in chapter 3. ‘Standard error’ error 
bars are also included.  
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  UDCA concentration 
  0.1mM 0.25mM 
CD
4+
 p
an
el
 - 
Di
vi
de
d 
ce
lls
 CD4+ all 0.98 0.24 
Th1 0.86 0.97 
Th1/Th17 0.9 0.76 
Th2 0.64 0.9 
Th17 0.74 0.69 
CD
8+
 p
an
el
 - 
Di
vi
de
d 
ce
lls
  CD8+ all 0.34 0.02 
Tc1 0.84 0.12 
Tc1/Tc17 0.64 0.27 
Tc2 0.11 0.03 
Tc17 0.63 0.29 
Tr
eg
 
pa
ne
l 
Di
vi
de
d 
ce
lls
 CD4+ 0.575 0.008 
Tregs 0.83 0.96 
CD45RO+ 0.95 0.44 
Table 4.3.3.2: p values for comparisons of populations of divided T cell subsets 
compared to carrier only 
T tests were carried out to compare numbers of divided T cells, within gated subsets, 
incubated with UDCA to those of the corresponding subsets but without UDCA. This table 
shows the p values of these t tests. Significant results are for 0.25mM UDCA, CD4+ cells 
in the Treg tube (p=0.008) and CD8+ T cells (all CD8+, p=0.02; Tc2, p=0.03). 
 
 
 
4.3.4: H69 cholangiocyte experiments 
4.3.4.1: xCELLigence results 
UDCA is added at the 24h point. Figure 4.3.4.1.1 shows the plotted results of average cell 
density over time. After addition of UDCA, the lines appear to indicate that the more UDCA 
there is in the culture medium, the less the cell density. 0.5mM UDCA and 1mM UDCA 
results appear to show a decrease in cell density with 0.25mM failing to increase and at 
0.1mM, cell density appears to continue to increase but at a lower rate than at 0.01mM 
UDCA and under. 0.01mM UDCA appears to give no effect on cell density. Figure 4.3.4.1.2 
shows the quantified area under curve values for the areas mapped out by the lines in figure 
4.3.4.1.1. Visually, UDCA concentration shows a negative effect on cell density. 
This is confirmed by the p values, shown in table 4.3.4.1, where 0.25mM, 0.5mM and 1mM 
all show a significant difference from E (p=0.031, p=0.004, p=0.026 respectively).  
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Figure 4.3.4.1.1: Graph of cell density of H69 cell line cells at different 
concentrations of UDCA over 96 hours 
This graph shows cell density of H69 cells at different UDCA concentrations including 
carrier alone (E) and no carrier (M). Each concentration was plated in duplicate and cell 
densities were averaged, then lines plotted based on these averages. These results can 
be quantified and compared by calculating the area under curve of each individual line.  
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Figure 4.3.4.1.2: Graph showing the area under curve values for each concentration 
of UDCA used on H69 cells 
This graph shows the area under curve for the average cell density at each concentration 
of UDCA used. Concentrations of 0.1mM and above appear to visibly show less cell 
density than the carrier. 
 
 
 
P values for area under curve 
 
  p 
Co
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at
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n 
UD
CA
 
m 0.348 
1mM 0.026 
0.5mM 0.004 
0.25mM 0.031 
0.1mM 0.054 
0.05mM 0.7 
0.01mM 0.385 
Table 4.3.4.1: p values for area under curve data 
P values are from t tests of area under curve data comparing to the ethanol carrier, E. 
0.25mM, 0.5mM and 1mM all show a significant difference from E (p=0.031, p=0.004, 
p=0.026).  
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4.3.4.2: Supernatant transfer assay 
Cells analysed by flow cytometry were analysed by gating criteria shown in figure 4.3.4.2.1 
where lymphocytes were gated from forward and side scatter, singlets were gated from 
lymphocytes, live cells were gated from lymphocytes, proliferated cells were gated from live 
cells and CD4+ and CD8+ is established by presence of anti-CD8+ PeCy7 antibody and/or 
anti-CD4+ APC-Cy7 antibody. Table 4.3.4.2 shows the proportions (in terms of percentage) 
of the divided cells that are each of the CD4/CD8 combination subsets, and the proportion 
of live lymphocytes which divided, for each volunteer and each condition of the experiment. 
As the values under the CD4/CD8 criteria headings are proportions of the live lymphocyte 
population, they do not indicate increases or decreases of these particular subtypes but 
instead analyse the whole population of divided cells and essentially the ratios of these 
different subsets within this population. Figure 4.3.4.2.2 is a bar chart showing comparable 
levels of the total divided T cell population average across the different criteria of cells 
cultured with: DMEM F12, Supernatant from confluent H69 cell culture, Supernatant from 
confluent H69 culture after addition of UDCA, Supernatant from H69 cells 1 day after their 
wash and media-change, Supernatant from H69 cells 2 day after their wash and media-
change, Supernatant from H69 cells 3 day after their wash and media-change, Supernatant 
from H69 cells 5 day after their wash and media-change and H69 cell lysate. Significant 
results from t-test comparison are shown with dashed lines and the denotation of 
significance by: * - 0.05>p>0.01, ** - 0.01>p>0.001, *** - 0.001>p>0.0001. The confluent 
media was found to give significantly less proliferation of T cells than DMEM alone (p<0.05). 
Therefore, other results were also compared with confluent H69 supernatant and those 
found to show less T cell proliferation were supernatant from H69 cells 1 and 2 days after 
having been washed of all UDCA (p<0.05; p<0.001). The T cell subtype composition of the 
divided cells was then analysed to determine if there is a difference in ratios of CD4+ and/or 
CD8+ of the divided cells in the presence of the different supernatants being investigated. 
Figure 4.3.4.2.3 shows the relevant proportions of CD4+CD8+, CD4+CD8-, CD4-CD8+ and 
CD4-CD8- T cells within the divided T cell population to determine if the CD4+/CD8+ T cell 
ratios are changing in response to a molecule released by H69 cells but there were no 
significant differences detected for these T cell subsets. 
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Figure 4.3.4.2.1: Gating of supernatant transfer assay  
The image shows how lymphocytes were gated based on their dye retention and antibody 
staining. Firstly, the lymphocytes are gated based on their known forward and side scatter 
properties which allows their visual distinction on the forward scatter/side scatter graph. 
Then singlets are selected which are those that have a proportional forward scatter height 
and area (reasoning explained in chapter 3). Alive cells are then selected based on their 
negative DAPI staining, detected in the BV421 channel. Divided cells are then gated round, 
which are those that do not fully stain with CFSE and have undergone at least one division. 
Cells are stained with anti-CD4 APC-Cy7 and anti-CD8 PE-Cy7. A graph of anti-CD4 APC-
Cy7 against anti-CD8 PE-Cy7 allows data collection on single-stained, double stained and 
unstained of these populations. Quadrant gates are based on single stained cells, FMOs 
and isotype negatives as per the methods outlined in chapter 3. 
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Volunteer Tube 
% 
divided 
Of divided population: 
CD4+Cd8+ CD4+CD8- CD8+CD4- 
CD4-
CD8- 
1 
a 37.6 4.1 36.2 55.5 4.2 
b 19.6 2.9 36.5 52.9 7.7 
c 14.8 1.2 40.8 41.0 17.1 
d 9.5 3.2 39.0 44.3 13.5 
e 7.0 2.9 36.0 43.7 17.3 
f 9.9 4.3 34.8 43.7 17.2 
g 19.8 7.9 32.9 50.6 8.7 
h 40.4 8.3 34.7 50.3 6.7 
2 
a 58.9 4.2 50.5 30.1 15.2 
b 33.6 2.8 55.5 25.4 16.3 
c 26.5 2.9 54.1 28.9 14.1 
d 2.5 0.0 22.5 16.1 61.5 
e 4.6 1.2 28.5 12.9 57.3 
f 23.2 2.1 61.4 22.5 14.0 
g 40.8 2.7 62.7 27.1 7.6 
h 43.1 3.6 49.8 26.1 20.4 
3 
a 55.0 1.5 44.3 45.7 8.5 
b 30.4 0.3 25.7 55.7 18.3 
c 20.9 0.1 25.5 51.1 23.4 
d 6.5 0.0 12.1 20.4 67.5 
e 7.6 0.0 19.3 23.2 57.5 
f 20.7 0.2 28.9 47.9 23.0 
g 40.3 0.4 31.9 56.0 11.7 
h 55.2 7.4 40.0 46.7 5.9 
Table 4.3.4.2: Table to show amounts of each cell type as a percentage of the parent 
group. 
 
This table shows the percentage of cells within a parent gate of the subgroup listed at the 
top of each column. The tube letter indicates the additive used, where: 
a – DMEMF12 
b – Supernatant from confluent H69 cell culture 
c – Supernatant from confluent H69 culture after addition of UDCA 
d – Supernatant from H69 cells 1 day after their wash and media-change 
e - Supernatant from H69 cells 2 day after their wash and media-change 
f - Supernatant from H69 cells 3 day after their wash and media-change 
g - Supernatant from H69 cells 5 day after their wash and media-change 
h – H69 cell lysate. 
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Figure 4.3.4.2.2: Chart to show significantly different results when comparing all 
conditions to DMEM only and with confluent supernatant 
Bar heights indicate the percentage of CD3+ T cells which proliferated, with different 
additives shown in the x axis. Significant results from are shown with dashed lines and the 
denotation of significance by: * - 0.05>p>0.01, ** - 0.01>p>0.001, *** - 0.001>p>0.0001. 
 
Figure 4.3.4.2.3: Chart to show percentages of divided cells of each of the different 
T cells investigated. 
Bar heights indicate the percentage of each cell type which had proliferated, with different 
additives shown in the x axis. There were no significant results when comparing to 
DMDMF12 alone or confluent supernatant.  
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4.4: Discussion 
4.4.1: Aims 
The primary aim of this chapter was to investigate if UDCA could be having a direct 
effect on lymphocytes important in PBC, particularly the T cells. An effect on both 
proliferation of T cells and also their reactivity to antigen was investigated.  The 
possibility of an indirect effect was also investigated by utilising the supernatant from 
a cholangiocyte cell line which had been treated with UDCA. 
Furthermore, it was hypothesised that UDCA may be having a selective effect on 
certain subsets of T cells, which may alter the profile of cytokines released which 
have an influence on isotype switching in the plasma cells. Therefore, a flow 
cytometry experiment was developed to investigate if UDCA was having a selective 
effect on different T cell subsets.  This data would then be compared with antibody 
data in chapter 6, which investigates the levels of antibodies of different isotypes, 
against the common autoantigens in PBC, in the serum of PBC patients. 
This chapter also used the cholangiocyte cell line to determine if any effect on 
proliferation was specific to T cells.   
 
4.4.2: Investigating a toxic effect of UDCA 
Apoptosis assays were carried out to investigate a toxic effect of UDCA. The initial 
apoptosis assay used concentrations up to 300µM over 3 days. This assay used 
carriers of ethanol and DMSO. This was to compare the solubility of UDCA in 
ethanol and DMSO to decide which carrier to use. The UDCA used is not soluble in 
water or media.  
None of the data in this study suggest that DMSO or ethanol are particularly harmful 
to cells at the concentrations used and there was no significant difference between 
apoptosis assay results when comparing DMSO to ethanol (p values not shown). 
Significantly different results when ethanol is used occur at 0h, 100µM (p=0.026) 
UDCA and 300µM (p=0.029), shown in figure 3.1.1. The significant p values at 0h 
in the ethanol experiment could be attributed to cells having not been mixed 
thoroughly or some being stuck together from the cell culture practise so that cells 
are not uniformly distributed in the culture, because after 24h the cell numbers are 
no longer significantly different regardless of UDCA concentration, so this is more 
likely a discrepancy relating to the culture of cells rather than toxicity of the drug. 
However, with DMSO, there is a less explainable pattern of significantly different 
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results, comparing to carrier alone. The results significantly different from carrier 
alone include for example at 24h, 100µM (p=0.016) and 120h, 100µM (p=0.029), 
which does not seem sensible given that there was no significant difference at any 
other time point for 100µM UDCA or for higher UDCA concentrations. One 
explanation could be that DMSO may be less soluble in cell culture medium than 
ethanol so that there may be pockets of higher concentration of DMSO, having a 
local toxic effect on the cells in some cases which is affecting the results and giving 
the significantly different counts. Because of this possibility, ethanol was used as 
the UDCA carrier for all further experiments involving the dissolving of UDCA. 
 
4.4.3: Investigating an antiproliferative effect of UDCA on T cells 
Although there is some data in the literature which suggests that cholangiocyte 
proliferation may be attenuated in the presence of UDCA (Munoz-Garrido et al., 
2015), no such study has been carried out on lymphocytes thought to be of 
importance in PBC, such as the T cells. 
Figure 4.3.3.1 shows that at increasing concentrations of UDCA, there are fewer 
cells proliferating into beyond the second division and figure 4.3.3.2 indicates 
significantly less proliferation between 300µM UDCA and carrier alone. This is novel 
preliminary evidence to suggest that UDCA may be having a direct effect on the 
proliferation of T cells. Section 1, Introduction, of this chapter outlines potential 
clinical relevance of an antiproliferative effect of UDCA on T cells.  
Following on from this, an assay was devised which would be able to differentiate 
the T cell sub-sets, such that CD4+ T cells, Th1, Th17, Th2, Th1/Th17, CD8+ T 
cells, Tc1, Tc2, Tc17, Tc1/Tc17, Treg cells and CD45RO+ Tregs could be counted 
as populations and compared. The generation of this assay is described in chapter 
3. Notable findings include significantly less proliferation in CD8+ T cells in response 
to UDCA, but also some data suggests that CD4+ may also be relevant. The 
experiment uses 2 tubes per volunteer, one for examining an effect on CD4+ and 
CD8+ T cells and another for examining Tregs, using a CD4+ marker. In the 
CD4+/CD8+ tube, there did not appear to be an impact on the proliferation of CD4+ 
T cells (p=0.24), however in the Treg tube a significant attenuation of proliferation 
of CD4+ T cells was detected (p=0.008). Therefore, in this study there is evidence 
to suggest an antiproliferative effect of CD4+ T cells by UDCA but it is only 
sometimes detected. There are differences between the 2 tubes which could 
account for the discrepancy. The Treg tube uses a fixation technique not applied to 
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the other tube; the Treg tube does not make use of the DAPI dye; the Treg tube 
does not use a CD8+ identifier. The fact that no CD8+ identifier was used in the 
Treg tube means that the effect identified could apply to all T cells, not just CD4+. 
The DAPI dye is not used in the Treg tube, meaning cells are gated on the 
lymphocyte population, not the live lymphocyte population, so it cannot be known if 
this effect would be detectable within the live population. However, no significant 
effect of increased UDCA on live cell percentage was found in the other tube. The 
discrepancy could be where examining the live and dead cell population, there will 
be less recorded proliferation of all cells as the dead cells will not proliferate, so any 
effect on proliferation of a population caused by UDCA may seem exaggerated due 
to the inclusion of dead cells. To surmount this, a dead/live cell identifier which is 
compatible with the fixation/permeablisation could be used instead of DAPI, and in 
both tubes. Some examples of these are Thermofisher Fixable Violet stain and 
Fixable Aqua stain, which use the BV421 and BV510 channels respectively, so this 
should not involve re-compensation of all dyes, none of which are in these channels.  
CD8+ T cells showed significantly less division in the presence of higher 
concentration of UDCA compared with the carrier of 0.3% ethanol alone. There was 
also a significantly larger proportion of CD8+ Tc2 T cells within the divided CD8+ 
population at 0.25mM UDCA compared with carrier alone (p=0.03). This could be 
suggested to indicate that this sub-population of CD8+ T cells is more resistant to 
the anti-proliferative effects of UDCA than other sub-types. Tc2 cells, or type 2 
cytotoxic T cells, are involved in activation of dendritic cells. Like Th2 cells, Tc2 cells 
secrete IL-4 and IL-5 and so may be involved in related functions such as stimulating 
B cell immunoglobulin isotype switching to IgE and recruiting eosinophils, which 
combat infections such as multicellular parasites (Kemp et al., 2005). 
However, the Tc2 population is extremely small with the difference only increasing 
in terms of percentage of live lymphocytes from 0.148% to 0.176% (averages) or 
0.87% of divided CD8+ T cells to 2.3% (averages). Therefore, any effect on these 
cells by UDCA is unlikely to show a large phenotypic difference compared with the 
action of other cells.  
There was no difference seen in proliferation of any of the Th subsets in the 
presence of UDCA compared to vehicle alone. Although unlikely, it is possible that 
with a more highly powered study small differences may become significant.  The 
volunteers available happened to be male and female and of vastly different ages, 
therefore their T cell subset blood levels could be influenced by age or gender, 
therefore a future study should involve sufficient volunteers to determine if there are 
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any fundamental differences between these groups. One study has shown a 
positive correlation between CD4+/CD8+ ratio and age and also a greater normal 
CD4+/CD8+ ratio range in males than females (Jentsch-Ullrich et al., 2005), 
therefore a further study should be powerful enough to account for these 
differences. 
Overall, the study investigated an effect on proliferation of T cells by UDCA and 
found a differential proliferation effect on T cell subsets, this data is interesting 
although not completely conclusive. This study is the first to investigate an 
antiproliferative effect of UDCA directly on T cells and shows promising evidence. A 
more thorough study is required to further underpin the types of T cell affected by 
UDCA in this way. The assay should involve different groups of individuals such as 
males of a young age group, males of an older age group, females of a younger age 
group, females of an older age group. This would mean that an age effect on the 
normal T cell profiles could be investigated while also investigating a differential 
effect on the proliferation of T cell subsets in an age and gender controlled manner. 
The groups should contain more individuals for a more highly powered study. 
Furthermore, any findings from this experiment should be confirmed by a Western 
blot staining for the extracellular proteins which identify these T cell sub sets or by 
RTqPCR of the T cells, to investigate proteins produced which would imply their 
subsets. 
 
4.4.4: Investigating an impact of UDCA on the reactivity of T cells 
in the ELISpot assay 
The ELISpot assay aims to mimic the environment in which lymphocytes release 
cytokines in response to a stimulus in a way that allows detection and quantification 
of the release of cytokines. This assay can be manipulated to provide different 
conditions to determine if the ability or inclination of a cell to respond to a stimulus 
is different depending on these conditions. In order to investigate if UDCA has an 
effect on a T cell’s ability to respond to antigen, a series of ELISpot assays were 
carried out on PBMCs from healthy volunteer blood and these were manipulated by 
using the absence or presence of various antigens, and different UDCA 
concentrations were investigated.  
Furthermore, to determine if any effect of the drug is due to toxicity or possibly a 
direct inhibition effect, a flow cytometry experiment was carried out on cells collected 
from the ELISpot assay and stained with DAPI to investigate the percentages of 
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alive and dead cells. It was found that there was no more death in cells at higher 
UDCA concentrations in the context of the ELISpot, when using the anti-CD3 
mitogen therefore any difference in response to antigen at difference concentrations 
of UDCA is likely to be due to an inhibition effect of UDCA on the ability of the T cell 
to react to antigen. However, at 1mM UDCA, when cells are not stimulated, there 
were significantly more dead cells identified (p=0.012). In light of this discrepancy 
between stimulated and unstimulated cells in the ELISpot assay, it could be 
suggested that UDCA is more toxic to cells at rest than it is to active cells.  One 
possible explanation for this may be an increased accumulation of the drug inside 
the resting cell and not the fast-dividing cell, however for this study it may be 
assumed that 0.5mM is the highest concentration investigated at which UDCA is not 
toxic to cells in the context of the ELISpot. 
The PBMCs only remain in the assay for 18-20h. A rapidly dividing human cell may 
take approximately 24h to divide (Yoon et al., 2010) therefore the ELISpot likely is 
not concerned with the division of T cells and only the reaction to antigen.  
All ELISpots were carried out using the capture antibody for IFN-γ, therefore all 
results obtained are analysed with respect to cells which release IFN-γ in response 
to the antigen in question. Therefore, this study is concerned with helper T cells, 
with a particular interest in Th1, and also cytotoxic T cells.  
When the ELISpot was carried out using an anti-CD3 mitogen to induce response 
in the T cells, it was found that there were significantly fewer cells reacting when the 
UDCA concentration was 0.5mM (p=0.002, table 4.3.2.2.4). However, when 
common antigens likely encountered by most healthy individuals were used to 
stimulate the T cells in a more realistic way, this significance was not apparent (table 
4.3.2.2.6). Those common antigens used were cytomegalovirus (CMV), Epstein 
Barr Virus (EBV) and salmonella. Although use of a common antigen is a more 
realistic way to stimulate T cells, different test antigens were used on each 
individual. In this study, there were a small number of individuals available and a 
small panel of test antigens, therefore a best antigen for each individual had to be 
established. Response to different antigens is always different, particularly between 
different individuals, therefore this may explain why there was no significance with 
the realistic antigen when the result was apparent with the anti-CD3 mitogen. A 
future study should use more volunteers and a larger panel of antigens in order to 
establish one common antigen to which all of the volunteers respond in a similar 
way and this ELISpot should be repeated. This is more likely to give an accurate 
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result. The fact that a significant difference was apparent with the anti-CD3 mitogen 
is evidence to suggest that there is an inhibition effect of UDCA on the ability of the 
T cells to react to antigen and therefore it should be further investigated. Given that 
this is the highest dose which did not indicate a significantly toxic effect on T cells, 
it may otherwise be that UDCA places T cells under stress and leaves them less 
able to respond to stimulus. 
 
4.4.5: Investigating an anti-proliferative effect of UDCA on a 
cholangiocyte cell line 
An xCELLigence assay was carried out to investigate an effect on proliferation of 
the cholangiocytes by UDCA. The cholangiocyte cell line H69 was used. The H69 
cell line is an immortalised cell line originally isolated form a liver harvested for 
transplantation, which has been transformed with simian vacuolating virus 40 to 
allow for continuous replication by suppression of cell death regulator p53 (Grubman 
et al., 1994). 
Flow cytometric analysis is not usually carried out to measure proliferation of 
adherent cells, but the xCELLigence assay can be used instead. The xCELLigence 
assay uses a gold plate with a voltage applied across it. A change in the ion 
concentration, which occurs when there is cellular proliferation, is detected by 
electrical impedance in the electrodes and this change is measured by the software 
(Ucran et al., 2010). 
Some evidence in the literature suggests that there may be an anti-proliferative 
effect on cholangiocytes by UDCA (Alpini et al., 2002). This group compared the 
numbers of cells expressing proliferating cell nuclear antigen (PCNA) which is an 
intracellular DNA scaffold protein and its presence is indicative of DNA replication, 
therefore cell proliferation. They found significantly less PCNA in the cholangiocytes 
of rats fed with UDCA or TUDCA than those of the control rats. Additionally, 
apoptosis was not found to be increased in those rats fed UDCA or TUDCA (Alpini 
et al., 2002). In accordance with this literature, the study in this chapter which 
investigates an antiproliferative effect using xCELLigence shows significantly less 
cholangiocyte proliferation at UDCA concentrations above 0.25mM as shown by the 
low index line in figure 4.3.4.1.1, low area under curve value in figure 4.3.4.1.2 and 
significant p values of 0.031 for 0.25mM, 0.004 for 0.5mM and 0.026 for 1mM. This 
data, although produced from only a single experiment, is useful as it not only 
supports that seen in the literature (Alpini et al., 2002) but also reflects that seen 
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from our own T cell proliferation experiments, indicating that UDCA may have an 
anti-proliferative effect on a number of different cell types. To further confirm this, 
other unrelated cell types could also be investigated for an antiproliferative effect 
due to UDCA presence and potential mechanisms of this effect could be 
investigated.  
 
4.4.6: Investigating an indirect effect of UDCA on the proliferation 
of T cells 
To further investigate the effect of UDCA on the cholangiocytes and the role of T 
cells, a supernatant transfer assay was carried out to examine if metabolites or other 
compounds released by cholangiocytes in response to UDCA presence, could then 
itself affect proliferation of T cells. T cells were cultured in 50% H69 media for the 
control and H69 supernatant form various cultured of H69 cells and the proliferation 
was compared by flow cytometry, gated shown in figure 4.3.4.2.1. Figure 4.3.4.2.2 
shows a significant difference between proliferation in DMEMF12 alone and 1, 2, 3 
and 5 days after H69 wash post-UDCA treatment (0.01>p>0.001), however there 
also appears to be significantly less proliferation when just confluent H69 media is 
used without any UDCA treatment (p<0.05), indicating that H69 cells may normally 
release a molecule which attenuates T cell proliferation. This is not completely 
surprising: although there is little in the literature to confirm this, one study has 
shown that healthy biliary epithelial cells BECs can regulate T cell proliferation both 
in a contact-dependent and contact-independent manner (Kamihira et al., 2004). 
The study also suggested that BECs release prostaglandin E2 (PG-E2), controlled 
by IL-1β and TNF-α and known to supress T cell signalling, which is the factor 
responsible for the attenuation in T cell proliferation (Kamihira et al., 2004). In order 
to investigate if there is an additional effect on T cell proliferation to do with UDCA 
treatment, the effects of supernatants post-wash on T cell proliferation were then 
compared with the confluent H69 media-containing cultures. Figure 4.3.4.2.2 shows 
that using H69 supernatant from culture from 1 and 2 days after wash post-UDCA 
treatment, there is less T cell proliferation than using confluent H69 culture (1 day – 
p<0.05; 2 days – 0.001>p>0.0001). Data from this experiment suggests that H69 
cells, which can be used as a model for BECs (Grubman et al., 1994), release a 
component, possibly PG-E2 based on the Kamihira study, which causes a decrease 
in T cell proliferation but also then if the H69 cells have been treated with UDCA, 
then there is an even greater effect. Furthermore, this effect can last for up to 2 days 
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post-UDCA exposure. This is evidence to suggest a new mechanism of action for 
UDCA.  
 
4.4.7: Conclusion 
This study has produced interesting data which suggests that UDCA may have an 
effect on cellular proliferation of a different cell types and activation of CD4+ T cells. 
Further experiments are required to confirm these finding and to elucidate futher the 
differential effect on different T cell subtypes. If any differences in the effect of UDCA 
on proliferation of T cell subtypes is found it may help to further our understanding 
of how UDCA elicits its effects in PBC patients.  Further experiments which then 
investigated the mechanisms by which this effect is mediated, and if there is a 
difference in this effect between responders and non-responders, would help to 
elucidate phenotypic differences between these patient groups. 
 
4.4.8: Further work 
This chapter gave little to suggest a differential impact of UDCA on CD4+T cell 
subsets, however, as the data suggests a CD8+ importance, the panel could be 
redesigned to investigate CD8+ subsets rather than CD4. This could include focus 
on CCR7 and CD45RA to help identify naïve(CCR7+CD45RA+), central 
memory(CCR7+CD45RA-), effector(CCR7-CD45RA+), effector memory(CCR7-
CD45RA-) CD8+ T cells to determine if there is a differential effect of UDCA on 
these subsets (Maecker et al., 2012). 
Additionally, the inclusion of a fixable live/dead stain such as ThermoFisher 
Live/Dead Fixible Aqua or Violet stain (using channels BV510 and BV421 
respectively) would allow for live/dead analysis of cells in the Treg tube. Additionally, 
this panel could be applied for use on patient peripheral T cells before and after 
significant UDCA usage for a more accurate determination of if the drug usage has 
an effect on the population of T cells.  
It has been suggested that prostaglandin-E2 is released by BECs which can cause 
a decrease in T cell proliferation by inhibiting the T cell receptors (Kamihira et al., 
2004). Combined with the supernatant transfer assay data from this chapter, this 
raises the question of if it is this same substance which is causing the further 
decrease in proliferation apparent when H69 cells have been incubated with UDCA 
or if UDCA stimulates the release of another compound which could be causing the 
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further decrease in T cell proliferation. To answer this question, a metabolomics 
experiment could be carried out on the supernatants collected and frozen from the 
transfer assay in this chapter. This would involve gas chromatography-mass 
spectrometry on the supernatants where the analytes are separated and compared 
to a size standard of known metabolites. This could identify the compound of 
interest, or could confirm increased levels of prostaglandin-E2 in the samples from 
UDCA-treated H69 cells. 
 
4.4.9: Limitations 
ELISpot assays were carried out using capture antibodies against other cytokines, 
such as IL-17, IL-5, IL2, IL15 (data not shown as spots were not countable for their 
tabularisation). However, these led to blackouts as plate optimisation was not 
effectively carried out beforehand. When experimenting with a new capture 
antibody, the cell number must be carefully titrated beforehand to obtain a range of 
cell concentrations in which plenty spots are visible, which reduces error in the data, 
but also not so many that they merge together making them uncountable. In this 
instance it was not possible to optimised prior to the experiments being performed 
as due to cost constraints there were insufficient reagents available to both titrate 
the plates or carry out the experiments. Therefore, the risk was taken to carry out 
experiments using estimated values. Future experiments would repeat all 
successful ELISpots carried out in this study and carry out those highlighted for 
future work but using new capture antibodies as well, such as IL-17, IL-5, IL-2, IL-
15. This would allow the assay to be carried out in the context of smaller populations 
of cells such that the effects in question on different T cell subtypes can be 
compared.  
Prior to this study, many possibilities for the effect of UDCA have been investigated, 
such as protection of cholangiocytes against apoptosis (Benz et al., 1998), an 
immunosuppressant effect in new tissue grafts (Zhang et al., 2009), increased 
expression of ion exchange proteins and multidrug resistance proteins on the 
canalicular surface (Beuers et al., 2001). However, this is the first study to 
investigate in such depth an effect of UDCA on the proliferation of T cells both direct 
and indirect. 
This study has uncovered more than one potential effect of UDCA on not only on 
the isolated T cells but also the T cells within the PBMC population. A control 
substance for UDCA was, however, not established. A control substance is used to 
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compare the compound of interest to a similar exogenous substance. It is used to 
investigate if there is an element of the documented effect which may be due to 
toxicity, or a property which could be present in many substances and is not 
necessarily unique to the compound being used. As this is one of the first studies to 
explore a direct effect on T cells of UDCA, it is difficult to predict which 
property/properties of UDCA is/are causing the effects on T cells uncovered in this 
study and if there could be similar compounds which could have similar effects.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5: The development of an ELISA assay 
using End Point Titre to compare serum levels 
of anti-PDC autoantibodies in UDCA responder 
and non-responder PBC patients. 
Abstract 
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Evidence suggests that within the population of patients with Primary Biliary 
Cholangitis (PBC), there are subgroups of patients with different forms of the 
disease with different severities and showing different blood biochemistry, notably 
those who respond to UDCA, ‘responders,’ and those who do not, ‘non-responders’.  
This chapter outlines optimising and testing the validity of autoantigen specific 
indirect end point titre enzyme-linked immunosorbent assays for their use in 
measuring antibody levels in PBC patients and healthy volunteers. End point titre 
ELISAs were used to investigate the magnitude of IgG antibodies against common 
autoantigens in PBC. These were then compared with values obtained by initial 
screening the serum for these antibodies to determine if by screening would be an 
adequate representation of the calculated end point titre. Results were compared 
by Spearman’s Rank correlation.  The results from this chapter will be brought 
forward into the next chapter for statistical analysis. Any differences found may 
further elucidate the mechanism behind the sub-grouping apparent in this disease 
and can help pave the way for more stratified treatment approaches. 
 
5.1: Introduction 
5.1.1: Common autoantigens in PBC 
The common autoantigens in PBC are discussed in more detail in chapter 1 and 
further on in of this chapter. The most common autoantibodies in PBC are those 
against E2 and E3BP subunits of Pyruvate dehydrogenase complex (PDC) 
(Harriman et al., 1998) (Jones, 2000) (Dedobbeleer et al., 2017). Further studies 
have narrowed down the most commonly recognised epitope to be a region within 
the E2ILD binding region but also highlighted the importance of other less common 
autoepitopes within the E2 subunit of PDC (Suhr et al.,1990). The subunits of E2 
and E3BP are very similar in structure and sequence, with a further study 
characterising the similarity between the dominant PBC autoepitope from E2ILD 
with a region within E3BP which both contain a lipoyl domain (Todryk et al., 2009). 
Therefore, it is possible that autoantigens could bind both epitopes due to epitope 
spreading. Figure 5.1.1 shows the similarity between the ILD autoepitope of E2 and 
the corresponding lipoyl domain of E3BP. 
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Figure 5.1.1: Domain diagram of PDCE2 and PDCE3BP to compare lipoyl domain 
autoepitope sequences. 
Adapted from ‘T cell responses to the putative dominant auto-epitope in 
primary biliary cirrhosis (PBC),’ (Palmer et al.,1999), this figure depicts a key region from 
within the ILD of E2 and the corresponding region of E3BP. The sequences are identical 
except for 2 residues: a Leucine/Alanine and an Alanine/Cysteine. 
 
5.1.2: Isotypes and class switching 
Briefly; to test for PBC, the AMA-M2 ELISA panel is used to detect anti-mitochondrial 
antibodies of the IgG isotype (Han et al., 2017) (section 5.1.3.5: AMA). In this study, the 
presence of various isotypes of patient antibody against the autoantigens is investigated. 
Cytokines released by CD4+ T cells can influence a plasma cell to undergo isotype 
switching, causing it to release a different isotype of antibody which still recognises the 
same antigen (Yu et al.). Chapter 4 postulates a selective effect of UDCA, the common 
therapy for PBC, on different subsets of T cell. Additionally, it has been heavily argued both 
within this work and also in the literature that PBC likely consists of different subsets, 
possibly with different biological underpinnings (Carbone et al., 2013). Some evidence from 
a genome-wide association study (GWAS) which may indicate a T cell influence to PBC is 
outlined below. 
 
5.1.2.1: Known isotype switching influence by T cell subsets 
It has been well-documented that some cytokines directly released by CD4+ T cells can 
directly affect isotype switching in B cells(Toellner et al., 1998). Furthermore, even very 
early on after differentiation, some T cells can be already influencing the antibody profile, 
therefore suggesting the T cell influence is of high importance to the antibody isotypes 
produced by B cells (Toellner et al., 1998). It is important to note, as outlined in the general 
introduction, that helper T cell CD40L binding to B cell CD40 is required to prime the B cell 
for T cell-dependent isotype switching. Although there is considerable variability within CD4+ 
T cell subsets, a general summary of the influence of each major subset is described below.  
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Th1 
Th1 cells release IFN-γ favours an IgG3 isotype in terms of its influence on class switching, 
and can downregulate IgG1 and IgE (Abbey and O'Neill, 2008).  
Th2 
Th2 release cytokines IL-4, IL-5 and IL-13, known to affect isotype switching. IL-4 has been 
shown to predominantly cause switching to the IgE isotype but may also influence switching 
to IgG1(Lebman and Coffman, 1988a). When there is IL-4 and IL-13 together, isotype 
switching can favour both IgG4 and IgE (Gascan et al., 1991). IL-5 has been shown not to 
cause isotype switching but to cause maturation of IgA-positive B cells into IgA-secreting B 
cells (Harriman et al.,1998). 
Th17 
The effect on isotype switching by Th17 cells is not generally well-understood. However, a 
study which co-cultured Th17 cells with B cells and measured isotypes production in 
response to Th17 cytokines has suggested that IL-17 on its own favours IgG3, whereas 
together with Th17-released IL-21, favours IgG1 (Mitsdoerffera et al., 2010).  
Treg 
Treg cells release IL-10 and TGF-β. IL-10 is known to induce class switching to IgG1 and 
IgG3 (Fujieda et al., 1998) or together with TGF-β, IgA1 and IgA2 (Zan et al., 1998). 
TFH 
Follicular B cell helper T cells (TFH) express IL-21 which has been shown to predominantly 
cause isotype switching to IgG1 (Mitsdoerffera et al., 2010). 
IL-6, released by macrophages, dendritic cells and B cells but also some epithelial and 
endothelial and some other non-haematopoetic cells, has been shown to act 
antagonistically to IFN-γ in that it can prevent IFN-γ mediated reduction in IgG1, but also is 
mediated by IL-21 to enhance a Th2 response phenotype (Dienz et al., 2009). 
 
5.1.2.2: Functions of different antibody isotypes 
The different antibody isotypes have different abundances, distributions and functions in 
the body. IgM is either used in monomeric form as part of the B cell receptor or is secreted 
in pentameric form. Membrane-bound IgM functions in combination with invariant proteins 
Igα and Igβ to form the B cell receptor, with the IgM functioning as the detector of antigen 
and the accessory Ig portions associating with IgM heavy chains to transport it to the cell 
surface and transduce the signal intracellularly. Secreted IgM is pentameric, giving rise to 
multiple possible binding rendering it particularly useful for activating the complement 
system.  
IgD forms the antigen recognition subunit of the BCR on naïve B but can also be secreted. 
IgD binds epitopes of low surface density on the target cell. IgD is able to bind basophils 
and mast cells to induce production of antimicrobial peptides.  
 147 
IgG has 4 subtypes denoted 1-4 based on their abundance. IgG3 has the greatest functional 
potency, followed by IgG1and then IgG2 and IgG4. IgG antibodies are particularly adapted 
for diffusion into extravascular sites. All IgG subtypes have the potential to neutralise 
pathogens. Particularly IgG1 and IgG3 are able to sensitise NK cells for killing of a pathogen 
and they are also able to sensitise mast cells (Lu et al., 2017). 
IgA is present in the serum in monomeric form and the mucosa in dimeric form. It is 
particularly effective for transport across epithelium and diffusion into extravascular sites 
(Lu et al., 2017). 
IgE is associated with a Th2 response and is able to sensitise mast cells. IgE is associated 
with allergies and parasite infection (Lu et al., 2017).  
 
5.1.3: Potential for genetic differences between groups  
A genome-wide association study (GWAS) was carried out which identified key at-risk 
alleles in PBC and other autoimmune liver diseases. Many of the loci of interest in PBC 
were those within genes involved in T cell maturation and signalling, including STAT4, IL-
12RB2, IL-12A, CD80, IL-7R, CXCR5 (Mells et al., 2013). The natures of the mutations in 
terms of their effect on their protein function were not outlined in the study and in addition 
no study has yet been carried out to determine any possible categorisation of the mutations 
in the context of responder/non-responder sub grouping. However, they do highlight 
pathways which may be of interest in PBC pathogenesis and there could be responder/non-
responder differences.  
Of particular interest, IL-12RB2 and IL-12A are both also involved in the differentiation of 
naïve T cells to Th1 in response whereby IL-12RB2 is a subunit of the IL-12 receptor and 
IL-12A is p35, the subunit of IL-12 not shared with IL-23 (Lupardus and Garcia, 2008). 
STAT4 is the transcription factor involved in mediating the response of IL-12 in the Th1 cell 
(Varikuti et al.). Th17-directing IL-23 shares a subunit, p40, and also a receptor subunit, IL-
12Rβ1, with IL-12, therefore the ratio of Th1/Th17 cells there are in the environment 
depends in part on the ratio of p35/p19, the IL-12 and IL-23 specific subunits, associating 
with p40 (Lupardus and Garcia, 2008). Th17 cells have been associated with advanced 
PBC and are thought to be proinflammatory in autoimmune diseases (Tabarkiewicz et al., 
2015). Any loss of function mutation in STAT4, IL-12A or IL-12RB2, could then cause a 
Th17 skew, potentially leading to a more aggressive disease. If any of these hypothesised 
genotypes is specific to responders or non-responders, it would likely be the non-
responding population, as the non-responders have an overall more progressive and fast-
advancing disease (Carbone et al., 2013). It is difficult to detect increased Th17 activity by 
isotype switching, as Th17 cells have not been shown to directly affect B cell isotype 
switching, however some studies in mice have shown that IL-17 and IL-21, released by 
Th17 cells, may cause isotype switching to IgG2α and IgG3; IgG2β and IgG1 respectively. 
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A Th1-dominant T cell population may be expected to show increased IgG2α but possibly 
also IgG3, and possibly also lower levels of IgG1 and IgE (Mitsdoerffera et al., 2010).  A 
Th17-dominant T cell population may be expected to show higher levels of IgG2β and IgG1, 
or possibly increased IgG2α and IgG3, depending on which cytokines are released 
(Mitsdoerffera et al., 2010). 
IL-7R, a gene encoding a receptor subunit for IL-7, is important for B and T cell 
development, but is also involved in V(D)J recombination in both T and B cells (Hamel et 
al., 2014). A study has shown that IL-7 may, in the presence of T cells, cause isotype 
switching to IgE and IgG4, therefore increased IgE or IgG4 in one group compared with the 
other may suggest it is worth investigating the possibility of a gene variant in IL-7R which 
may genetically distinguish the groups (Jeannin et al., 1998). 
CD80, although expressed on dendritic cells, activated B cells and monocytes, is important 
for T cell activation and survival as it provides a co-stimulatory signal for the TCR/CD3 
interaction (Matsumoto et al.). 
TFH cells are an example of cell that expresses CXCR5. This cytokine is important for 
migration into B cell follicles in lymph nodes where the TFH cells induce maturation of B 
cells to antibody-secreting or memory B cells (Mitsdoerffera et al., 2010). TFH predominantly 
secrete IL-21 which encourages isotype switching to IgG1 (Spolski and Leonard, 2010). 
From all of the above information, it is possible that different patients present different 
isotypes of antibody against autoantigens within the PBC population potentially due to 
influence of cytokines produced by CD4+ T cells. Therefore, the presence of isotypes IgG 
(and its subtypes of IgG1, IgG2, IgG3 and IgG4), IgA, IgM and IgE will all be investigated 
in this study. 
 
 
 
 
 
 
5.1.4 The ELISA assay 
5.1.4.1: Indirect ELISA 
ELISA is an assay which can measure levels of a biomarker such as a protein, peptide, 
hormone or antibody in a given substance. Detection and measuring of the response is 
facilitated by the detection antibody conjugated to an enzyme which, when the correct 
substrate is added, gives a coloured product, the intensity of which is read in a plate reader 
and displayed on relevant software. The detector antibody conjugate and necessary 
substrate can vary. In the case of this chapter, levels of antibody are being investigated in 
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patient serum. The indirect ELISA, depicted in figure 5.1.4.1, is most appropriate because 
it offers 2 levels of specificity: specific binding of the target molecule (serum antibodies) and 
their specific detection (Wang et al., 2017) whereas other methods such as the direct ELISA 
do not, and so are more prone to non-specific binding and background (Chughtai et al., 
2017).  
 
 
Figure 5.1.4.1: Diagram of the indirect ELISA 
This diagram shows an illustration of the molecules making up the indirect ELISA in place 
where presence of the primary antibody is the antibody being detected. The antigen is 
fixed to the well bottom surface. 
 
 
 
 
 
 
5.1.4.2: End point titre ELISA 
Usually, in an ELISA assay, standard samples will be included. These contain the molecule 
of interest at known concentrations so that the absorbance values from the test wells can 
be compared with absorbance values from the standard wells on a graph to determine the 
concentrations of the molecule of interest in the test wells (Whitehead et al., 2017). For 
experiments conducted in this study, a size-standard was not available therefore, the 
alternative method, the end point titre method, was used. The end point titre is arguably 
more accurate as the result is an estimation calculated from several test result points rather 
than one comparison to one size standard (Dey et al., 2008).  
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If the protein coating concentration is kept the same, as the sample is diluted, there is a 
specific corresponding absorbance pattern which can be plotted on a graph. Illustrated in 
figure 5.1.4.2.1, as the dilution factor increases, initially there is no change to the 
absorbance reading. This is because the equipment is only able to measure absorbance 
values up to a limited intensity, but also the sample may be so concentrated that all of the 
capture protein molecules on the well floor are completely saturated with antibody, so any 
additional antibody is washed away and is not read. This is shown by the initial plateau on 
the graph and is the first limitation. The next stage is the linear region where the capture 
protein becomes unsaturated because the concentration of the antibody in the sample no 
longer exceeds the capacity of the protein coating. In this region, ever increasing dilution 
gives a corresponding ever decreasing absorbance reading, as there are fewer subsequent 
detector antibodies to provide the output read as the absorbance reading, labelled ‘linear 
region’ in the graph (Kannian et al., 2007). Then there is another plateau where the antibody 
is diluted such that the signal is no longer distinguishable from background absorbance, 
illustrated as the second plateau in the graph, so ever-increasing dilution factors give no 
effect on the absorbance value. This is another limitation of the assay. 
In order to carry out the end point titre ELISA, the linear region is of key importance because 
this is where there is a proportional relationship which can be exploited for predictive 
calculations (Dey et al., 2008). If there was no limitation in the capacity of the equipment to 
measure absorbance values based on dilution, this linearity would be apparent throughout 
the graph line. As the concentration of the antibody cannot be directly measured or inferred 
in the capacity of this study, there is another method used to directly compare relative 
amounts of antibody within samples. If there were no limitations described above, then 
theoretically, a sample could be diluted down until a zero absorbance value is reached 
(Miura et al., 2008). Therefore, the amounts of dilution required for each sample to reach 
this zero-absorbance value can be compared between samples and are directly related to 
the amount of antibody in the sample. The amount of dilution required to achieve this 
hypothetical zero absorbance value is the end point titre (Dey et al., 2008). Calculation of 
the end point titre is illustrated in figure 5.1.4.2.2, there the axis have been switched such 
that the graph resembles the form y=-mx+c. The y intercept, where x=0, then corresponds 
to the hypothetical zero absorbance value (Frey et al., 1998). 
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Figure 5.1.4.2.1: Illustration of a graph of dilution of sample against absorbance 
reading for end point titre ELISA.  
The illustration depicts the normal curve established when increasing dilutions of sample 
are plotted against ELISA absorbance readings. There are 2 plateau regions, 
representative of limitations of the assay, and one linear region, labelled, representative of 
an inverse proportion relationship between the dilution of the sample and the absorbance 
read value. 
 
 
 
 
 
Figure 5.1.4.2.2: Graph of sample absorbance read against initial sample dilution 
value for end point titre calculation 
This is an example graph to show how the end point titre, or EPT, is established from a 
graph of different dilutions of the sample. The end point titre is read off the graph when 
the linear line of the form y=-mx+c is extrapolated back to the x=0 value, or the y axis. 
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5.1.4.3: Optimisation of the protein coating concentration 
The ELISA assay must be optimised for antigen coating concentration. The ideal coating 
concentration is not so low that all protein quickly becomes saturated and does not give a 
true reading but also the ELISA reader has an upper limit as to what intensity can be read, 
therefore the protein coating cannot be too high that the machine cannot distinguish 
different values.  
The ideal plate coating concentration will be such that a dilution of the original sample 
applied to this ELISA will give a reading that is in the linear range of dilution values, such 
that the well surface is not saturated which would be wasteful of product but also such that 
the concentration is not so low that the read values are negligible. The dilution factor chosen 
should be within the linear range. For this study, due to there not being an exhaustive supply 
of antigen as it was generously supplied by Newcastle University and not generated on site, 
the dilution factor was established such that it would be efficient use of the proteins 
available: not excessive or wasteful. 
 
 
 
 
5.1.5: Aims of this chapter 
The evidence discussed above suggests that there may be subtypes of PBC patients. Given 
that some of the genes highlighted by the GWAS study cited are known to influence isotype 
switching, it is possible that different isotype patterns of specific autoantibodies may be 
seen in patients from different groups. The primary aim of this experiment is development 
of an assay which will be used to determine accurate autoantigen specific antibody titres 
from patient serum.  The results from these assays will be analysed along with patient data; 
statistical data and analysis of the data is in chapter 6. 
 
5.2: Methods 
5.2.1: Isolation of bE2/E3BP and recombinant human proteins 
Biochemical disassociation of bE2/E3BP was performed by the Dr Jeremy Palmer group, 
Newcastle University. Bovine heart tissue was mechanically disrupted before the tissue was 
lysed using a high sucrose concentration, Glaspergen beads and a magnetic stirrer. The 
sample was centrifuged 3 times at 1000 x g for ten minutes each with discarding of the 
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pellet, then at 14500 x g for fifteen minutes to obtain the mitochondrion fraction. This fraction 
was resuspended in 10% glycerol 10mM potassium phosphate and tosyl-L-lysyl 
chloromethane hydrochloride then frozen for 24h at -50OC. Mitochondria were then freeze 
thawed to disrupt the membranes and then centrifuged at 27000g for 30 minutes and the 
pellet resuspended in 10% glycerol 10mM potassium phosphate with 1 mM-dithiothreitol 
and centrifuged again. The pellet was then discarded and the supernatant pH-adjusted 
before further centrifugation steps to isolate the mitochondrial pellet. Then, to purify the 
mitochondrial pellet, it was first resuspended in 10% glycerol 10 mM potassium phosphate 
with 1 m-dithiothreitol and 1 mM Na-p-tosyl-L-lysine chloromethyl ketone (TLCK) to give a 
final protein concentration of 8-12 mg/ml. This was then stored at -50oC. 
The recombinant human proteins E2, E2ILD and E3BP were grown in recombinant E. coli 
then purified, method not provided. Final concentrations were: bovine heart isolated 
E2/E3BP complex, bE2/E3BP (9mg/ml); rhE2 (1.5mg/ml); rhE2ILD (7mg/ml); rhE3BP 
(1.4mg/ml).  
 
 
 
 
 
5.2.2: Optimisation of the protein coating concentration 
First, an initial screen was carried out using an estimated coating concentration of antigen 
for all patients using the IgG-all secondary antibody from Sigma Aldrich, which is a pool of 
subtypes of IgG antibody. This is the antigen currently used in clinical PBC diagnostic AMA 
assays, therefore was likely to give high readings. The dilution of the first antigen, rhE2, 
was 1 in 100 of the initial 1.5mg/ml and the patient serum was screened at 1 in 25 dilution 
by the method in section 3.3. The patient with the highest screen result was then chosen 
for protein coat optimisation. This is important because the optimisation must aim to take 
into account the maximum achievable result for a given coating concentration and must be 
designed to be relevant for the highest response patient. The ELISA was repeated using 
patient serum at concentration 1 in 25 and different protein coat concentrations. A low 
dilution of patient serum ensured saturation of the coating antigen would be established in 
order to be able to visualise the full graph pattern for protein coating and most accurately 
establish the ideal coating concentration. 
This was repeated for all test antigens. 
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5.2.3: ELISA screen 
Each plate was coated with protein coat solution, with its protein concentration established 
in the protein coat optimisation stage, at a volume of 50µl/well. 96 well Nunc-ImmunoTM 
MicroWellTM immunoassay plates were used throughout, obtained from Sigma Aldrich. 
Plates were incubated overnight at 4oC.  The plates were then washed three times with 
PBST and 200µl blocking solution was added to each well. This was then incubated for one 
hour at room temperature. The plates were then washed with PBST 3 times and the 
samples diluted 1 in 25 were added, 50µl per well. Samples consisted of the diluted serum 
of 77 PBC patients and 34 healthy volunteers, all in duplicate, plus at least 4 blank wells for 
normalising. The plates were left at room temperature to incubate for one hour. The plates 
were then emptied into virkon solution and washed 6 times with PBST. The secondary 
antibodies were then added to required concentration (as outlined below). The plates were 
then incubated at room temperature for 1 hour. The plates were then washed in PBST 6 
times. The plates were then developed according to the procedure for the particular 
secondary antibody. 
Secondary IgGall, IgA or IgM: 
The substrate was made up of 25ml citrate phosphate buffer, 1 20mg tablet of OPD and 
20µl H2O2. 100µl substrate was added to each well and the plate was incubated for 10 
minutes. 25µl H2SO4 was added to each well to stop the reaction and the plate was read on 
the plate reader. 
Secondary IgG1, IgG2, IgG3 or IgG4: 
The particular types of secondary antibodies used of these antibodies did not contain the 
horseradish peroxidase conjugate, therefore this had to be added. These are biotinylated 
antibodies. 
The avidin-HRP conjugate was added at a concentration of 1 in 10000, 50µl to each well. 
The plate was incubated at room temperature for 1 hour. The plate was then washed for 
one hour and developed using the substrate, consisting of 25ml citrate phosphate buffer, 1 
x 20mg tablet of OPD and 20µl H2O2. 100µl substrate is added to each well and the plate 
was incubated for 10 minutes. 25µl H2SO4 was added to each well to stop the reaction and 
the plate was read on the plate reader. 
Secondary IgE: 
The IgE secondary antibody used had a different substrate and different mechanism of 
action to all others. Development required p-nitrophenyl phosphate, PNPP, rather than 
OPD. The PNPP tablet was dissolved at 1.0mg/ml in Mg2+ substituted diethanolamine.  
200µl was added to each well and then allowed to incubate for 30 minutes. The reaction 
was then stopped by addition of 50µl NaOH per well and plates were read at 405nm on the 
plate reader. 
 
 155 
5.2.4: Short dilutions 
Only the secondary antibody of IgGall, a pool of antibodies for all of the IgG isotypes, was 
used in the end point titre assays. End point titre results were to be compared with results 
from the screens to determine if the screen alone is an accurate representation of the end 
point titre results, such that screens alone could be used in future analysis.  
The values from the initial screen were used to estimate the start dilution for the short 
dilution for each patient. The method used was the same as in section 5.2.3, however using 
1 in 2 serial dilutions of serum from each patient, in duplicate. This stage required an 
element of trial and error but resulted in graphs showing in linear regions for all patients for 
graphs of dilution against absorbance. The R2 value of the line of each graph was calculated 
on Microsoft Excel, using the correlation coefficient function, described in 5.2.5.1. This was 
to ensure that the lines were linear such that EPT could accurately be estimated. For this 
to be possible, the R2 value needed to be above 0.6, as this is the generally recognised cut 
off for strong linear correlations.  
 
5.2.5: Statistics 
5.2.5.1: Linear regression 
Linear regression was carried out for all short dilution graphs. The correlation of dilution 
against absorbance is found using the function in Microsoft Excel software, however can 
also be calculated using the formula below: 
 
R2 is established by squaring the R value achieved using this formula (Colin Cameron and 
Windmeijer, 1997). (Data was first verified to be normally distributed – not shown.) 
The R2 value relates to how accurate the regression line is as an approximation of the real 
data points (Park et al., 2017).  
 
5.2.5.2: Spearman’s rank correlation coefficient 
The Spearman’s rank correlation coefficient is a statistical test to assess how closely the 
trend in one set of data can be expressed as a function of that of another. It explores 
whether there is a monotonic relationship between the two data sets or not (Spearman, 
1904).  
The data in each group is ranked in order of magnitude. Labelling one group x and the other 
y, the difference, d, between the ranks is calculated for each measurement, always in the 
order of d = x rank – y rank. As a test of accuracy, the total of the differences should be 
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zero. The differences in the ranks are then squared and then the squares are totalled. The 
Spearman’s Rank value, rS, is calculated using the following formula: 
 
(Spearman, 1904). 
This formula was then applied to the end point titre results for all short dilutions for all 
samples and their initial screen average value to determine if the screen alone would be an 
adequate assay, rather than having to use short dilution for the rest of the secondary 
antibodies.  
 
5.3: Results 
5.3.1: Optimisation of the protein coating  
Figure 5.3.1 shows graphs of dilution of protein coating against absorbance for a constant 
primary antibody concentration. Arrows show where the dilution of protein coating has been 
established based on criteria from methods, section 5.2.2. 1/1000 dilution was decided for 
rhE2 and rhE2ILD and 1/500 for E3BP and bE2/E3BP.  
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Figure 5.3.1: Graphs of dilution of the protein coating for each of the PBC antigens.  
The graphs show the plotted values for dilution of antigen against absorbance value read. 
The arrows show where the region of the graph is tracked to the x axis to establish the 
corresponding dilution factor. 
 
5.3.2: Initial screen results and end point titre tabularised results 
Results from screens and end point titres are displayed in combined tables, figure 8.4 
(appendix). The R2 values are listed to indicate the strength of the relationship between end 
point titre and initial screen average amount. The initial screen average was calculated by 
first removing the average blank value, then averaging the 2 screen readings. Graphs for 
each patient are also shown in the appendix displaying the R2 value. 
The tables (figure 8.4, appendix) shows all of the screen values, normalised by subtraction 
of the average blank reading. The blank reading average was calculated by averaging the 
screen values for 10 wells which only contained well protein coating and diluent used to 
dilute the serum, rather than diluted serum, and these were developed as normal. 
Normalised screen results were averaged and displayed under the heading ‘Average 
Screen’. Where there is no entry in the table indicates a patient eliminated by being unable 
to satisfy the criteria of being able to give an end point titre value. For the antigen rhE2, 
patients 28 and 31 were eliminated; for rhE2ILD patients 51, 58, 69 and 74-78 were 
eliminated; for rhE3BP, patients 19, 25, 31, 42, 51, 66, 68, 69, 74 and 75 were eliminated; 
for bE2/E3BP, patients 5, 7, 10, 18, 20, 21, 23, 25, 28, 31, 34, 42, and 58 were eliminated. 
Patients eliminated at this stage were only eliminated for the Spearman’s Rank correlation 
analysis against screen values for IgGall, but were included in further analysis as they could 
still show high levels of other isotypes. 
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Volunteer 
number 
IgGall 
rhE2 rhE2ILD rhE3BP bE2/E3BP 
Avg. 
Screen 
Avg. 
Screen 
Avg. 
Screen 
Avg. 
Screen 
1 0.0255 0.0465 0.0220 0.1320 
2 0.0000 0.0160 0.0000 0.0835 
3 0.0000 0.0000 0.0000 0.0225 
4 0.0175 0.0140 0.0000 0.0905 
5 0.0470 0.0400 0.0125 0.1180 
6 0.0400 0.0475 0.0000 0.0865 
7 0.0000 0.0000 0.0000 0.0000 
8 0.0310 0.0270 0.0190 0.0810 
9 0.0000 0.0000 0.0000 0.1065 
10 0.0190 0.0300 0.0870 0.1110 
11 0.0765 0.1320 0.1135 0.0970 
12 0.0365 0.0395 0.0350 0.1405 
13 0.0580 0.0555 0.0690 0.1175 
14 0.0820 0.0400 0.0290 0.0965 
15 0.0505 0.1130 0.0760 0.1125 
16 0.0380 0.0465 0.0200 0.1180 
17 0.0000 0.0000 0.0000 0.5100 
18 0.0865 0.1310 0.0305 0.1235 
19 0.0275 0.0175 0.0500 0.2090 
20 0.1230 0.0055 0.0290 0.1545 
21 0.0970 0.0180 0.0775 0.1220 
22 0.1250 0.0370 0.0590 0.0630 
23 0.0710 0.0000 0.0365 0.1650 
24 0.0360 0.0000 0.0010 0.1540 
25 0.0000 0.0000 0.0000 0.8280 
26 0.0390 0.1485 0.1400 0.1210 
27 0.0500 0.0065 0.0025 0.1415 
28 0.0375 0.0390 0.0585 0.1235 
29 0.0645 0.0170 0.0520 0.0760 
30 0.0715 0.0515 0.0595 0.1030 
31 0.0295 0.0170 0.0020 0.0645 
32 0.0335 0.0115 0.0000 0.1735 
33 0.0000 0.0000 0.0000 0.5245 
34 0.0890 0.0630 0.0000 0.1915 
Table 5.3.2: Lists of averaged, corrected absorbance values for IgGall Healthy 
Volunteer screens. 
This table displays all averaged, corrected absorbance values for IgGall antibodies and 
shows those needing to be ‘cut-off’ in bold. This includes volunteer 20 for rhE2IgGall; 11, 
15 and 26 for rhE2ILDIgGall; 11 and 26 for rhE3BPIgGall; 25 and 33 for bE2/E3BPIgGall. 
These readings were too high as per the cut-off criteria.  
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5.3.3: Cut-offs 
A cut-off was required to determine if any healthy volunteers should be excluded as positive 
outliers. Equipment and materials for diagnosis of PBC in healthy volunteers was not 
available so healthy volunteers could not be excluded based on our determination of them 
being formerly undiagnosed PBC patients. Many studies involving ELISA assays in the past 
have excluded negative sera based on them being outliers based on their values being over 
2 or 3x the standard deviation away from the mean for negative sera, however this method 
is often unnecessarily high and may therefore lower the sensitivity of the assay. Instead, a 
specific factor can be applied to the standard deviation based on the required confidence 
value and the number of controls. This method is especially beneficial when many controls 
are used, as number of controls negatively influences the factor. The cut-off can be 
calculated by: 
Cut-off = x̄ + SD(f) 
where f = t√((1+(1/n)), 
where patients are excluded if their average absorbance is > this cut-off value. x̄ is the 
averaged screen value for the measurements of all patients for the particular antibody, t is 
the minimum t value corresponding to the required confidence interval and n is the number 
of measurements, or number of controls in this case (Adair et al., 1989). As shown in table 
5.3.3 (and also in chapter 6), those eliminated for Spearman’s Rank correlation coefficient 
comparison of EPT and screen were: volunteer 20 for rhE2IgGall; 11, 15 and 26 for 
rhE2ILDIgGall; 11 and 26 for rhE3BPIgGall; 25 and 33 for bE2/E3BPIgGall.  
For healthy volunteers, it was important to eliminate outlier values because they could be 
indicative of undiagnosed PBC, however all patients have been given confirmed diagnosis 
of PBC, therefore assuming all diagnoses to be correct, it was important to keep all patient 
data as this chapter aims to establish conclusions based on the PBC population, which will 
include patients negative for certain antibodies. Given that PBC is diagnosed based on 
other factors than only antibody presence, it is unlikely that a negative outlier could be 
indicative of a wrongly-diagnosed PBC patient, who is actually disease-free. Therefore, it is 
more accurate to maintain patient outliers and instead use statistical analyses not sensitive 
to outliers, i.e. non-parametric analyses.  
 
 
 
 
 
 
 
 
 
 160 
  x̄ SD 1.756xSD Cut-off 
List HVs to cut 
off 
rhE2 IgGall 0.0441 0.035 0.0614 0.1056 20 
 IgG1 0.0213 0.0575 0.1009 0.1222 17, 26. 
 IgG2 0.0350 0.0406 0.0713 0.1063 32, 34. 
 IgG3 0.0459 0.1056 0.1855 0.2313 11 
 IgG4 0.0192 0.0213 0.0374 0.0566 1, 6, 14. 
 IgA 0.0753 0.1132 0.1988 0.2741 30 
 IgM 0.1224 0.1788 0.3140 0.4364 (None) 
 IgE 0.0002 0.0011 0.0020 0.0022 16 
rhE2ILD IgGall 0.0356 0.0404 0.0709 0.1064 11, 15, 26. 
 IgG1 0.0489 0.0495 0.0870 0.1359 11, 16, 30, 33. 
 IgG2 0.1483 0.1326 0.2328 0.3811 6 
 IgG3 0.0664 0.0963 0.1692 0.2356 11, 22, 30. 
 IgG4 0.0167 0.0154 0.0270 0.0437 14, 19. 
 IgA 0.0417 0.0629 0.1104 0.1521 18, 26. 
 IgM 0.1226 0.1648 0.2894 0.4121 5 
 IgE 0.0147 0.0189 0.0333 0.0480 10, 12, 16. 
rhE3BP IgGall 0.0319 0.0367 0.0644 0.0962 26, 11. 
 IgG1 0.0493 0.0706 0.1239 0.1732 19, 30. 
 IgG2 0.0832 0.1157 0.2031 0.2863 13, 19. 
 IgG3 0.0284 0.1040 0.1827 0.2111 11 
 IgG4 0.0105 0.0241 0.0422 0.0528 1, 2, 6, 11. 
 IgA 0.0441 0.0467 0.0819 0.126 2 
 IgM 0.1312 0.0907 0.1593 0.2903 5, 14. 
 IgE 0.0206 0.0475 0.0833 0.1039 2, 27. 
be2/E3BP IgGall 0.1577 0.1585 0.2783 0.436 25, 33. 
Table 5.3.3: Table of calculations and exclusions for healthy volunteer screens. 
This table lists the values calculated required to determine patients to cut off for each 
antibody, as per the formulae: 
Cut-off threshold = x̄ + SD(f) 
where f = t√((1+(1/n)). 
The table then lists the patient numbers for those cut offs deemed outliers as per these 
calculations.  
x̄ is the average absorbance value across all healthy volunteers for this antibody; SD is 
the standard deviation from the mean; 1.756 is the calculated SD multiplier as per f = 
t√((1+(1/n)); the cut-off is the minimum average absorbance ‘cut off’ as an outlier; ‘HV’ 
stands for Healthy Volunteer and the final column lists all ‘cut’ healthy volunteers. 
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5.3.4: Outliers in patient data 
The patient data screens were all checked for normality and outliers. These are all shown 
in chapter 6. Software SPSS was used to calculate normal distribution. At the stage of 
comparing screen values to EPT, all outliers were kept in because the study aims to be as 
inclusive of all PBC patients as possible and this data will be used to investigate grouping 
of the patients, therefore it is important to keep outliers and use Spearman’s Rank 
correlation, which is not sensitive to outliers.  
 
5.3.5: End point titre graphs 
All end point titre graphs are shown in combined figures 8.5 (appendix) and include 
correlation coefficients. R2 values to show how strongly the data points used for the 
extrapolation to x=0 are included on each graph. The R2 value shows how strong a linear 
relationship there is between the dilution and the absorbance. Some short dilutions, for 
example for patient 28 for the rhE2 antigen, the R2 value was below 0.6 even when many 
different dilution series were investigated, therefore it was determined that the linear region 
for the curve for these patients could not be established, perhaps because there was too 
little of the antibody in question in their serum, therefore they were excluded from EPT 
calculations. All patients giving a linear region with R2 value above 0.6 were kept for EPT 
analysis. 
The EPT strategy was applied to healthy volunteers to establish the cut-off end point titre 
value for EPT, such that all values calculated in patients which were considered not 
significantly different from healthy volunteers could be excluded from further analysis. 
Healthy volunteers were subjected to long dilutions of their sera and measured for 
absorbance using the same method as in section 3.4, however no healthy controls showed 
a negative linear region, the strength of which measurable by an R2 value above 0.6 for 4 
consecutive points, in their plotted graphs of absorbance against dilution. Therefore, the 
end point titre as per the method applied in this chapter could not be calculated. The healthy 
volunteers all likely had no detectable levels of the antibodies in question in their sera. Some 
patients also failed to show any such linear region for some antibodies, and so were 
excluded from the Spearman’s rank calculation with screen averages, as they, too, likely 
did not have a detectable level of the particular antibody in question.  
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5.3.6: Spearman’s Rank Correlation Coefficient results 
To determine the relationship between end point titre and antibody screen, a Spearman’s 
rank correlation test was carried out on end point titre results and average screen results. 
Patients were excluded by 2 criteria: failing to show a linear region with R2>0.6 in the dilution 
ELISA or failing to exceed the cut-off screen value. 
Prior to Spearman’s rank correlation coefficient, the EPT data and average screen data 
were tested using SPSS for normal distribution and outliers. The data was not normally 
distributed based on Shapiro-Wilk and Kolmogorov-Smirnov tests, both described in 
chapter 6. For EPT data, the Shapiro-Wilks normality statistic was 0.847 (p=0.000) and the 
Kolmogorov-Smirnov 0.183 (p=0.000). Results for screen data were 0.920 (p=0.000) and 
0.153 (p=0.000) respectively, which causes for rejection of the null hypothesis of the data 
fitting the normal distribution. Skewness z values were 4.921 and -2.545, which show high 
skewness in opposite directions, further indicating the data were not normally distributed. 
These data are contained in chapter 6. 
Table 5.3.6 shows the results of the calculation of spearman’s rank correlation coefficient 
for comparing screen results with EPTs. The results for rhE2, rhE2ILD and rhE3BP show 
strong correlations with rs values of 0.624, 0.805 and 0.805, however bE2/E3BP gave an rs 
value of 0.592. As the bovine protein is less representative of the human protein and 
represents a complex of proteins which the recombinant human version are used, this is 
the least relevant of the antigens used. This protein was excluded from further analysis. 
The high rs values indicate there is a relationship between the data, however the normal 
distribution test data indicates that the relationship is not linear and non-parametric tests 
must be used.  
 
Antigen rs p 
rhE2 0.624 <0.0005 
rhE2ILD 0.805 <0.0005 
rhE3BP 0.805 <0.0005 
bE2/E3BP 0.592 <0.0005 
Table 5.3.6: Table of Spearman’s Rank correlation coefficient values and the 
relevant p values. 
The table shows the results from the Spearman’s rank correlation coefficient when the 
relationship between the end point titre and the average normalised screen values is 
investigated. 
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5.4: Discussion 
5.4.1: Aims 
The aim of this chapter was to develop an assay which could be used to compare levels of 
different isotypes of antibodies against the autoantigens in PBC in PBC patients. This 
involved analysing the optimisation procedure to determine if using the average screen 
value was sufficient or if carrying out a short dilution was always required. 
 
5.4.2: Discussion of results 
End point titre (EPT) ELISAs were carried out on each patient for an accurate estimation of 
their dilution required to give a hypothetical zero absorbance value for antibodies of the IgG 
isotype pool, IgGall, against rhE2, rhE2ILD and rhE3BP. This is the most accurate and 
reliable method of ELISA to use as it gives a method for direct comparison between 
patients. A minimum of 4 data points are used to calculate the EPT, rather than an average 
of 2 or 3, giving it greater accuracy (Dey et al., 2008). It is important that measurements are 
taken using the linear fraction of the dilution against absorbance graph, and this can be 
verified by a high R2 value of correlation coefficient which assesses the linear nature of the 
data points. In addition, a high R2 value gives increased likelihood that the extrapolation of 
the line will be accurate and lead to an accurate EPT value.  
ELISA plates were coated with the antigens as per ideal concentrations established in the 
plate coating optimisation assay. Duplicated screens were carried out to obtain an average 
screen value rather than one value to minimise error. Screen results were then compared 
to EPT results by Spearman’s Rank correlation coefficient statistical analysis. This analysis 
was chosen to explore if there is a monotonic relationship between results of the screens 
and EPT results, such that for all other experiments screen could be used rather than the 
serum consuming EPT method. As shown in table 5.3.6, all antigens except bE2/E3BP 
showed a significant relationship between EPT values and normalised screen averages, 
therefore it was decided that the screen values would be used for future experiments. Table 
5.3.6 also shows p values of the spearman’s rank correlation coefficient. The rs value 
assesses the strength of the relationship where 0.6 or above is generally considered a 
strong relationship. The p value suggests the confidence interval, such that for example a 
p value of 0.05 gives a confidence interval of 95% so it can be assumed with 95% 
confidence that the correlation described in strength by the magnitude of the rs value is 
accurate for the data. The p values for the Spearman’s rank correlation coefficients are all 
rounded to 0.000, therefore it can be estimated that at least 99.95% of the data points can 
be assumed to follow the relationship (Spearman, 1904). Therefore, it can be assumed with 
high confidence that conducting screen only calculations to investigate levels of IgM, IgA, 
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IgE and the IgG subtypes will strongly follow results which would have been obtained in 
carrying out end point titre dilution experiments.  
The screen only tests are favourable because there is a limited supply of protein provided 
by Newcastle University. Additionally, there could be diagnostic implications which will be 
favoured by using only the screen method. If, in chapter 6 it is shown that there are levels 
of the antibodies tested for in this study that they could be used in PBC diagnoses in the 
future then it is less time consuming and more cost effective for hospital diagnostics to do 
screens rather than serial dilutions as the serial dilutions use considerably more reagents 
and involve more calculations. Similarly, if it is found that there are antibodies of significantly 
different levels between responders and non-responders, such that an assay similar to this 
is used in the future to distinguish responders from non-responders, the same cost and time 
effective advantage applies. 
 
5.4.3: Discussion Summary 
The implications of practise for this research will be its eventual use towards a potentially 
diagnostic tool for early determination of the type of PBC the patient has. The EPT 
correlated with the screen values such that by screening all patients for all antigens and 
using the range of secondary antibodies outlined in the methods, there is a large amount of 
data which can now be further analysed for any significant differences between responders 
and non-responders.  
 
5.4.4: Limitations 
A limitation of the screen average rather than using the EPT is that unlike EPT, the screen 
uses only 2 data points and it cannot be made certain that the linear portion of the graph is 
being represented. However, patient serum and coating antigen are in limited supply, 
therefore, it would be impractical to carry out short dilutions for every patient for every 
antigen and secondary antigen. Upon testing of this assay, if there are any significant 
findings, as in any differences between responder group and non-responder group, those 
antigens and discovered to be of interest could in future work be re-analysed using the end 
point titre method.  
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Chapter 6: Investigating differences in immune 
responses between PBC patients that are 
responders and non-responders to UDCA  
Abstract 
Recent research suggests that PBC should be treated as two or more separate disease 
subsets due to apparent differences in severity, clinical biochemical parameters and 
response to Ursodeoxycholic Acid (UDCA). UDCA is the current blanket therapy given in 
PBC, however it is ineffective in 20% of patients: “non-responders”. Categorisation as a 
non-responder requires inability of the drug to significantly lower a patient’s blood AST, ALP 
and bilirubin levels during a significant period of time, usually one year after UDCA is first 
administered. It is likely that these patients have a more severe autoimmune disease and 
that the failure of treatment may reduce the effectiveness of any potential anti-inflammatory 
drugs. Further elucidation of these subsets is crucial to stratify patients and potentially allow 
the development of differential therapies which may benefit these “non-responders”. 
Multiple indirect enzyme-linked immunosorbent assays (ELISAs) were carried out to 
measure antibody titre and therefore detect patterns of auto-antibody isotypes in serum 
from PBC patients known to be “responders” (62) or “non-responders” (15) to UDCA. 
Recombinant human PBC autoantigens E2, E2 inner lipoyl domain (E2ILD) and E3 binding 
protein (E3BP) were used to uncover statistically significant differences in antibody 
responses.  Using Mann Whitney analysis, it was found that compared to responders, non-
responders have higher levels of anti-E2 IgE (p=0.025), anti-E2ILD IgA (p=0.047) and anti-
E2ILD IgG3 (p=0.01). The study also found that men with PBC, generally considered non-
responders, have significantly lower levels of some antibodies, which are normally higher 
in non-responders: anti-E2IgE (p=0.003) and anti-E2ILD IgG3 (p=0.05). This is further 
evidence that men with PBC may constitute their own sub group of non-responders. 
Differences in antibody isotype to dominant autoantigens suggests that there may be 
significant functional differences in T helper cell subsets in each patient group. Further 
investigation into the differences between these subsets could in the future provide a 
diagnostic tool which could be used early on in diagnosis to categorise patients for stratified 
treatment. 
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6.1: Introduction 
6.1.1: Background 
Chapters 1 and 5 outline a study carried out in 2013 by Carbone and colleagues which 
found that there are key differences between patients that respond and those that do not 
respond to therapy of ursodeoxycholic acid (UDCA), normally given to all patients. Studies 
have shown that as many as 20% of patients may not respond to this blanket therapy, in 
that there is insufficient slowing of disease progression and levels of enzymes in the blood 
which can indicate liver damage fail to drop to what are considered ‘normal’ levels, outlined 
in the main introduction (Carbone et al., 2013). 
In the study investigating differences between groups, the main difference of interest was 
age, whereby patients who are younger at diagnosis were more likely to fit the criteria for 
non-response and patients who are older at diagnosis are more likely to fit the criteria for 
non-response(Carbone et al., 2013). Figure 6.1.1 displays this suggested grouping system 
in a flow chart format. ‘Response status’ was determined by Paris I criteria, which groups 
patients based on their serum levels of known biological markers indicative of liver damage. 
These compounds are further outlined in section 6.1.2. According to the Paris I classification 
criteria, a PBC patient is considered a ‘responder’ to UDCA if, after 1 year of monitoring 
while taking UDCA, they satisfy the following: their alkaline phosphatase level is ≤3x the 
upper normal limit, their aspartate transaminase level ≤ 2x the upper normal limit and 
bilirubin level within the normal range. The accepted ‘normal’ limit or range of these factors 
can differ depending on the laboratory or geographical area, although some values quoted 
frequently in the literature are within this chapter. As outlined in chapters 1 and 5, the 
Carbone and colleagues study also identified that males may make up their own sub-group, 
with an aggressive form of the disease but different characteristics to female non-
responders, and also sub-classified the non-responders based on different liver 
biochemistry(Carbone et al., 2013).  
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Figure 6.1.1: Hypothetical grouping diagram of PBC patients 
This figure depicts the proposed grouping of PBC patients in recent literature (Carbone et 
al., 2013). PBC patients, according to their analysis, can be split into those who respond 
to UDCA, ‘responders,’ and those who do not, ‘non-responders.’ Non-responders can be 
further subdivided based on their blood biochemistry where younger non-responders tend 
to be classified as ‘non-reponders’ based on ALT and AST levels, whereas the older non-
responders tend to be so-classified based on high ALP or bilirubin adapted from Carbone 
et al. 2013 (Carbone et al., 2013). 
 
It is important to acknowledge that PBC patients have been grouped based on whether or 
not they ‘respond’ to current therapy. This was one of the first studies to attempt to provide 
statistical backing to the idea that PBC may be made up of different sub groups which may 
require their own therapies, however it is important to provide a biological reasoning why 
some patients ‘respond’ and others do not(Carbone et al., 2013). Therapy for the disease 
will continue to improve and be further stratified based on what is discovered which can 
more accurately define the groups of PBC patients, and possibly there are more groups 
within PBC patients to be discovered. Further elucidation between the subgroups of the 
patients will not only allow better understanding of and the development of better treatment 
for PBC patients, but it will also enable the subgroups to be more accurately defined such 
that they will no longer be defined based on response to a drug but can be identified based 
on biological properties of the patients. 
It has been well-documented that PBC is likely a multi-factorial disease. Factors such as 
environment, history of infection, genetics and others may all contribute to development of 
the disease (Jones, 2003). This is outlined in further detail, such as possible pollutants 
which may contribute to PBC formation, in the main introduction (Jones, 2003). Additionally, 
presence of anti-mitochondrial antibodies, which is hallmark to most PBC patients, seems 
to be insufficient to cause disease on its own (Ozaslan et al., 2016). Factors which 
 168 
contribute to PBC are explored more in chapter 1, Introduction.  Previous results chapters 
further outlines a potential genetic input from data obtained in a genome-wide association 
study. The GWAS data, as well as other environmental factors outlined in chapter 1, 
introduction, has yet to be analysed in the responder/non-responder context, but may be of 
importance in the sub-grouping of PBC patients.  
One potential argument for a reason why there are phenotypically different groups within 
the PBC population is that there could be different T cell responses to the antigen leading 
to one more aggressive disease form and another less aggressive form. Chapter 1, 
Introduction, suggests other diseases where the type of helper T cell response can be 
critical in determining whether the patient has an active or resistant disease state. There 
could be measurably different T cell profiles between patient groups in PBC giving rise to 
different disease phenotypes. In order to measure and compare the T cell profiles in PBC 
patients, T cells from patient blood can be counted and classified within their subtypes, as 
described in chapters 3 and 4, however patient cells were not available for this study. 
Previous results chapters outline how the different cytokines released by different T cells 
could lead to different characteristic antibody profiles which could be measurable by ELISA. 
For example, as outlined in chapter 5, a prominent Th1 response could lead to a 
predominant IgG3 profile, with low levels of IgG1 and IgE (Mitsdoerffera et al., 2010). A 
predominant Th2 response could show abundant IgG4, IgE and/or IgG1 (Lebmann and 
Coffman 1988). A predominant Th17 response could show raised IgG1 and IgG3 
(Mitsdoerffera et al., 2010). If there are different antibody profiles for different subgroups of 
PBC then this may direct further studies such as what might be the influence of other factors, 
such as a genetic or environmental influence, on these antibody profiles.  
Studies have shown that cytokines produced by Tregs, IL-10 and TGF-β, together induce 
switching to IgA1 and IgA2; Th2 cytokines IL-4 and IL-13 induce class switching to IgG4 
and IgE; Th1-released IFN-γ favours IgG3 switching (Tangye et al.2002).   
 Elucidating any antibody patterns between groups is one step towards understanding on a 
cellular level why there are different groups within the disease.  
 
6.1.2: Clinical liver evaluation  
When a patient has a blood liver panel assessment, the levels of many enzymes and 
proteins are measured. This is because levels outside of normal parameters can indicate 
PBC but also other illnesses. A specific range of different characteristics must be measured 
in order to determine the correct illness while ruling out other potential illnesses.  
PBC is either diagnosed from a blood test carried out because PBC is suspected or from a 
routine blood test. Therefore, symptoms at diagnosis can range from none to some or all 
of: lethargy, pruritis, joint pain, dryness of the mouth, yellowing of the skin and eyes(Gatselis 
et al.).  
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A liver panel assessment will be carried out on the patient’s blood and many different factors 
will be assessed to help determine the disease status. Blood alkaline phosphatase (ALP), 
aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin, 
antimitochondrial antibodies (AMA) and antinuclear antibodies (ANA) are measured and 
often a liver biopsy will also be taken(Patel and Seetharam, Song et al.). The test for PBC 
consists of serum AMA titres over 1 in 40, (rest of PBC identifiers),  
This chapter includes clinical data regarding these parameters for the patients in this study 
therefore a brief overview of the components tested is incorporated below.  
 
6.1.2.1: Aspartate Transaminase (AST)  
AST catalyses the reversible reaction of: 
Aspartate + αketoglutarate ⇌ oxaloacetate + glutamate 
In amino acid catabolism, this reaction involves formation of glutamate which is then broken 
down by oxidative deamination forming ammonium ions which are then excreted in the 
urine. This reaction is also important in anaboilism of the non-essential amino acid of 
glutamate used in protein synthesis (Sookoian and Pirola, 2012). 
AST is associated with parenchymal cells therefore damage to parenchymal cells of the 
liver can cause its excessive release into the blood stream to above normal levels (6-34IU/L 
for females; 8-40IU/L in males)(Nyblom et al., 2006, Chen et al., 2016). Therefore, raised 
AST is a biomarker in PBC. 
 
6.1.2.2: Alkaline Phosphatase (ALP) 
Alkaline phosphatases are present in many tissues, including the liver and bile duct. It is a 
membrane bound enzyme which catalyses the removal of a phosphate group from another 
protein and may also carry out a transphosphorylase reaction if there is high concentration 
of phosphate accepting sites. In the context of PBC, damage to the bile ducts and later the 
liver causes the release of the enzyme into the bloodstream, which can cause an ALP level 
to rise above the normal 20-140IU/L (Millán, 2006). 
 
6.1.2.3: Alanine Transaminase (ALT) 
ALT is an enzyme which catalyses the reaction: 
L-glutamate + pyruvate ⇌ α-ketoglutarate + L-alanine 
This reaction is the biosynthesis of alanine from pyruvate and a branched amino acid, in 
this case glutamate. This method can also synthesise valine, leucine and isoleucine. In the 
reverse direction, an amino group is removed from alanine and added to α-ketoglutarate for 
L-glutamate biosynthesis.  
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Although present in many tissues, ALT is most prevalent in the liver. Raised ALT of 34 IU/L 
for females or 52 IU/L for males is hallmark for hepatocellular injury (Farrell and Larter, 
2006). 
 
6.1.2.4: Bilirubin 
A normal blood bilirubin level is between 0.3mg/dL to 1.0mg/dL. A breakdown product of 
red blood cells, biliurubin in circulation is taken up by healthy hepatocytes to be conjugated 
to glucoronic acid and excreted in bile. A liver functioning less than normally will be able to 
take up less bilirubin and so lead to greater levels in the blood (VanWagner and Green, 
2015). 
 
6.1.2.5: Anti-mitochondrial antibodies (AMA) 
AMAs are discussed in greater detail in (reference the section of my introduction). PBC is 
not the only disease in which AMAs have been identified in the patients. A list of antigens 
has been discovered and categorised into groups M1-M2 depending on the type of disease 
they are relevant to. The M2 group contains the autoantigens relevant in PBC, these being 
proteins of the α-ketoacid dehydrogenase complex family of enzymes found in the inner 
membrane of mitochondria, including 2-oxoglutarate dehydrogenase complex (2-OGDC), 
branched chain 2-oxoacid dehydrogenase complex (BCOADC) and pyruvate 
dehydrogenase complex (PDC)(Fussey et al., 1991b). All of these enzymes are important 
in respiration. Presence of AMA is assessed using an ELISA panel screening for the M2 
antigens.  
AMA is detected by ELISA. There is a series of autoantigens which can indicate liver 
autoimmune disease, denoted M1-9. M2 contains those antigens relevant in PBC: the 2-
oxo acid dehydrogenase complex (2-OADHC) enzymes which are located in the inner 
mitochondrial membrane and contain PDC (Berg and Klein). It has been reported that 90-
95% of PBC patients test positive for AMA.  
 
6.1.2.6: Anti-nuclear antibodies (ANA) 
ANA is detected by ELISA(I Peene, 2001). Occuring in approximately 50% of patients, 
ANAs relevant in PBC include: anti-gp210 antibodies, anti-sp100 antibodies and other 
ANAs. Gp210 is a nuclear pore protein and sp100 is a nuclear body protein. Others include 
ANAs against centromere proteins, histones and nuclear lamins but anti-gp210 and anti-
sp100 are the main ANAs in PBC and most exclusive to PBC (Worman and Courvalin). 
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6.1.2.7: Biopsy 
Although rarely required today, a biopsy may confirm PBC in those patients with markedly 
raised AST (>5x normal) without the expected corresponding marked raise in ALP (<1.5x 
normal), however if both ALP and AST are markedly raised as expected to the thresholds 
for PBC diagnosis then a biopsy is not required(Zein et al.). The biopsy is carried out to 
visually confirm small bile duct damage in the absence of the adequate blood data.  
Non-response to treatment with UDCA is usually defined by Paris I criteria which states that 
to have clinically responded to treatment, readings must satisfy: ALP≤3x normal, AST≤2x 
normal and normalised bilirubin level (Trivedi et al.). 
The factors measured to test for PBC could be indicative of another liver disease, therefore 
the results must be compared to those for other liver diseases before a PBC diagnosis is 
decided on.  
 
6.1.3: The use of liver damage enzymes in diagnosis of PBC 
6.1.3.1: Aspartate transaminase and Alanine transaminase: AST, ALT. 
When the AST level is higher than ALT, this is not necessarily indicative of liver disease 
because muscle damage from a myopathy disease, disease of the skeletal muscles 
lowering their function, could also cause increased blood AST(Cobbold et al., 2010). To rule 
this out, often another muscle damage indicating enzyme such as creatine kinase will also 
be measured (Cobbold et al., 2010). Creatine kinase is raised in myopathies but is not 
known to be raised in PBC. When AST is twice as high or more (2:1 ratio or higher) than 
ALT, this is suggestive of alcohol liver disease and is supported by high gamma glutamyl 
transferase, not known to be raised in PBC (Moussavian Sn Fau - Becker et al.). A high 
AST:ALT ratio could also be present in a cirrhotic hepatitis C patient with alcoholic liver 
disease(Sheth et al.). ALT is found predominantly in the liver and is therefore a more 
accurate indicator of liver inflammation than AST, however the list of diseases elevated ALT 
could indicate is extensive. AST and ALT are not accurate measures of liver function without 
also measuring other components. 
 
6.1.3.2: Bilirubin  
High bilirubin is also suggestive of liver disease or damage but has an extensive list of 
diseases which could account for it, including Gilbert’s syndrome, a genetic disorder 
causing jaundice and hyperbilirubinemia(Bosma et al., 1995) for small increases, hepatitis, 
a viral infection,  for moderate increases or severe liver failure from cirrhosis or Crigler-
Najjar Syndrome, a genetically inherited inability to metabolise bilirubin(Jansen, 1999), with 
very high bilirubin.  
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6.1.4: Chapter Aims 
Chapter 5 outlines development of an assay which can be used to elucidate differences in 
antibody patterns between the different PBC subgroups. The next logical step is to use a 
multitude of statistical analyses in attempt to discover if there may be statistically significant 
differences in antibody patterns between different types of PBC patients, or their clinical 
parameters. Patient serum used in chapter 5 was provided alongside patient data such as: 
age, age at diagnosis, date of recruitment to the study, months since recruitment of blood 
draw, sex, ethnicity, years since UDCA start. This data will be included in analysis in attempt 
to further subdivide the patient groups and test if our patient data is a fit for the model 
outlined by Carbone et al(Carbone et al., 2013).  
 
This chapter aims to: 
x Elucidate key differences between groups of non-responder and responder patients 
regarding their serum levels of different autoantibody isotypes. 
x Provide statistical backing, where possible, to any discovered differences between 
responder/non-responder sub-grouping. 
x Explore the differences between males and females. 
x Explore the impact phenotypic data measured before this study compared with the 
impact of any further differences discovered in this study.  
x Discuss wider implications of the data found in this study and discuss how further 
studies can refine that discovered in this chapter. 
 
6.2: Methods 
6.2.1: Methods introduction 
6.2.1.1: Samples provided 
Samples were kindly provided by Dr Vinod Hegade at Newcastle University as part of a 
larger study. Staff at Newcastle University had carried out various tests on the serum and 
also gathered background information on the patients.  
 
6.2.1.2: Information provided 
Patient information includes some gaps in place for some data sets. Patients were asked 
to give consent for their information to be used. Gaps in the data indicates where a patient 
has not provided consent for a certain piece of data to be used in this study or where data 
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could be inaccurate or was not yet measured on the date of sample collection. All patient 
data is provided in figure 8.1-8.3 in the appendix. 
This study was a blind study in that this patient data was only made available after all serum 
ELISA data had been collected. 
6.2.1.2.1: Responder/Non-responder 
 
Arguably the most important information, a patient’s responder or non-responder status is 
provided. This is calculated based on Paris I criteria, which uses the ALP, AST and bilirubin 
level of the patient after one year on UDCA, as per section 6.1, introduction of this chapter, 
to determine if the patient’s liver biochemistry has adequately ‘normalised’ for them to be 
considered a ‘responder’. It is unknown the exact ‘normal’ values for bilirubin, ALP and ALT 
used, but they likely resemble those values in section 6.1. 
6.2.1.2.2: Sex 
 
Sex of patient was provided. This is important because some data has indicated that men 
and women with PBC have some striking dissimilar characteristics (Lucey et al., 1986). It is 
important to obtain gender information to investigate if there are differences in antibody 
isotypes between gender which could further elucidate these potential different types of 
PBC. 
6.2.1.2.3: Age 
 
Age of patient is provided which is important because age is thought to be a key predictor 
of response, with older patients much more likely to respond to the current therapy than 
younger patients, who tend to have a more aggressive disease type (Carbone et al., 2013). 
Age refers to age at date blood was drawn. 
6.2.1.2.4: Ethnicity 
 
Ethnicity is provided because studies have shown that there may be differences in 
symptoms and disease severity between different ethnic groups. United States PBC 
patients were divided into Caucasian, African-American and Hispanic groups and it was 
found that non-caucasians had significantly more severe liver disease, more decreased 
physical activity and worse pruritis than Caucasians, not explained by another factor such 
as age (Peters et al., 2007). Therefore this data is collected for use in this study where 
possible.  
6.2.1.2.5: Cohort 
 
Some patients included in the study were UDCA-naïve. These patients were to be 
compared with those administered UDCA because any difference in these groups based 
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on antibody isotype patterns may suggest a direct effect on the immune system of UDCA 
which may be causing this effect. Data has shown that UDCA may have a direct effect on 
the T cells in vitro, specifically affecting the proliferation of CD8+ T cells (chapter 4). The 
UDCA-naïve patients are Cohort B while all taking UDCA are Cohort A. 
6.2.1.2.6: Weight 
 
Little has been found linking weight and PBC severity, however it has been suggested that 
UDCA administration may be associated with weight gain(Siegel et al.). Weight is not 
provided as a series of values over time so this will not be further explored in this study. 
Weight is mostly important in this study as it allows calculation of UDCA dosage per unit 
weight of the patient (see methods).  
6.2.1.2.7: AMA and ANA 
 
Data on whether the patient is AMA positive or negative is provided. Although it could be 
suggested that AMA negative patients should be eliminated from the study as this is a study 
testing for AMA, the panel which will be used is far more thorough than that currently used 
for PBC diagnosis so AMA negative patients are kept in this study in case any anti-
mitochondrial antibodies not currently tested for are found in those patients. ANA status is 
important because the ANA antigens differ from the AMA antigens and so may illicit a 
different immune response which could be detected in the pattern of antibodies screened 
for in this study. 
6.2.1.2.8: Blood Biochemistry 
 
The patients’ ALT, ALP and bilirubin blood levels are provided. These are all relevant in 
establishing a PBC diagnosis but also have been implicated in the responder/non-
responder proposed grouping (Carbone et al., 2013). Patients used in this study were 
categorised as ‘responder’ and ‘non-responder’ based on their measurements of these 
levels and how they fit Paris I criteria, however it is unknown the exact normal limits that 
were used in calculating this. Additionally, as ‘response’ and ‘non-response’ is a fairly new 
concept, it is unknown exactly when the patients were classified as ‘responder’ and ‘non-
responder’ and if they were all classified at the same time or not. Additionally, past ALT, 
ALP and bilirubin measurements are not included, only those of at the time the sera 
provided were drawn and analysed.  
 
6.2.1.2.9: Other 
 
The dosage of UDCA is dependent on the patient’s weight, therefore any investigation into 
the effect of UDCA dosage on antibodies produced or other characteristics such as liver 
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biochemistry must also take weight into account. An estimate of the patient’s dose per unit 
weight is calculated by dividing their dosage of UDCA, which is provided in mg, by their 
measured weight in kg. This is an estimate because studies have shown that weight may 
increase with UDCA therefore with a potentially changing weight it is impossible to have a 
thoroughly accurate weight measurement for a patient.  
Other factors which require further calculation refer to those referring to time. Date of 
diagnosis and date of start of UDCA treatment are provided, along with date blood was 
drawn. Time since UDCA start and time since diagnosis are calculated based on this data.  
 
6.2.2: Statistical Analyses 
6.2.2.1: Normal distribution 
A normal distribution test is carried out to determine if magnitudes of data follow a bell-
shaped curve pattern or not. The bell-shaped curve pattern is suggestive of a ‘normal’ set 
of data, meaning data is spread about the mean in a pattern which can be expected, 
therefore it is likely there may be little of interest in the patterning of the data. The normal 
distribution is carried out on dependent variables, or the data sets which are measured 
against another factor, or with another factor in consideration: the independent variable. 
There are two main tests for normal distribution, each with their strengths and weaknesses. 
In general, for sample sizes above 50, the Kolmogorov-Smirnov test for normality is applied 
and for sample sizes under 50 the Shapiro Wilk test for normality is applied. An alternative 
method for the Shapiro Wilk test has been developed and applied to software packages 
such as SPSS, therefore it can be used for sample sizes of up to 2000. In addition to this, 
the kurtosis and skewness of sample can also be measured for more information regarding 
the distribution of the data. The kurtosis refers to the heaviness of the tails of the data, or 
the proportion of the samples that resides in the tails, and the skewness refers to the 
symmetry, or lack thereof, of the data. In this context, normal distribution is assessed in 
order to determine which statistical tests may be used to analyse relationships within the 
data, therefore the Kolmogorov-Smirnov will be the only necessary information(Ghasemi 
and Zahediasl, 2012).  
The Kolmogorov-Smirnov test compares the data with a standard normally distributed data 
set and assesses how close a fit the data is to this model. This is applied to all dependent 
variable data in order to highlight data of interest and to help determine which further 
statistical analyses may be used.  
When the test is carried out, a p-value is provided. P-values of less than 0.05 suggest that 
the data is not normally distributed and therefore there is likely an external factor influencing 
the data causing a skew or unexpected patterning. This data is of interest in analysis.  
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6.2.2.2: Mann Whitney 
The Mann Whitney U-test is a statistical test which determines whether an independent 
group of values is significantly greater or lower than another. The data within the groups 
must measure a dependent variable and be ordinal or continuous and not normally 
distributed. There are two proposed hypotheses, the null hypothesis, N0, and the alternative 
hypothesis, N1, as described below. 
N0: It is equally likely that a randomly selected value from 1 group will be greater or less 
than a randomly selected value from the other group. 
N1: It is not equally likely that a randomly selected value from 1 group will be greater or less 
than a randomly selected value from the other group.  
The data in each group is ranked in order of magnitude. If there is a repeated value, all rank 
numbers covered by this value are averaged and this average is the rank assigned to this 
value. Points are then assigned to each group. For every sample in a group, a point is given 
to the group for every sample in the other group which is greater in magnitude than this 
sample. This is applied to every sample in every group. The sum of points for each group 
is calculated and the smaller of the two values is designated ‘U’. The z value is calculated 
from the following formula where 1 and 2 refer to each group: 
𝑧 =
𝑈 − 𝑛𝐴𝑛𝐵2
√
𝑛𝐴𝑛𝐵(𝑛𝐴 + 𝑛𝐵 + 1)
𝑛𝑡𝑜𝑡
 
 
The confidence interval is 0.05, so 0.9750 Area in body is used in the z table, giving a z 
value of 1.96. If the calculated z is < -1.96 or > +1.96, the null hypothesis is rejected and 
the alternative hypothesis is taken (DeLong et al., 1988).  The Kruskal-Wallis is a similar 
test used for comparison of more than 2 groups, or ‘k’ groups. The test is applied to give an 
overall statistic for differences between the k groups, then another statistic for each single 
group to group comparison is also calculated.  
2.2.3: Spearman’s rank correlation coefficient 
The Spearman’s rank correlation coefficient is a statistical test to assess how closely the 
trend in one set of data can be expressed as a function of that of another. It explores 
whether there is a monotonic relationship between the two data sets or not (Choi, 1977).  
The data in each group is ranked in order of magnitude. Labelling one group x and the other 
y, the difference, d, between the ranks is calculated for each measurement, always in the 
order of d = x rank – y rank. As a test of accuracy, the total of the differences should be 
zero. The differences in the ranks are then squared and then the squares are totalled. The 
Spearman’s Rank value, rS, is calculated using the following formula: 
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The Spearman’s Rank table displays the minimum required rS value for a certain confidence 
interval required and for a given number of values, n. If the calculated rS is greater than that 
displayed in the table, then there is a statistically significant monotonic relationship between 
the 2 data sets (Rozeboom).  
This test is used when data is not normally distributed or has outliers because the outcome 
is based rank rather than data values (Choi, 1977). 
 
6.2.3: Methods Implementation 
All statistical analysis are carried out using IBM SPSS Statistics 24 software. 
Tests for normality including skewness, kurtosis, Kolmogorov-Smirnov and Shapiro Wilk 
were carried out on all continuous data sets to determine the types of follow-up analyses 
which could be used.  
The Mann Whitney test was carried out on all nominal data, this being: cohort, gender, ANA 
status, AMA status and responder/non-responder status, to compare differences between 
groups within this data set.  
Spearman’s Rank correlation was carried out on all scale data sets, those being all 
continuous data sets, in order to assess all correlations between data.  
A multivariate regression and multinomial logarithmic regression were then carried out to 
determine the extent of the importance of factors discovered to be significant in previous 
analyses and to assess the relevance of the data. 
 
6.2.3.1: Regression analysis using R and R studio 
Once preliminary statistical analyses have been carried out, including Mann Whitney and 
Spearman’s Rank, then those factors deemed significant can be selected for regression 
analysis. A multivariate linear regression is carried out when the dependent variable, for 
example response, can be considered numerical, or continuous data, whereas a 
multinomial logarithmic regression is carried out if the dependent variable is binary or 
nominal, for example one of 2 possibilities: ‘responder’ or ‘not responder’. These analyses 
can indicate the weight that certain factors can have in ascertaining the likelihood of the 
independent variable outcome.  
6.2.3.2: Error correction 
The more statistical comparisons that are made, the greater the chance is of a ‘Type 1 
error’. A type 1 error occurs when a null hypothesis is wrongly rejected, or a difference is 
taken to be significant when it is not. The likelihood of obtaining a type 1 error increases 
with the number of comparisons made on a data set. For comparison between groups, the 
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significance level must be altered based on the number of comparisons. For a number, k, 
of groups, the original significance level is divided by the answer to k(k-1)/2, to give the new 
significance level, α. For Mann Whitney analysis where only 2 groups are compared, this is 
2(2-1)/2 = 1, so the p value is maintained. For Kruskal-Wallis, if there are 3 groups then the 
α for 95% confidence becomes 0.05/(3(3-1)/2) = 0.0167. 
 
6.3: Results 
6.3.1: Normal Distribution 
Normal distribution tests were carried out on absorbance values from ELISA screens 
outlined in chapter 5, and were also carried out on data for dependent variables in data 
obtained in the patient information. 
Tables 6.3.1.1 to 6.3.1.5 show the results for calculation of normal distribution criteria. 
Skewness and Kurtosis are considered such that normal distribution can be considered for 
rejection if the z value, calculated by the statistic divided by standard error, is below -1.96 
or above +1.96 for 95% confidence. Shapiro-Wilk (S-W) and Kolmiogorov-Smirnov (K-S) 
tests for normality are factors which can be used for rejection of the null hypothesis for 
normally distributed data if the p value is below 0.05, indicating there is only a 5% chance 
that the data happen to be unlike the normal distribution model by chance and not because 
they do not actually fit the model. Values which can be used to consider rejection of the null 
hypothesis for a data set of normal distribution are shown with a grey background. To carry 
out parametric analysis between responder and non-responder groups, both responder and 
non-responder data must satisfy the null hypothesis. Normal distribution for all data 
ungrouped was also carried out to determine if parametric correlation analyses could be 
carried out. Data was also tested for outliers. Outliers were kept in for analysis because the 
eventual aim of the grouping of PBC patients across all studies is to eventually design 
therapies which can work for all PBC patients. Therefore, they must be taken into 
consideration when attempting to sub-group patients.  
As can be seen by tables 6.3.1.1 to 6.3.1.5, for most data sets there is at least one criterion 
which is suggestive that the null hypothesis for normal distribution should be rejected. For 
example, bilirubin levels for responder patients have an extremely high kurtosis statistic of 
37.045, and a relatively low standard error of 0.668, and corresponding z value of 55.457. 
The kurtosis is a measure of how much of the data resides within the tails of the distribution, 
therefore a high kurtosis indicates that much of the data resides in the tails. 55.457 is far 
out of the range of -1.96<z<+1.96, therefore the null hypothesis cannot be assumed as the 
data does not enough resemble the ‘bell shape’ with such a heavy distribution of data at the 
extremes. ALP for all patients has a skewness value of 2.407 and a standard error of 0.291, 
therefore the z value of skewness per unit standard error is 8.271, again outside the range 
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of -1.96<z<+1.96, therefore the data shows too much of a positive skew for it to be classified 
as normally distributed. rhE2IgE data for responders is one example of a data set where 
the data do not fit the normal distribution by K-S or S-W criteria (p=0.000; p=0.000 
respectively). Therefore, when calculations are carried out to determine if the data are 
similar enough to hypothetical normal distribution data, there is a less than 0.1% likelihood 
of observing the data in its distribution if the data is in fact normally distributed, therefore 
with a confidence interval of 95% the null hypothesis is rejected and this data is assumed 
to be not normally distributed. 
As there are very few data sets which do fit the normal distribution, non-parametric tests 
will be carried out throughout this chapter.  
 
 
Table 6.3.1.1: Normal distribution assessment of autoantibody readings for all PBC 
patients 
Assessments of normal distribution were carried out using the Kolmogorov-Smirnov (K-S) 
test and the Shapiro-Wilks (S-W) test. 
Assessments for skewness and kurtosis were also carried out to assess whether the data 
was weighted towards one side or not and the weight of the data in the tails were also 
carried out.  
Values in grey squares indicate criteria for which the null hypothesis of normally 
distributed data is rejected.  
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Table 6.3.1.2: Normal distribution assessment of autoantibody readings for the 
responder group of PBC patients. 
Assessments of normal distribution were carried out using the Kolmogorov-Smirnov (K-S) 
test and the Shapiro-Wilks (S-W) test. 
Assessments for skewness and kurtosis were also carried out to assess whether the data 
was weighted towards one side or not and the weight of the data in the tails were also 
carried out.  
Values in grey squares indicate criteria for which the null hypothesis of normally 
distributed data is rejected.  
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Table 6.3.1.3: Normal distribution assessment of autoantibody readings for the 
Non-responder group of PBC patients 
Assessments of normal distribution were carried out using the Kolmogorov-Smirnov (K-S) 
test and the Shapiro-Wilks (S-W) test. 
Assessments for skewness and kurtosis were also carried out to assess whether the data 
was weighted towards one side or not and the weight of the data in the tails were also 
carried out.  
Values in grey squares indicate criteria for which the null hypothesis of normally 
distributed data is rejected.  
 
Table 6.3.1.4: Normal distribution assessment of autoantibody readings for all 
healthy volunteers 
Assessments of normal distribution were carried out using the Kolmogorov-Smirnov (K-S) 
test and the Shapiro-Wilks (S-W) test. 
Assessments for skewness and kurtosis were also carried out to assess whether the data 
was weighted towards one side or not and the weight of the data in the tails were also 
carried out.  
Values in grey squares indicate criteria for which the null hypothesis of normally 
distributed data is rejected.  
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Table 6.1.3.5: Normal distribution assessment of hospital-recorded data for all PBC 
patients and the groups of responders and non-responders. 
Assessments of normal distribution were carried out using the Kolmogorov-Smirnov (K-S) 
test and the Shapiro-Wilks (S-W) test. 
Assessments for skewness and kurtosis were also carried out to assess whether the data 
was weighted towards one side or not and the weight of the data in the tails were also 
carried out.  
Values in grey squares indicate criteria for which the null hypothesis of normally 
distributed data is rejected.  
 
 
6.3.2: Spearman’s Rank Correlation Coefficient 
All variables were tested against each other for a significant positive or negative correlation 
by Spearman’s Rank Correlation Coefficient. Coefficients and p-values are shown in tables 
6.3.2.1 and 6.3.2.2 and scatter graphs with the line of best fit indicating the relevant R2 value 
are included in the appendix.  
Significant findings for patient data are positive correlations between age and years since 
diagnosis; age and age at diagnosis; age and years since UDCA treatment began; bilirubin 
and ALT; bilirubin and ALP; ALT and ALP. There were significant negative correlations 
between age and ALP; age and ALT.  
Comparing each data set with the others can indicate relationships which may be of interest 
in responder/non-responder categorising.  
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Spearman’s rank correlation was carried out to compare all continuous data with other 
continuous data. This stage is equivalent to carrying out a ‘scatter plot matrix’ which 
precedes a multivariate or multinomial regression analysis. To have insight into which 
characteristics may be exerting an influence on each other before factoring in the grouping 
of interest, for example whether a patient is a responder or non-responder, can highlight 
where inclusion of more than one of these factors may be redundant and also which factors 
are likely influencing the outcome on their own. For example, if age correlates strongly and 
positively with weight, then weight and age may not necessarily contribute an original 
influence into whether or not a patient is a responder to UDCA and it would be redundant 
to use both age and weight in the regression stage. 
Table 6.3.2.1 shows the results of patient data gathered at the Freeman hospital where all 
factors are analysed against each other in Spearman’s Rank correlation analysis. 
Generally, where the rs value is between 0.00-0.19, there is a very weak correlation, 
between 0.2-0.39 indicates weak correlation, 0.4-0.59 indicates a moderate correlation, 0.6-
0.79 indicates a strong correlation and 0.8-1 indicates a very strong correlation. The p value 
indicates the likelihood of observing this correlation if the null hypothesis of no correlation 
were true. Age shows a positive correlation with years since diagnosis, age at diagnosis 
and years since UDCA therapy began, with p values all below 0.05 (p=0.012, 0.000, 0.022 
respectively) but only weak correlations with years since diagnosis and years since UDCA 
therapy began, (rs= 0.309 and 0.295 respectively) but a very strong correlation with age at 
diagnosis (rs = 0.819).  
Years since diagnosis correlates strongly with a significant p value with years since UDCA 
therapy began (rs=0.722, p=0.000).  
Bilirubin shows a moderate positive correlation with both ALP and ALT (rs= 0.418 and 
0.445; p=0.000 and 0.000 respectively). ALP and ALT show a strong positive correlation 
(rs=0.727, p=0.000).  
No other factors appeared to show a significant correlation with each other.  
Patient serum hospital-measured criteria were also correlated against serum antibody 
levels for an idea of if any antibodies being investigated might correlate with these data due 
to factors not necessarily relating to their response. For example, there is a weak negative 
correlation between weight and 2 IgG1 isotype antibodies, rhE2ILD (rs=-0.274, p=0.049) 
and rhE3BP (rs=-0.351, p=0.016), therefore there could be a tendency for levels of IgG1 
antibody to drop as weight increases due to weight-related factors not necessarily related 
to disease.  
Those antibody levels which appear to correlate with bilirubin, ALP and ALT may be of 
interest in PBC response grouping because UDCA response is assessed based on bilirubin, 
ALP and ALT. The table shows many potentially interesting correlations, highlighted in bold, 
with significant p values and weak-to-moderate correlation coefficients.  
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Although interesting on its own, to address the main question of this chapter, this data must 
be analysed in the context of the results form the Mann Whitney analysis. 
 
Table 6.3.2.1: Table of correlations for patient data 
This table shows the results from Spearman’s Rank Correlation Coefficient analysis 
between patient data. 2-tailed analysis is used because both positive and negative 
relationships are being investigated. ‘Tails’ can be likened to a skew in the data and a 
skew in either direction would be relevant. 
Significant findings are shown in bold.  
Key –  
Corr.Coeff.: Correlation Coefficient 
Sig.(2-: Statistical significance, or p-value, based on 2-tailed analysis.  
N: Number of data sets in the analysis. 
 
 
 
 
 
 
 
 
 
 
 
 185 
 
Table 6.3.2.2: Table of correlations for ELISA absorbance data 
This table shows the results from Spearman’s Rank Correlation Coefficient analysis of patient data 
against ELISA data for absorbance values for the different isotypes of antibody against the different 
autoantigens. 2-tailed analysis is used because both positive and negative relationships are being 
investigated. ‘Tails’ can be likened to a skew in the data and a skew in either direction would be 
relevant. Significant findings are shown in bold.  
Key -  
Corr.Coeff.: Correlation Coefficient 
Sig.(2-: Statistical significance, or p-value, based on 2-tailed analysis.  
N: Number of data sets in the analysis. 
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6.3.3: Mann Whitney 
Mann Whitney analysis was carried out as a non-parametric comparison of means based 
on ranked data, between nominal data groups, most importantly between responder/non-
responder groups, but also to determine if AMA negative patients should be kept in for 
analysis and if there was likely a gender difference. 
Results from the Mann Whitney are in figures 6.3.3.1 to 6.3.3.6 and also tables 6.3.3.1 and 
6.3.3.2. 
Firstly, antibody levels across PBC patients on the whole were carried out against healthy 
volunteers to determine which antibody isotypes against which antigens were raised in PBC 
and which were insignificant. It was found that all except the IgG4 isotypes showed 
significantly higher levels in PBC patients compared to healthy volunteers, therefore all 
except IgG4 isotypes were kept in for further analysis. Table 6.3.3.1 shows p values of 
0.542, 0.958 and 0.323 comparing PBC patient levels of antirhE2IgG4, antirhE2ILDIgG4 
and antirhE3BPIgG4 respectively, whereas all other p values comparing PBC patient levels 
to healthy control levels were 0.000 or 0.001 (rhE3BPIgG1). Then levels of the remaining 
antibodies were further investigated for differences between responders and non-
responders. Table 6.3.3.2 shows that those showing significantly different levels between 
responders and non-responders are then rhE2ILDIgG3 (p=0.010), rhE2ILDIgA (p=0.047) 
and rhE2IgE (p=0.025).  
Mann Whitney analysis was also carried out on hospital-obtained data and those factors 
where there was a difference between responder and groups were Age(p=0.002), Age at 
diagnosis(p=0.030), ALP(p=0.000) and ALT(p=0.000). 
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Figure 6.3.3.1:  Bar charts for autoantibodies showing significant difference by 
Mann-Whitney comparison 
The absorbance for antibodies in the ELISA assay are plotted, grouped into responders 
and non-responders. Those shown are those where the p value was <0.05, giving a 
significant difference. 
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Figure 6.3.3.2:  Bar charts for liver biochemistry measurements 
The clinical liver data were plotted grouped into responders and non-responders. Those 
shown are those where the p value was <0.05, giving a significant difference. 
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Figure 6.3.3.5:  Boxplots and mean bar charts for age criteria 
The age at diagnosis and age at time of sample collection are plotted grouped into 
responder and non-responder groups. Those characteristics shown have a significant 
difference between responders and non-responders where p<0.05. 
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Figure 6.3.3.6: Male and female significant differences for autoantibody levels 
These figures show the autoantibodies found to be significantly different in levels between 
males and females where p<0.05. 
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Antibody 
Healthy 
Controls vs 
PBC 
P value 
UDCA 
responders 
vs Healthy 
Controls 
P value 
Non-
responders 
vs Healthy 
Controls 
P value 
UDCA 
responders 
vs Non-
responders 
P value 
     
αrhE2 IgGall <0.0005 <0.0005 <0.0005 0.375 
αrhE2ILD IgGall <0.0005 <0.0005 <0.0005 0.330 
αrhE3BP IgGall <0.0005 <0.0005 <0.0005 0.059 
αrhE2 IgG1 <0.0005 <0.0005 <0.0005 0.142 
αrhE2ILD IgG1 <0.0005 <0.0005 0.003 0.845 
αrhE3BP IgG1 0.001 0.004 0.008 0.985 
αrhE2 IgG2 <0.0005 <0.0005 <0.0005 0.197 
αrhE2ILD IgG2 <0.0005 <0.0005 <0.0005 0.068 
αrhE3BP IgG2 <0.0005 <0.0005 0.002 0.774 
αrhE2 IgG3 <0.0005 <0.0005 <0.0005 0.054 
αrhE2ILD IgG3 <0.0005 <0.0005 <0.0005 0.010 
αrhE3BP IgG3 <0.0005 <0.0005 <0.0005 0.076 
αrhE2 IgG4 0.542 0.840 0.333 0.421 
αrhE2ILD IgG4 0.958 0.689 0.849 0.774 
αrhE3BP IgG4 0.323 0.475 0.672 0.924 
αrhE2 IgA <0.0005 <0.0005 <0.0005 0.251 
αrhE2ILD IgA <0.0005 <0.0005 <0.0005 0.047 
αrhE3BP IgA <0.0005 <0.0005 <0.0005 0.098 
αrhE2 IgM <0.0005 <0.0005 <0.0005 0.058 
αrhE2ILD IgM <0.0005 <0.0005 <0.0005 0.271 
αrhE3BP IgM <0.0005 <0.0005 <0.0005 0.552 
αrhE2 IgE <0.0005 <0.0005 <0.0005 0.025 
αrhE2ILD IgE <0.0005 <0.0005 <0.0005 0.070 
αrhE3BP IgE <0.0005 <0.0005 <0.0005 0.491 
Table 6.3.3.1: Table of p-values for Mann Whitney analysis 
This table shows the p value data for figures 3.1.1-3.1.8. Significant finds are in bold with 
the comparison in question at the top of the column and the antibody isotype and 
autoantigen it is against at the left hand side of each row.  
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Table 6.3.3.2: Table of p value results for all Mann Whitney analysis 
This table shows the p values for all Mann Whitney assessments carried out with the most 
important also being displayed in chart form in other figures. All findings are explained in 
the discussion section.  
Significant findings are in bold.  
The criteria being analysed for differences between subgroups thereof is denoted at the 
top of each column with the criteria being measured and compared to the left of each row. 
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6.3.4: Power of the study 
The power of the study can indicate if the sample size is large enough to rely on conclusions 
gathered from a study and can also indicate the likelihood of there being type II errors, as 
in null hypotheses maintained when they ought to have been rejected. Statistical power is 
defined as ‘the probability that an effect will be detected if there is one’ and is mathematically 
related to the standardised error, which is the difference between the 2 means per unit 
standard deviation; the threshold probability for rejecting the null hypothesis (α); if there are 
different sized groups, the proportion of subjects in each group. Power can also be 
expressed as 1-β, where β is the probability of making a type 2 error, or the probability that 
a null hypothesis is not rejected when it ought to be.  
As the effect size before the study is unknown, it is difficult to calculate the power of a study, 
however it can be calculated the effect size that can be confidently detected based on power 
of 0.8. With a power of 0.8, it can be estimated that 80% of effects will be detected given 
the sample size and gives a 20% chance of a type II error. As the variance of each data set 
is different to the next, it is less useful to calculate the actual statistical power of each 
different variable, as this will provide different values for each element of the study, and 
more useful to compare, at each point, whether or not the power is as good as 0.8, which 
is generally accepted in the literature for giving a low type II error rate.  
Table 6.3.4 shows the minimum standardised effect (SE) detectable given 0.8 power and 
the numbers of participants used. All values in the calculated SE column are lower than 
those in the minimum required for 0.8 power column except for ALP and ALT. For example, 
for anti-rhE2IgE, which was discovered to be significantly different between groups, the 
standard effect was 0.597, whereas it may usually take a minimum difference with a 
standard effect of greater than this (0.8) to confidently detect this difference. This implies 
that the study is underpowered for the sizes of effect being detected. This means that 
conclusions may still be drawn from the data, however there is a high chance of type II error 
and it is likely that some of the variables would be found to give significant differences 
between responders and non-responders had there been more participants in each 
category. If there is a significant difference in the minimum standard error detected in this 
study, being 0.110 for anti-rhE2ILDIgM, given 20% non-responders and 80% non-
responders within patients, this would require 4054 participants to detect using the sample 
size calculator at http://www.sample-size.net/sample-size-means/, before correcting for 
using non-parametric analyses. 
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6.3.4.1: Antibody levels 
Using http://www.sample-size.net/sample-size-means/ it was calculated that given 
15 non-responders and 62 responders, 80% of real relationships with a 
standardised effect size of approximately 0.8696 and over can be detected, 
meaning samples with a mean difference per unit standard deviation of 0.8696 and 
over can be detected. A smaller standard deviation allows for a smaller mean 
difference to be detected and a larger standard deviation requires a larger mean 
difference to be detected. 
 
6.3.4.2: Other Patient Data 
As there are some missing values for patient data, a new minimum standardised error exists 
for every comparison. The minimum effect size confidently detectable for a power of 0.8 are 
in table 6.3.4. The values show that any significant differences in age (SE=1.042, >0.980), 
age at diagnosis (SE=1.411, >0.980), ALP (SE=1.767, >0.893) and ALT (SE=1.925, 
>0.893) discovered would come from adequately powered studies such that should any of 
these show differences which are insignificant, this is unlikely to be due to a type II error. 
However, other criteria such as weight (SE=0.257, <1.042) do not come from adequately 
powered studies to be able to confidently determine whether they have insignificant 
differences between groups or have a significantly different difference which cannot be 
detected due to the low power of this study. 
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Used in 
study:    
S.E. 
Min. 
SE for 
power 
0.8   N R N NR μ R μ NR σ 
rhE2 
IgG1 62 15 0.891 1.178 0.679 0.423 0.800 
IgG2 62 15 0.443 0.522 0.305 0.261 0.800 
IgG3 62 15 0.757 1.162 0.676 0.598 0.800 
IgG4 62 15 0.027 0.018 0.045 0.209 0.800 
IgA 62 15 0.374 0.459 0.377 0.227 0.800 
IgM 62 15 0.590 0.832 0.507 0.477 0.800 
IgE 62 15 0.228 0.475 0.414 0.597 0.800 
IgGall 62 15 0.696 0.758 0.271 0.229 0.800 
rhE2IL
D 
IgG1 62 15 0.339 0.461 0.375 0.326 0.800 
IgG2 62 15 0.653 0.810 0.624 0.251 0.800 
IgG3 62 15 0.903 1.308 0.785 0.516 0.800 
IgG4 62 15 0.030 0.021 0.051 0.170 0.800 
IgA 62 15 0.450 0.658 0.455 0.458 0.800 
IgM 62 15 0.982 1.035 0.474 0.110 0.800 
IgE 62 15 0.600 0.911 0.644 0.483 0.800 
IgGall 62 15 0.618 0.697 0.287 0.272 0.800 
rhE3BP 
IgG1 62 15 0.247 0.141 0.487 0.217 0.800 
IgG2 62 15 0.270 0.326 0.319 0.175 0.800 
IgG3 62 15 0.254 0.520 0.466 0.570 0.800 
IgG4 62 15 0.007 0.013 0.021 0.309 0.800 
IgA 62 15 0.189 0.285 0.211 0.456 0.800 
IgM 62 15 0.723 0.803 0.476 0.167 0.800 
IgE 62 15 0.070 0.168 0.152 0.646 0.800 
IgGall 62 15 0.543 0.667 0.259 0.478 0.800 
Age 46 10 62.300 49.500 12.280 1.042 0.980 
Age Diagnosis 46 10 51.090 36.560 10.300 1.411 0.980 
Weight 38 9 75.880 71.490 17.051 0.257 1.042 
Years since 
Diag. 47 9 11.640 10.330 6.825 0.192 1.020 
Yrs on UDCA 44 9 10.700 8.000 6.571 0.411 1.020 
UDCA dose/kg 37 9 12.550 11.470 3.667 0.295 1.053 
Bilirubin 49 15 9.143 12.270 10.146 0.308 0.893 
ALP 49 15 
126.22
0 
375.53
0 
141.08
2 1.767 0.893 
Table 6.3.4: Table of effect size. 
This table shows the effect size confidently detectable by this study based on a desired 
statistical power of 0.8. This is the power level usually strived for in the literature as it 
leads to only a 20% chance of type II error. The observed effect size, SE, can be 
compared to the maximum SE detectable if power level were at 0.8. Where SE is greater 
than Min. SE for power 0.8, the study can be considered ‘adequately’ powered assuming 
20% type II error rate which is generally accepted in the literature. 
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6.3.4.3: Male and Female 
There were differences discovered between male and female groups, disregarding 
responder/non-responder grouping.  
With only 3 males and 62 females, the minimum standard error for confident 
detection of 80% of relationships is 1.621. The standard errors between males and 
female groups are 0.915 for rhE2ILDIgG3, 0.974 for rhE2ILDIgA and 0.685 for 
rhE2IgE (not shown), therefore there may be other significant antibody differences 
between males and females that this study is not powerful enough to uncover. 
Additionally, to require confident detection of these 3 differences given a likelihood 
of 20% of other comparisons to also be actually significant but undetected, the 
number of females would be required to be at least 195 and males 10, as calculated 
using http://www.sample-size.net/sample-size-means/.  
 
6.3.5: Kruskal-Wallis 
The Kruskal-Wallis would be useful if in this study it was of interest if the groups 
differ compared to each other and also to healthy volunteers. In a question regarding 
if there are any significant differences between Healthy Volunteers, Responders and 
Non-responders, a Kruskal-Wallis determines whether there is a significant 
difference between the means of the 3 groups of healthy volunteers, responders 
and non-responders. Results are shown in table 6.3.5. rhE3BPIgG3 appears of 
significant interest, with chi-squared value of 6.261 and p value of 0.012, showing a 
large difference with high significance.  
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Table 6.3.5: Chi-squared values and relevant p values for Kruskal-Wallis comparison of 
means. 
This table shows the chi-squared values and relevant p values for Kruskal-Wallis analysis between 
3 groups of Responders, Non-responders and Healthy volunteers. The IgG3 isotypes appear to be 
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of most relevance looking at the disease of PBC as a whole and taking healthy volunteers into 
consideration.  
6.3.6: Multinomial analysis 
In this stage, factors of significance in the previous sections were taken and further analysed 
for their relative influence on a patient’s response status to determine if the response of a 
patient could be accurately predicted given the data from previous sections. As blood levels 
of all independent variables were not available and based on all data which was available, 
the best formula which could be established was one which may predict whether a patient 
would have been designated a responder or non-responder one year after diagnosis, given 
data available at time of blood draw.  
Response was initially calculated using ALP, ALT and bilirubin criteria, presumably 1 year 
after UDCA treatment was commenced, as outlined in section 6.1. Exact blood levels of 
these at diagnosis were not made available to this group, therefore it is unknown if these 
levels have altered, and by how much, since the patient was designated a responder or 
non-responder. A prediction can be made on if the ALP and ALT measurements, at time of 
blood draw, of the PBC patients in this study as a whole are reflective of those at diagnosis. 
Table 6.3.2.1 indicates that on Spearman’s Rank correlation, there is no significant 
correlation between years since diagnosis and ALP (All PBC – rs=-0.047, p=0.721; 
Responders – rs=0.018, p=0.903; Non-responders – rs=0.075, p=0.847) or ALT (All PBC – 
rs=-0.101, p=0.442; Responders – rs=-0.035, p=0.847; Non-responders – rs=0.142, 
p=0.715). Therefore, it can be assumed that ALP and ALT are not significantly different to 
at the time of diagnosis and it would be unfair to include ALP and ALT in predicting a 
patient’s UDCA responder status, given response/non-reponse was first allocated based 
on these levels. Therefore, those factors of interest are Age, age at diagnosis, 
antirhE2ILDIgG3 level, anti-rhE2ILDIgA level and anti-rhE2IgE level.   
Those factors which were found to be of interest in Mann Whitney analysis (age, age at 
diagnosis, rhE2IgE, rhE2ILDIgG3, rhE2ILDIgA) are referred to on table 6.3.3.2 and were 
carried forward to look for correlations between these. Spearman’s rank correlation 
coefficient indicates that there is a very strong positive correlation between age at blood 
draw and age at diagnosis (rs=0.819, p=0.000). rhE2IgE, rhE2ILDIgG3 and rhE2ILDIgA do 
not correlate with age, however rhE2IgE shows a weak negative correlation with age at 
diagnosis (rs=-0.369,p=0.045). Additionally, there was found to be positive correlations 
between rhE2IgE, rhE2ILDIgG3 and rhE2ILDIgA. Positive correlations between factors 
does not necessarily mean that they are not contributing independently to response status, 
but indicates there could be an underlying factor governing those factors that correlate 
strongly with each other. 
The factors of age, age at diagnosis, rhE2IgE, rhE2ILDIgG3 and rhE2IgA could, then, be 
brought forward for multinomial regression. Based on the data available, the multinomial 
regression formula would be designed to predict if a patient would have been designated 
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‘responder’ or ‘non-responder’ by Paris criteria one year after their diagnosis given their age 
at time of blood draw, so for example time ‘T’; their age at diagnosis; their anti-rhE2ILDIgG3 
level at time T; their anti-rhE2ILDIgA level at time T; their anti-rhE2IgE level at time T.  
 
Y ~ x0 + b1x1 + b2x2 + b3x3 + b4x4 + b5x5 
For ln[P(non-responder)/P(responder)], to give the probability that a patient is a non-
responder, rather than a responder, given the combined products of the levels of the 
independent variables and their co-efficients.   
where: 
x1 is age, b1 is the co-efficient for age; 
x2 is age at diagnosis, b2 is its coefficient; 
x3 is rhE2ILDIgG3 level, b3 is its co-efficient; 
x4 is the rhE2ILDIgA level, b4 is the co-efficient; 
x5 is the rhE2IgE level, b5 is the co-efficient; 
x0 is the Y intercept. 
The data is input in table form into R studio and the R command of  
> multinom(formula = out ~ Age + Agediag + rhE2Ige + rhE2ILDIgg3,  
data = Patientdata). 
 
where ‘out’ is the pre-defined name for Responder/non-responder category with Responder 
as the reference.  
The formula which can be inferred by the intercepts and coefficients provided by R: 
Ln[P(Non-responder)/P(Responder)= 
11.694-(-0.154xAge)+(-0.158xAge at 
diagnosis)+(2.023xrhE2ILDIgG3)+(0.1541xrhE2ILDIgA)-(-1.835xrhE2IgE) 
The significance of each independent variable in the formula of each of these is by finding 
the z statistic and converting this to a p value. The z statistic can be calculated by dividing 
the coefficient by the standard error. 
Intercept: z=11.694/5.802=2.016, p=0.044 
Age: z=-0.154/0.106=-1.459, p=0.145. 
Age at diagnosis: z=-0.158/0.107=-1.475, p=0.141. 
rhE2ILDIgG3: z=2.023/1.367=1.480, p=0.139. 
rhE2ILDIgA: 0.154/1.343=0.115, p=0.909. 
rhE2IgE: z=-1.835/2,215=-0.828, p=0.408. 
When the z values are converted to p values, it can be determined that no criteria input into 
the equation provide any significant ‘strength’ to the equation as all of the p values are 
greater than 0.05.  
This information is also available using the commands: 
> z <- summary(mymodel5)$coefficients/summary(mymodel5)$standard.errors 
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> p <- (1 - pnorm(abs(z),0,1))*2 
As none of the p values are significant, it is not necessary to test the formula, however if 
there were variables providing significant strength to the formula it would then be 
appropriate to remove those not providing significant strength, recalculate the formula and 
then test the new formula by the steps below. 
If p values for antibodies were found to be significant, and were subsequently kept in the 
formula and a working formula for prediction of whether a patient is a responder or non-
responder had been established, the formula would then have to be tested. As none of the 
p values were under 0.05 (explained in discussion), this was not the case and therefore it 
can be determined that although significant differences between means by Mann Whitney 
analysis were found, these antibody levels on their own do not significantly define whether 
a patient is a responder or non-responder. If there were significant p values, the formula’s 
accuracy would then be tested as below. 
The assessment of percentage of accurate guesses by the formula based on how many of 
the actual results can the formula estimate would then be carried out. The R command for 
this is:  
> predict([model name],[data name])  
which produces probabilities of the values being the observation value, rather than the 
reference value, in this case the probability of being a non-responder rather than a 
responder, given the formula.  
The commands:  
> cm <- table(predict([model name]),[data name]$[Reference factoral]) 
> print(cm) 
then provide a table of the numbers of correct guesses and number of incorrect guesses.  
Odds-ratio calculation would then be calculated for relative correctness of the formula by: 
OR = (a/c) / (b/d) 
Where OR is odds ratio and (a/c) is (actual number of non-responders/actual number of 
responders) and (b/d) is (formula’s guessed number of non-responders/formula’s guessed 
number of responders). 
This would give an estimate of how reliable the formula is for predicting the outcome, or 
predicting the dependent variable. 
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6.4: Discussion 
6.4.1.1 Patient Data – Spearman’s Rank Correlation Coefficient 
Using all patients, Spearman’s rank correlation showed strong positive correlations 
between bilirubin, ALT and ALP (p<0.001 across the board), as shown in table 6.3.2.1. 
These markers are all known to be indicative of liver damage. In addition, age correlated 
negatively with ALP (p=0.014) and ALT (p=0.006) which implies a strong association 
between age and liver damage. This association is indicative that patients at a lower age at 
time of serum draw and also diagnosis may have worse liver function, which is in agreement 
with the observation in the literature that younger patients are more likely to be non-
responders regarding the current therapy with a more aggressive disease. 
ALP and ALT did not, however, correlate significantly with age at diagnosis apparent in 
table 6.3.2.1 (p=0.152 and 0.059 respectably), however this could be due to the fact that 
most patients are at a very early disease state at diagnosis, therefore do not yet have raised 
ALP or ALT.  The age range at which patients can be diagnosed is large and up to 60% of 
patients are asymptomatic at diagnosis therefore patients across all ages at diagnosis may 
have liver function tests only just within the diagnostic range(Prince et al., 2004). Even early 
non-responders may have ALP and ALT only just in the diagnostic range, but then their 
disease goes on to progress more quickly than the responders.  
Age at date drawn and age at diagnosis correlate positively (p<0.001, shown in table 
6.3.2.1) meaning the older any given patient is at the time of blood drawn, the older they 
likely were when diagnosed. This could indicate that there are narrow parameters of length 
of time a patient in this study has been diagnosed with PBC for. This could be because 
eventually patients require a new liver or perhaps die of an unrelated cause, to do with old 
age. 
Some factors correlate positively due to their relation to time, such as age at diagnosis and 
years since UDCA administration: UDCA is usually administered early in diagnosis. These 
factors were not taken into account during analysis because correlation may be a result of 
relation to time.  
 
6.4.1.2 Patient Data - Mann Whitney  
Patients of different nominal groups were also compared, by Mann Whitney analysis, based 
on information provided alone to investigate any phenotypic grouping.  
There were no significant differences in different gender groups regarding age at draw, age 
at diagnosis, weight, UDCA dosage, bilirubin, ALT or ALP. There were few male participants 
giving limited statistical power so a future study should aim to recruit more men with PBC. 
A surprising find was no significant difference regarding weight between the genders 
(p=0.06, table 6.3.3.2), as it would be expected for men to have a significantly greater weight 
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than females, suggestive that there may have been limited significance power or women in 
the study are significantly heavier than the normal population whereas men are not, or men 
are lighter than the general population of men whereas the women were not. The average 
weight of PBC females in the study was 76.1kg compared to the national average of 70.2kg, 
whereas the average weight of PBC males in this study was 87.1kg compared to 83.6kg 
(table 8.1-8.3, appendix). It could be argued that there could be an element of males being 
underweight whereby females are overweight, but another study gathering weight of age 
matched healthy volunteers and more males to increase the statistical power would be 
required in order to give real evidence for this. It has been discussed in this chapter that the 
power of this study is limited, therefore if the weights of patients in this study do mimic the 
normal population with a difference between males and females, it may not be detectable 
in this study. 
There were no significant differences across cohort A and B groups regarding age at draw, 
age at diagnosis, weight, UDCA dosage, bilirubin, ALT or ALP, shown in table 3.3.2 where 
all p values exceed 0.05. One surprising find is that UDCA naïve patients did not show any 
difference in liver biochemistry results (bilirubin – p=0.866; ALT – p=1.000; AST – p=0.651) 
compared with those already taking UDCA, when UDCA is thought to normalise liver 
function tests in most patients. On further investigation, many of these patients were missing 
liver biochemistry results, but additionally therefore were likely very early in disease state, 
therefore only minor liver damage had yet occurred. Cohort B patients were likely not yet 
on UDCA due to their only having just been diagnosed and only in monitoring stage of 
treatment.  
As all patients were either white or with non-disclosed ethnicity, no comparison between 
ethnic groups could be carried out which is one limitation of the study.  
There were no significant differences between AMA and ANA positive and negative groups 
regarding age at draw, age at diagnosis, weight, UDCA dosage, bilirubin, ALT or ALP, 
shown by p values in table 3.3.2. This might imply that a patient’s AMA or ANA status is not 
indicative of their liver function, and therefore potentially also disease severity, or age or 
weight, therefore it is not likely a determining factor of their response or non-response status 
based on predictions by Carbone and colleagues(Carbone et al., 2013), according to the 
data in this study.  
The most interesting find of this strand of the study was the key differences in groups within 
the response/non-response comparison. There was no difference in weight, UDCA dosage 
or bilirubin between responder/non-responder groups, indicated by p values in table 6.3.3.2. 
The result for weight was not surprising as there has been little or no evidence to suggest 
that weight differs in these groups. Regarding dosage, the lack of a difference suggests that 
physicians have not increased patients’ dosage based on non-response. This is likely due 
to the growing understanding that there are different sub-types of the disease and no 
evidence suggests it would be beneficial to raise UDCA beyond currently applied levels in 
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a patient suspected to be a non-responder. Bilirubin does not appear to differ between 
responders and non-responders. A higher bilirubin would have been suspected in the 
younger patients with more aggressive disease, however blood serum bilirubin has been 
found to increase with age which may explain the insignificant result (Boland et al., 2014).  
Patients denoted responders had a significantly higher age at time of draw (p=0.002) and 
diagnosis(p=0.02) than those denoted non-responder, shown by p values in table 6.3.3.2 
and shown in graphical form in figure 6.3.4.2. Non-responders have significantly higher 
ALP(p<0.001) and ALT(p<0.001) than responders, shown in p value in table 6.3.3.2 and in 
graphical form in figure 3.4.1. This is congruent with the grouping system suggested by 
Carbone and colleagues, established by their statistical analysis of responders and non-
responders. That our data can replicate their grouping system is largely important because 
confidence in this system and reliance on a study with 2353 participants provides 
confidence to the data in this study and any differences in antibody subtypes we find 
between responders and non-responders based on these criteria (Carbone et al., 2013).  
It was intended to further divide the non-responders to investigate if they can be further 
subdivided into the older and the younger non-response groups to verify the claim the older 
group of non-responders are likely to fail to meet response criteria because of raised 
alkaline phosphatase and bilirubin whereby younger non-responders fail to do so due to 
raised ALT/AST. All attempts to further categorise the non-responders and gain significant 
results were unsuccessful. This is likely due to there being few non-responding patients in 
the study: only 15. Some of these patients were missing data, leaving the usable non-
responders in this context at only 8. Although this is a large enough group to compare with 
the non-responder group and obtain significant results, this is insufficient data to further 
divide and achieve significant results and therefore inadequate statistical power. In addition, 
many patients were missing data, for example there were two non-responders whose age 
was missing. Further studies should work to specifically recruit the non-responder cohort 
and stringent patient data should be kept. This is a limitation which could not be surmounted 
in this study as serum was obtained from an external source and therefore patients were 
recruited and patient data was obtained by an external group. 
One limitation of the study was in that clinical data established from patient blood was 
unavailable for the healthy volunteers due to lack of assays for detecting ANA, ALP, ALT 
and also as none of the healthy volunteers have a PBC diagnosis, they cannot be 
categorised as responders or non-responders; similarly none are taking UDCA, therefore 
years since UDCA start cannot be taken into account. The healthy volunteers are crucial as 
they allow comparison of antibody levels against the non-PBC group, such that those 
isotypes higher than the healthy level can be selected for further analysis. The IgG4 isotype 
of all autoantigens was found to be of levels in PBC patients not significantly higher than in 
healthy controls therefore this isotype was excluded from further analysis.  
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6.4.3 ELISA results 
Data from Chapter 5 were analysed using statistical analysis as below.  
 
6.4.3.1 Normal distribution 
Firstly, the presence of each dependent variable was checked for normal distribution and 
levels were compared with healthy controls. Data that is not normally distributed or is 
skewed is more likely to be of interest because it implies a change in the level in response 
to another factor, rather than patients generally having levels clustered around the most 
common value which would be expected under uninfluenced conditions.  
Regarding serum antibody levels, it is important to firstly compare patient levels with healthy 
controls to determine which types of antibody appear to be unimportant in PBC regarding if 
their levels are raised in PBC. Those with an insignificant difference in Mann Whitney 
analysis between patients and healthy controls are likely antibodies not important in PBC 
and therefore can be disregarded. The IgG4 isotypes were the only isotypes found to be 
present in levels not significantly greater than in the PBC patients when compared by Mann 
Whitney analysis: anti-rhE2 IgG4 (p=0.542), anti-rhE2ILD IgG4 (p=0.958), rhE3BP IgG4 
(p=0.323), indicated in figure 6.3.3.2. This suggests that IgG4 class switching is not an 
important factor in PBC. This may also imply that cytokines which cause IgG4 switching are 
also unimportant, such as IL-4, produced by Th2 cells. This seems to contradict one study 
which has suggested that IgG4 should be measured as standard in PBC diagnosis when 
the patient does not respond to UDCA based on a case study of one patient (Takemoto et 
al.), however the data in this study shows no significant difference between non-responders 
and healthy volunteers thus refuting this suggestion. The study is an example of overlap 
with PBC and IgG4-related disease (IgG4-RD), which is an inflammatory disease involving 
infiltration of lymphocytes into tissues which could be one or more of many throughout the 
body, and PBC. Both are rare diseases and so overlap between these two diseases is 
extremely rare. Although there are more documented cases(Takasumi et al.), there is 
insufficient evidence in the literature or this study to suggest that IgG4 levels should be 
measured as a standard diagnostic protocol for PBC or PBC overlap with IgG4-RD.  
 
6.4.3.2 Spearman’s Rank Correlation Coefficient 
Many antibody isotypes correlate positively with bilirubin, ALT and ALP. This indicates 
which antibodies are likely to be important in disease progression. The greater the 
autoimmune response the more tissue destruction there is so those isotypes which correlate 
to known signs of liver injury, such as raised ALT, ALP and bilirubin, are likely to be involved 
in or indicative of the autoimmune response. In particular, anti-rhE2 IgG3, anti-rhE2ILD 
IgG3, anti-rhE2ILD IgA, anti-rhE3BP IgA and anti-rhE2IgE are of interest as their serum 
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levels appear to correlate positively with ALP, ALT and bilirubin (p values shown in figure 
3.2.2, for example: anti-rhE2IgG3, p=; anti-rhE2ILD IgG3, moderate correlation with ALT, 
p=0.000; anti-rhE2ILD IgA, weak correlation with ALT, p=0.002; anti-rhE3BP IgA, moderate 
correlation with ALP, p=0.001; anti-rhE2IgE, weak correlation with ALT, p=0.001). As none 
of these correlations are considered strong based on rs>0.6, possibly there are 
multifactorial relationships between the variables. 
Although there was insufficient statistical power to further subdivide the non-responders 
based on criteria outlined by Carbone and colleagues, our data does indicate which 
particular isotypes could be associated with the particular criteria which Carbone and 
colleagues suggest could be indicative of further subdivisions of the non-responders. 
According to the literature, the non-responders can be further subdivided into the younger 
non-responders usually with higher ALT and the older non-responders usually with higher 
bilirubin and higher ALP. Therefore investigating which isotypes are associated with these 
specific increases could highlight pathways for future investigation in elucidating the 
differences between the separate non-responder groups. Anti-rhE2ILD IgG1 level 
correlated positively with bilirubin level and anti-rhE2 IgA correlated positively with ALP 
level, associated with the older non-responders, whereby levels of anti-rhE3BP IgM was 
shown to correlate positively with ALT, associated with the younger non-responders, 
therefore the underlying mechanisms causing isotype switching to IgG1 and IgA, and also 
lack of switching, resulting in IgM, could contain a differentiating factor between these 
groups which are within the non-responder group. Therefore, further work into elucidating 
the differences in the non-responder sub groups could focus on pathways leading to IgM 
and IgA or IgG1. Interestingly the difference was only observed with the specific autoantigen 
stated and not across the panel of autoantigens, therefore different autoantigens could be 
elucidating different responses in terms of antibody isotype switching. 
 
6.4.3.3: PBC vs Healthy volunteers: Mann whitney and Kruskal-Wallis. 
Comparisons of PBC patients and healthy volunteers were carried out as an initial test to 
assess which antibodies may be of interest in overall disease. One main investigation into 
this study is if there may be differences in isotype switching in responders and non-
responders. If non-responders undergo isotype switching in a different way to responders, 
then likely there may be some levels of isotypes within a PBC group which are low levels, 
like healthy volunteers, but raised in the other groups to a significantly higher level than 
healthy volunteers, but these difference may be difficult to detect when comparing PBC 
patients to healthy volunteers. For this reason, Mann Whitney data comparing only 
responders and non-responders was used for the bulk of the analysis. Kruskal-Wallis data 
indicates which autoantibodies may be of interest if those used in this study were of such 
different levels among the 3 groups that they could be used for diagnosis not only of PBC 
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but also on response to UDCA likelihood. PBC is already considered diagnosable, so for 
this chapter to add to the field of PBC diagnosis would require subgroup diagnosis, which 
has been shown not to be possible using data gathered in this study. The Kruskal-Wallis 
data, shown in table 6.3.5, indicates that if comparison between the 3 groups were feasible 
that the IgG3 isotype against the E3BP antigen may be of interest, given a p value of 0.012 
for significance between responders and non-responders considering 3 groups. The 
multinomial regression analysis indicates that differences of antibodies between responders 
and no-responders are not significant for diagnosis or prediction of response alone, 
therefore likely more data would be required to postulate an assay for diagnosis including 
sub-grouping. Further work to possibly establish a diagnostic assay which could sub-group 
patients is described within the multinomial analysis sections of this chapter.   
 
6.4.3.3.1: Mann Whitney 
 
There were no significant differences in levels of any isotype between ANA positive and 
negative groups. 
Only some antibodies were shown to have significantly lower levels in AMA negative 
patients compared to AMA positive patients, therefore AMA negative patients were kept in 
for full analysis. These were: anti-rhE2 IgGall (p=0.002), anti-rhE2 IgG1 (p=0.023), anti-
rhE2 IgG2 (p=0.026), anti-rhE2ILD IgGall (p=0.023), anti-rhE2ILD IgE (p=0.035), displayed 
in table 3.3.2. It should be noted that these isotypes were not considered relevant in other 
finds of this study therefore the inclusion of AMA negative patients did not affect other finds. 
The IgGall is a secondary antibody which recognises all IgG isotypes, and the IgG1 is the 
only which is statistically negative so it is possible that in this instance IgGall is 
representative of raised IgG1 and not all IgG subtypes, as the rest of the IgG subtypes are 
not raised.  
The most important find was when comparing responder and non-responder groups. The 
non-responders were shown to have significantly higher levels of the antibodies anti-
rhE2ILD IgG3(p=0.01), anti-rhE2ILD IgA(p=0.047) and anti-rhE2 IgE(p=0.025) indicated by 
p values in table 6.3.3.2 and data shown in figures 6.3.3.4, 6.3.3.6 and 6.3.3.8. Clear 
differences in the spread of data is apparent in the box plots and bar charts show clear 
differences in the average absorbance values across responder and non-responder groups. 
Furthermore, these are all antibodies found to correlate with liver damage blood biomarkers 
ALP, ALT and bilirubin. This is the first instance of an antibody pattern difference being 
discovered between responder and non-responder groups and could indicate a potential 
difference in the underlying mechanisms. 
Further ELISAs must be carried out to monitor patients at various different disease stages. 
For example, patients very early in diagnosis yet late enough to obtain responder/non-
responder status may form one group, patients at middle-stage of disease progression may 
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form another group and late stage patients a third group in order to compare antibody 
patterning at the different stages throughout disease progression and determine if there is 
a change in antibody patterning as the disease progresses. Data obtained in this study uses 
patients at various disease stages, some diagnosed as early as 1992; and also some only 
newly diagnosed; some patients with liver function tests as high as 13mg/dL bilirubin, 
438IU/L ALP and 150IU/L ALT; some with 5mg/dL bilirubin, 54IU/L ALP and 9IU/LALT. 
Symptomatic disease state and liver function would be an appropriate grouping factor rather 
than years since diagnosis as years since diagnosis does not take into account the disease 
history pattern, whereby patients experience a steep drop off in health at a given time 
(Jones, 2003) and the fact that patients do not necessarily enter the disease progression 
stage at a constant time. The reason for this study would be to monitor any changes in 
antibody differences between responders and non-responders as the disease progresses 
but also because if a diagnostic tool is to be developed then it is most important to elucidate 
any antibody differences early on in the disease such that a patient can be placed on an 
appropriate treatment course as early as possible to have maximum impact in slowing or 
stopping disease progression. The data which was available for this study was insufficient 
to characterise a patient as early, mid or late disease state, therefore this analysis could not 
be carried out as an extension of the completed study described.  
There were no significant differences between cohorts A and B, indicated by p values in 
table 6.3.3.2 which all exceed 0.05 (the smallest being 0.068 for rhE2ILDIgG2), for 
comparison by Mann-Whitney analysis, comparing cohort A, patients on UDCA, and cohort 
B, UDCA naïve patients. This may suggest that expression of all of the isotypes neither 
increases nor decreases after commencing UDCA treatment, however this is not supported 
in the Spearman’s Rank correlation coefficient results, from table 6.3.2.2, which does 
suggest a related change in levels of certain antibodies with time taking UDCA. These are 
anti-rhE2IgGall (rs=0.291,p=0.023), anti-rhE2ILDIgGall(rs=325,p=0.01), 
rhE3BPIgGall(rs=0.322,p=0.011), anti-rhE2IgG3(rs=0.257,p=0.05) and anti-
rhE2ILDIgE(rs=0.276,p=0.050). All of these relationships have rs values of below 0.4, 
therefore indicate weak relationships which may not be directly governed by UDCA use 
over time but another factor which may also correlate with UDCA over time.  Notably, there 
was no difference between UDCA naïve and UDCA-taking patients of the antibodies found 
to be of interest comparing responders and non-responders: anti-rhE2ILD IgG3(p=0.05), 
anti-rhE2ILD IgA(p=0.037) and anti-rhE2 IgE(p=0.025). This is an area of interest for the 
future: to uncover if a difference in antibody profiles between responders and non-
responders is similar to that of patients pre- and post- UDCA. More on this is covered in the 
future work section. 
Males are significantly less likely to respond to UDCA therapy, however they do not appear 
to fit the same response/non-response phenotypic pattern as females. For example, it has 
been found in early phenotyping studies that females tend to experience more pruritus, 
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abdominal pain and weight loss than males, however males experience more jaundice, 
jaundice-associated pruritus and upper gastrointestinal bleeding than females(Rubel et al., 
1984). Males have also been shown to have significantly higher bilirubin levels even when 
normal gender differences are taken into account (Carbone et al., 2013). Data from this 
study also suggests that men may not fit the same responder/non-responder patterning as 
females. There are only three antibodies which differ significantly in levels between males 
and females in this study: anti-rhE2 IgE (p=0.003), anti-rhE2ILD IgG3 (p=0.05) and anti-
rhE3BP IgA (p=0.037). All of these are lower in males, however two of these are those 
antibodies identified as being higher in non-responders than responders: anti-rhE2 IgE 
(p=0.025) and anti-rhE2ILD (p=0.01). This then poses the question of where males fit in the 
ever branching PBC picture. Section 6.3 outlines how there is likely high type II error in the 
comparison of responders and non-responders and of males and females. A study 
containing more participants, ideally inclusive of a more even ratio of males/females, would 
increase the statistical power of the study and the relative differences between males and 
females and how these may differ from differences between ‘responders’ and ‘non-
responders’. 
In addition, none of the males had recorded whether they are a responder or non-responder 
to UDCA, therefore the effect of response on gender could not be investigated in this future 
study. Males were therefore all left out of analysis comparing responders and non-
responders, without this necessary data.  
Overall, the Mann-Whitney analysis carried out in this study shows that there are some 
detectable large differences between certain different antibody levels, however the study 
likely lacks statistical power required to detect all significant differences. This has to do with 
number of participants but also the variance of the data, which could not be predicted before 
this study. 
Given that the differences between responders and non-responders uncovered in this study 
were particularly relevant as their mean differences per unit standard deviations were 
relatively high, suggesting a large mean difference and/or a low data variance, both factors 
which suggest a relevant difference. It is therefore important to consider a reason for the 
difference in these antibodies between groups of PBC patients and consider any underlying 
T cell activity which could be influencing this patterning, relating to previous chapters.  
IgE 
Firstly, focussing on IgE, although IgE class switching can in some circumstances be 
attributed to T follicular helper cells releasing IL-4 (Meli et al.), this is unlikely to be the case 
in this context because IL-4 released by TFH has also been shown to increase class 
switching to IgG4 (Akiyama et al.) and there is no evidence of there being raised IgG4 in 
PBC in this study. IL-13 levels have been shown to be raised in sera of PBC patients (Landi 
et al., 2014). IL-13 is primarily produced by Th2 but may also be produced by Th1 or Th17 
cells.  
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IgG3  
IFN-gamma and IL-10: 
IgG3 isotype class switching is associated with a Th1 response, whereby Th1 cells release 
IFN-γ which induces antibody isotype switching to IgG3 (Mortensen et al., 2015). In addition, 
it has long been established that IL-10, produced by a plethora of different leucocytes, can 
also induce isotype switching to IgG1 and IgG3 (1994, Saxena et al., 2015). 
IgA 
It is known that release of IL-5 by Th2 cells can induce isotype switching to IgA (Harriman 
et al.). However, TGF-β released by Tregs may also induce class switching to IgA 
(Dedobbeleer et al.).  
 
As there could be many different underlying mechanisms causing the isotype switching to 
the isotypes in question, it raises the question of which of these mechanisms and underlying 
cell action could be important in PBC. Utilisation of the Flow Cytometry assay optimised in 
chapter 3 on PBC patients could begin to answer this question. 
To explore why these particular isotypes of antibodies against particular autoantigens, and 
not across the board of all autoantigens explored, seems to differentiate responders and 
non-responders, an ELISpot experiment should be carried out, as per the method in chapter 
4. The ELISpot would use PBMCs isolated from PBC patient blood, and also use healthy 
controls. This ELISpot would include wells coated with antibodies against the different 
cytokines known to cause switching to certain isotypes of antibody. The PBMCs would then 
be added and challenged with autoantigens such that there is a challenge in at least 
triplicate of every cytokine-antigen combination. The response by T cells in terms of the 
cytokines released when challenged with the autoantigens can then be quantified by 
counting and analysing the number of spots produced in each well. If the experiment is 
carried out across many patients, a tendency towards the type of antibody response against 
that antigen may be apparent, which could not only determine if the different autoantigens 
can illicit different responses but also explore a T cell basis to the antibody isotype 
patterning seen in the data in this chapter. If the PBMCs are stained with CFSE prior to the 
ELISpot, then they may then be harvested and analysed by flow cytometry using the assay 
designed and optimised in chapter 3. Post-ELISpot, the cells would be stained for 
extracellular markers to allow their discrimination based on their T cell subtype and their 
proliferation in response to the different autoantigens may be compared.  
 
 
6.4.4: Multinomial regression 
Section 6.3.6 outlines a multinomial regression which was designed to determine if, given 
the data available, the patients’ responder/non-responder categorisation could be 
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predicted, with a particular interest in how important the antibody levels found to be 
significantly different between responders and non-responders were.  
Although the levels of rhE2ILDIgG3, rhE2ILDIgA and rhE2IgE appear to be significantly 
different in non-responders compared to non-responders, they possibly carry insufficient 
strength to be considered for diagnostic purposes. At this stage it may often be appropriate 
to consider testing for homogeneity of variance of all of the independent variables and if this 
is not satisfied, data can be transformed, and then it may fit the multinomial regression 
formula, but in this study it has already been established that there are likely many type II 
errors so this is best saved for a more highly powered study, such that more independent 
variables may be carried forward for multinomial regression. A more highly powered study 
involving more participants, i.e. more responders and more non-responders, may be less 
sensitive to type II errors and would possibly detect more antibodies of interest in terms of 
different levels between responders and non-responders, which could then be used in 
multinomial regression.  
 
6.4.5: Future work and limitations of this chapter 
Something not covered in this chapter is any relationship between the autoantigens 
recognised by a patient and the isotypes of antibodies produced in response to each 
antigen. There may be a relationship between isotypes of antibodies produced and the 
autoantigen(s) recognised by the patient. In order to answer this question, first a competitive 
ELISA experiment would have to be carried out to estimate the amount of response to an 
antigen that is measured due to antibody cross-over. For this chapter, there was not enough 
available autoantigen for coating of the ELISA plates to cover this. The competitive ELISA 
answers the question of if one antibody may be promiscuously binding to other antigens. In 
this context, some anti-rhE2ILD-recognising antibodies in patient sera may be binding to 
the rhE2 protein coat. Therefore it is unknown in this chapter what proportion of the results 
from ELISA screens were from contributions made by other antibodies than that being 
tested at the time. The competitive ELISA involves incubating the patient serum with an 
autoantigen then detecting for the presence of all autoantigens being used, separately, by 
the indirect ELISA technique used in this study. An autoantigen should ‘inhibit’ itself such 
that when a certain concentration of autoantigen is added to the serum and incubated 
before ELISA, there will be no response. Then other autoantigens incubated with this serum 
will give less than ‘normal’ readings if they are competing for the protein coat with the 
antibody in question. The extent of competition exerted by an antibody against an 
autoantigen on another can be quantified by using different dilutions of autoantigen in the 
patient serum, or different serum dilutions for a fixed autoantigen concentration, and the 
extent of this competition indicates the extent of cross-reactivity between antibodies.  
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Once this has been established, then antibody isotype responses for individual 
autoantigens can be investigated, correcting for cross-reactivity, using the Kruskal-Wallis 
comparison for k groups test. It is important to consider the importance of power of the 
experiment, as using Kruskal-Wallis involves dividing the p value for confidence by k(k-1)/2, 
so for example investigating 8 different isotypes would involve an alpha level of 0.05/28 = 
0.00179. Section 6.3 outlines the importance of consideration of power in an experiment. 
It is important to note that this study assumes minimal cross-reactivity, as it is not corrected 
for, and this is due to there being a limited amount of autoantigen protein available, but 
further studies should carry out cross-reactivity experiments as standard. 
Additionally, it is important to acknowledge that this study does not take advantage of all 
autoantigens found to be of importance in PBC, only those which were available, so a larger 
scale study could use a wider range of autoantigens.  
 
6.4.6: Concluding remarks: The future for PBC diagnosis? 
A future study to generate a diagnostic formula for PBC could involve large groups of 
UDCA-naïve PBC patients and healthy volunteers with no detectable PBC by diagnostic 
criteria or raised AMAs above the ‘cut-off’ for negative sera. ALP, ALT and levels of different 
isotypes of the autoantibodies would be gathered. Sera from these same PBC patients one 
year on, at the point of ‘response/non-response’ categorisation based on ALP and ALT, 
would then have the same results gathered from these 1-year-on sera. Comparison of ALP, 
ALT and autoantibodies from pre- and post- UDCA levels and analysing any responder/non-
responder differences could indicate if the different antibody profiles may be due to a 
response to UDCA or already present. If it is established that there is a notable difference 
in antibody levels in the UDCA-naïve sera between those who would go on to be responders 
compared with those who would go on to be non-responders, then this would be indicative 
of there being a potential diagnostic difference between these patients. 
The above experiment could also include other factors of PBC-predictive interest. Those 
found to show significant difference between healthy volunteers, those that go on to be 
responders and those that go on to be non-responders found in early serum samples can 
be applied used in multinomial regressions after adjustment of p values based on 3 groups. 
Comparisons to the healthy control would be carried out with those who would go on to be 
responders and those who would go on to be non-responders. Those factors with significant 
z-calculated p values from multinomial regression would be kept in the formula and the 
formulae would be tested. The resultant formulae would be: 
YR= ln[P(responder)/P(Healthy)]= x0 + x1b1 + x2b2….. 
YN=ln[P(Non-responder)/P(Healthy)]=x0+x1b1+x2b2…  
(where the ‘x’ and ‘b’ values are specific for each formula). 
Taking exponentials to both sides gives: 
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P(Responder)/P(Healthy) = eYR and P(Non-responder)/P(Healthy) = eYN. 
These can be combined to give: 
P(Healthy) = 1/(1+eYR+eYN) 
Given that P(Healthy)+P(Responder)+P(Non-responder) must total 1 (all possible 
outcomes), 
(1-P(Healthy))/P(Healthy) = eYR + eYN 
and 1/P(Healthy) = 1 + eYR + eYN 
P(Healthy) = 1/(1+eYR+eYN) 
P(Responder) = eYR/(1+eYR+eYN) 
P(Non-responder) = eYN/(1+eYR+eYN) 
Once this formula is designed with the relevant coefficients and intercepts, and tested on 
large groups of patients, a computer programme calculation could be designed in which the 
measurements of characteristics found to be significant predictors of no PBC, response and 
non-response in all previous stages could be entered and a probability for someone 
suspected of having PBC for them being healthy, a PBC UDCA responder or a PBC non-
responder would be given based on these criteria.  
Alternatively, for a formula which applied to only PBC-confirmed patients could be 
expressed as: 
Y = ln[P(Non-responder)/P(Responder)=x0+x1b1+x2b2+…..  
can give  
P(Non-Responder)/P(Responder)=eY 
P(Non-responder)+P(Responder)=1 
Substitute in P(Non-responder)=1-P(Responder) 
(1-P(Responder))/P(Responder)=eY 
1-P(Responder) = P(Responder)(eY) 
1=P(Responder)(eY) + P(Responder) 
1/P(Responder)= 1+eY 
P(Responder)=1/(1+eY). 
This could also be calculated to find P(Non-responder) rather than P(Responder).  
This would then give the probability of a PBC patient being a non-responder or a responder, 
depending on how the equations are rearranged, provided all of the factors are shown to 
be accurate responder/non-responder predictors.  
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7: General Discussions 
7.1: Results Summary 
7.1.1: Chapter 3: Design of an assay which can distinguish 
between different subsets of T cell for use in categorising 
patient subgroup T cell populations and to investigate any 
skewing ability of UDCA on T cell populations. 
One aim of this chapter was to design a method for the distinguishing of different T 
cell subsets. This assay would have two primary applications. Patient T cell subsets 
could be investigated for any potential difference pertaining to their response/non-
response status and potentially also their length of time on the drug ursodeoxycholic 
acid (UDCA). This assay would also be used on PBMCs isolated from healthy 
volunteers to investigate the effect on the T cell population under proliferative 
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conditions and in the presence of UDCA, to determine if UDCA may be altering the 
population of activated T cell subsets.  
Data from this assay would be useful because it would potentially help to underpin 
the differences between patients that do respond to the current therapy and those 
who do not. It is important not only to identify if there are specific T cell profiles 
identifiable of the different PBC subgroups but also if this could be UDCA-directed 
or the result of another factor. There are many potential factors which can contribute 
towards PBC development, such as genetics and environmental factors, discussed 
in chapter 1, therefore it is important to distinguish if these differences could be a 
direct impact of the drug or genetic or environmental and if they can be controlled. 
Additionally, if it were discovered that there are different T cell subsets important in 
the different PBC subsets, this could lead to measurably different antibody 
concentrations in patient serum, discussed in chapter 1 and also this chapter.  
This assay is useful to help elucidate the role of CD4+ T cells in PBC. Studies 
already carried out have investigated the role of CD4+ T cells in immunological 
dysfunction. One such study investigated the importance of then-Ras gene in TCR 
signalling and have identified microRNAs (miRNAs) which can dysregulate TCR 
expression and dampen the CD4+ T cell response in PBC (Nakagawa et al., 2017). 
Other studies have gone so far as to investigate CD4+ subsets and their potential 
importance in PBC in mouse models and have found that hepatic Th2 and Treg cell 
populations are increased in disease mice(Zhang et al., 2017), however none have 
used human PBC patient blood samples and compared CD4+ T cell profiles in the 
comparison of responders with non-responders.  
The design and testing of an assay to identify T cell subsets was successful, with a 
flow cytometric panel designed which could identify Th1, Th2, Th17 and Treg cells. 
Patient blood samples were initially anticipated which would allow for the completion 
of this aim, however administration difficulties led to their being unavailable for the 
time frame of this project. The panel was, however, used in the following chapter to 
investigate if UDCA influences proliferation of T cell subsets in healthy volunteers.  
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7.1.2: Chapter 4: Further elucidating the mechanism of action of 
UDCA in PBC: investigating a direct effect on T cells in the 
cholangiocytes 
 
One aim of this chapter was to implement the assay designed in the chapter ‘Design 
of an assay which can distinguish between different subsets of T cell for use 
in categorising patient subgroup T cell populations and to investigate any 
skewing ability of UDCA on T cell populations.’ This entailed investigation into if 
there may be any differences in T cell subsets having differential impacts in patients 
of the different subgroups in PBC. Additionally, this chapter investigated if there was 
a UDCA influence in a T cell’s ability to carry out essential functions such as 
surmount a response to antigen or proliferate. Finally, the chapter investigated if 
UDCA influences the proliferation of cholangiocytes lining the small bile ducts, but 
also if it influences the types of cytokines they release which may then influence 
proliferation of the T cells.  
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Investigating any effect of UDCA which could be of clinical relevance is important 
because the identification of different subgroups of patients was initially carried out 
based on response to this drug, therefore investigating the impact of the drug in 
responders may uncover key pathways and processes which differ between 
responders and non-responders. It is important to directly study the impact of UDCA 
on the cholangiocytes as these are the primary cells damaged in this disease and 
the initial site of inflammation. Protection of the structural integrity of the small bile 
ducts is key to prolonging liver survival and therefore patient wellbeing and survival. 
The disease is amplified by the auto-reactive immune cells causing and 
perpetuating inflammation in the disease site. It has been reported that removal of 
the stimulus can render a patient able to regenerate organ health (Jones 1999). As 
the disease is autoimmune and removal of the stimulus is impossible, dampening 
down the immune response becomes the key method for therapeutic intervention. 
If UDCA has an impact on dampening down the immune response, this is of clinical 
importance because uncovering the specific biological impact could highlight areas 
for investigation for elucidating responder/non-responder differences. 
Studies into the effect of UDCA on the cholangiocytes have been carried out, some 
focussing on their proliferation, and data in this study further confirm this. It has been 
known for some time that UDCA can reduce proliferation in rat cholangiocytes by 
activation of Ca2+-dependent signalling (Marzioni et al. 2006). Data in this thesis 
investigates if there is a similar attenuation of proliferation on human cholangiocyte 
cell-line H69 cells by UDCA and confirms a significant decrease compared with the 
ethanol control at concentrations of 0.25mM (p=0.031), 0.5mM (p=0.004) and 1mM 
(p=0.026). The data in this thesis goes further and suggests that the cholangiocytes 
may also alter their cytokine secreting profile in response to UDCA, as T cells 
incubated in the supernatant of previously UDCA-treated cholangiocyte cell line 
(H69) cells show significantly less proliferation compared with untreated H69 cell 
culture. The effect was measurable with culture 1 and 2 days post-wash (p<0.05; 
p<0.001).  
Importantly, data in this thesis have shown that there is a significant reduction of 
CD8+ T cell proliferation as a direct effect of UDCA (p=0.03). Many studies have 
outlined the importance of CD8+ T cells in PBC. It has been known for some time 
that infiltration into the liver of autoreactive CD4+ and CD8+ T cells is an early event 
in PBC and infiltrating CD8+ T cells have been known for some time to be key 
mediators of tissue damage (Palmer et al.,1999). Taken alongside the data from the 
ELISpot assays, that responsiveness of some CD4+ T cells to antigen may be 
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attenuated in the presence of UDCA (at 0.5mM, p=0.002; at 1mM, p=0.0006), this 
could suggest that the drug has an effect on both CD4+ and CD8+ T cells, but the 
effects may be different.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.1.3: Chapter 5: The development of an ELISA assay using End 
Point Titre to compare serum levels of anti-PDC 
autoantibodies in UDCA responder and non-responder PBC 
patients. 
This chapter aimed to design an assay which would allow the quantification of anti-
PDC autoantibodies in patient blood for their direct comparison. Importantly, it 
needed to be determined if patient anti-PDC titres could be accurately quantified 
using a screening method rather than the more time consuming short dilution end 
point titre method. An assay which can be carried out quickly and in a cost-effective 
method is important for if this method could go on to have diagnostic applications. 
This assay could identify differences in the antibody profiles of different patient 
subsets to be identified to further elucidate key differences between the sub groups 
of PBC patients. If patient blood samples had been received from patients and their 
T cell subset profiles had been established, the data in this chapter may have been 
able to confirm the impact of the T cell with the antibodies produced by the plasma 
cells acting as a read out of the cytokine instructions received from the T cells. 
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Additionally, this assay could allow for the determination of if responders and non-
responders have antibodies targeting different epitopes of PDC subunits. 
The primary aim of this chapter was to determine if screening patient serum with 
optimised protein concentration is accurate enough a representation of their 
autoantibody titre for the use of screens to be used in further experiments to 
determine significant differences between autoantibody levels of different patient 
groups. This was achieved, with screen duplicate results following Spearman’s 
Rank correlations of rs>0.6 and p>0.0005 for the antigens of rhE2, rhE2ILD and 
rhE3BP. 
 
 
 
 
  
 
 
 
 
7.1.4: Chapter 6: Investigating differences in immune responses 
between PBC patients that are responders and non-
responders to UDCA  
The aim of this chapter was to apply statistical analysis to all patient data including 
that obtained in the autoantibody screens from the previous chapter and attempt to 
uncover some statistically significant differences in patient subgroups, with the 
particular focus on any difference between UDCA responders and non-responders.  
The data uncovered in this chapter does provide the first instance of levels of 
autoantibodies which are significantly different between responders and non-
responders.  
While current research focuses on development of new drugs which can be used 
instead of or in conjunction with UDCA (Suraweera et al. 2017), this chapter 
focusses on starting to underpin the biological reasoning behind why patient 
subgrouping was initially discovered.  
This chapter was successful, most importantly in that there were some antibodies 
discovered which are significantly overproduced in non-responders compared to 
responders, which were anti-rhE2ILDIgG3 (p=0.01), anti-rhE2ILDIgA (p=0.047) and 
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anti-E2IgE (p=0.025). Additionally, there was a difference in antibody profiles 
discovered between males and females whereby males with PBC were found to 
have significantly underproduced anti-rhE2IgE (p=0.003), anti-rhE2ILDIgE (p=0.05) 
and anti-rhE3BPIgA (p=0.037) compared to females. These data indicate that 
although there may be an underlying B- or T-cell difference orchestrating the 
difference in antibody profiles uncovered here between responders and non-
responders, the difference in disease severity between males and females is 
possibly differently orchestrated. This is novel data which is the first to identify a 
significant difference in disease phenotype between patient groups in PBC. 
 
 
 
 
 
 
 
 
 
7.2: Further work 
There is considerable expansion on this body of work which can help further the 
progression of this disease to one which has treatments in line with stratified 
medicine.  
Individual results chapters outline how each separate piece of work can be 
furthered, but to take all chapters together there are some key questions which are 
arisen from the findings in this thesis.  
One such question stems from findings that UDCA may be affecting proliferation of 
different T cells differently. It then becomes important to consider why this might be 
the case. It becomes important to consider the proliferation mechanisms of CD4+ T 
cells and CD8+ T cells. Propagation of the T cell signal intracellularly, once there 
has been a TCR antigen recognition event and complex formation at the cell surface 
(outlined in general introduction), with the tyrosine phosphorylation of 
immunoreceptor tyrosine-based activation motifs (ITAMs) in the cytoplasmic 
domains of CD3. The TCR-CD3 complex contains 10 functional ITAMs, allowing for 
functional differentiation from ITAMS of other immune cells (Guy et al., 2013). 
Further differentiation in downstream signalling can arise with the inclusion of CD4 
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or CD8 and whether the cell is memory or effector (Guy et al., 2013). To elucidate 
why UDCA may be having a differential impact on CD4+ and CD8+ T cells, the 
inclusion of a flow cytometric panel which also distinguishes effector and memory 
could uncover further differences and then allow postulation of why this differential 
effect is seen, and thus further uncover pathways of interest in the mechanism of 
action of UDCA. Such a panel would include CCR7 and CD45RA antibodies, where 
CCR7+CD45RA+ are naïve, CCR7+CD45RA- cells are effector, CCR7-CD45RA+ 
cells are central memory and CCR7-CD45RA- cells are effector memory. The flow 
panel for determining the impact of UDCA on T cell subsets would be repeated using 
a larger number of volunteers and the inclusion of these markers. Further flow 
cytometry assays could intracellularly stain for cytokines known to induce class 
switching in B cells.  
Additionally, as the impact of UDCA can vary between patients, establishing the 
extent of this which could be due to the body’s ability to metabolise the drug could 
be investigated. If responders and non-responders metabolise the drug differently, 
this could help explain the large discrepancy seen in its effectiveness between 
patient groups. In 2012, Dilger and colleagues carried out pharmacokinetic profiling 
of the bile acids entering the duodenum from the liver to investigate UDCA 
metabolism and its enrichment (Dilger et al.,2012). This experiment repeated in the 
context of responders and non-responders could offer some insight into any 
differential metabolism of UDCA between the response/non-response groups. 
Taking findings from this experiment could bring into contextual relevance some 
findings in this thesis: UDCA appears to attenuate T cell proliferation, particularly 
CD8+ T cells and may also render CD4+ T cells less able to recognise antigen, so 
if some patients are unable to metabolise UDCA in such a way that it can be 
effective, then different UDCA analogues could be investigated for those individuals.   
The largest improvement which could be made to this work would be the inclusion 
of patient cells. This would potentially allow for all experiments carried out in this 
thesis to be done so with the aim of directly elucidating differences between patient 
subgroups. Although some progress has been made towards elucidating potential 
differences in the comparison of autoantibody profiles between responders and non-
responders and also males and females, with the inclusion of blood cells there could 
be comparison of the impact of UDCA on proliferation and antigen recognition of T 
cells between responder and non-responder groups. If no difference were 
discovered, then this would point towards a potential other impact such as a liver or 
microbiome metabolomic influence whereby the drug is less accessible to the non-
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responders, to do with how it is processed. Inclusion of patient cells would also give 
the potential for those genes of interest in the GWAS carried out by Mells and 
colleagues in 2013 to be sequenced and analysed for the SNPs, in the context of a 
responders and non-responders comparison to determine if an SNP profile may 
possibly dictate response (Mells et al., 2013). Most importantly, flow cytometric 
analysis of the T cells in patient blood including intracellular staining of cytokines 
could help elucidate the reason why the different antibody profiles were discovered 
between patient groups and if there is influence from T cell cytokines.  
The era of stratified medicine calls for personalisation of therapy. While much 
research is being carried out into new drugs which are effective on a greater 
percentage of PBC patients, outlined in the main introduction, these in general are 
only prescribed after up to a year of the patient on UDCA, an ineffective drug for up 
to 20% of patients (Carbone et al.,2013) and additionally a new study suggests the 
onset of jaundice is a risk with rapid switching of UDCA to obeticholic acid, an FXR 
ligand effective in the UDCA non-responding population (Quigley et al., 2018). It is 
imperative to further work to establish a diagnostic assay which can allow for early 
application of the appropriate therapy. For this to be possible, a large-scale 
comparison study must be undertaken of a large number of patients taking into 
account their response or lack thereof to UDCA. UDCA is known to be metabolised 
by bacteria in the gut, and a recent study has analysed the microbiome of PBC 
patients and found that the microbiome is altered in PBC and partly restored after 
UDCA therapy (Tang et al., 2017). This data in light of whether or not a patient was 
classified as a ‘responder’ to UDCA could highlight some microbiomal differences 
and possibly areas where microbiome manipulation could be therapeutically 
beneficial. Additionally, if the GWAS by Dilger and colleagues in 2013 were 
extended to include a comparison of responders and non-responders then this could 
reveal some SNPs which may predispose a particular disease phenotype (Dilger et 
al.,2012).  
 
7.3: General remarks 
This thesis has made considerable progress in untangling the differences between 
the elusive subgroups of PBC, helping take this disease into the era of stratified 
medicine. The concept of response/non-response was first conceptualised given 
comparisons between patients and their response to UDCA. The impact of UDCA 
has been investigated and has highlighted key potential mechanisms of action, 
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namely on proliferation of CD8+ T cells and antigen recognition of CD4+ T cells. 
Additionally, a discrepancy between responders and non-responders in antibody 
titre has been identified in that non-responders have higher levels of rhE2ILDIgG3 
and rhE2ILDIgA, so taking this antigen on its own could indicate IFN-γ and TGF-β 
influence, but further work has been suggested which could confirm this in the way 
of flow cytometry of patient T cells. Overall, this thesis is the first piece of work to 
suggest biological reasoning behind the detected phenotypic differences between 
groups of PBC patients and highlights the importance of directing further research 
into this disease down a stratified approach.  
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Chapter 8: Appendix 
 
Figure 8.1: Raw patient data provided by freeman hospital, patients 1-35. 
W indicates white; F indicates female; M indicates male; NR indicates 
non-responder; R indicates responder; A indicates not UDCA-naïve; B 
indicates UDCA-Naïve.  
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Figure 8.2: Raw patient data provided by freeman hospital, patients 36-73. 
W indicates white; F indicates female; M indicates male; NR indicates 
non-responder; R indicates responder; A indicates not UDCA-naïve; B 
indicates UDCA-Naïve.  
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Figure 8.3: Raw patient data provided by freeman hospital, patients 74-80. 
W indicates white; F indicates female; M indicates male; NR indicates 
non-responder; R indicates responder; A indicates not UDCA-naïve; B 
indicates UDCA-Naïve.  
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Figure 8.5: Graphs of absorbance against dilution factor to calculate 
end point titre 
This figure shows line graphs of all patients which, in their end point titre 
experiment for the IgGall antigen, gave an R2 correlation coefficient of over 
0.6. The intercept on the y axis shows the end point titre, or dilution of 
serum required to give a hypothetical zero absorbance. This is calculated in 
Microsoft Excel using the ‘display line on graph’ function where the line is 
given of the form y=-mx+c and where ‘c’ is the end point titre. Shown are the 
line graphs of all patients who did not fail to give a linear region between 4 
points, indicated by R2>0.6. 
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Figure 8.4: Tables of results for screens and end point titres 
Spearman’s Rank Correlation coefficient was carried out to assess 
the relationship between columns Average Screen and EPT.  
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a. Antibodies 
Antibody 
against Fluorochrome Clone Source Cat. Number 
CD3 PerCPvio700 BW264/56 Miltenyi 130-100-458 
CD3 BV421 OKT3 Biolegend 317344 
CD3 BV510 OKT3 Biolegend 317331 
CD4 APC OKT4 eBiosciences 17-0048-41 
CD4 PerCPCy5.5 OKT4 eBiosciences 45-0048-42 
CD4 APC eFluor780 OKT4 eBiosciences 47-0048-41 
CD4 APC-H7 RPA-T4 Biolegend 560158 
CD4 APC-Cy7 A161A1 Biolegend 357416 
CD4 BV510 SK3 BD 562970 
CD4 APC eFluor780 RPA-T4 eBiosciences 47-0049-41 
CD4 APC M-T466 Miltenyi 130-098-133 
CD8 PECy7 RPA-T8 eBiosciences 25-0088-42 
CD8 FITC BW135/80 Miltenyi 130-098-059 
CD8 APC OKT8 eBiosciences 17-0086-71 
CD14 FITC 
1.1.1.1 TÜK4 
Miltenyi 130-098-063 
CD25 PE BC96 eBiosciences 12-0259-42 
CD45RO PerCPCy5.5 UCHL1 eBiosciences 46-6457-41 
CCR6 APC R6H1 eBiosciences 17-1969-41 
CXCR3 BV421 G025H7 Biolegend 353715 
CXCR3 PerCPCy5.5 ICS/CXCR3 BD 560832 
FoxP3 PECy7 PCH101 eBiosciences 25-4776-41 
 
b. Isotype controls 
Fluorochrome Isotype Clone Source 
Cat. 
Number 
BV421 IgG2αmouse MOPC-173 Biolegend 400267 
PECy7 Rat IgG2α κ eBR2a eBiosciences 25-4321-81 
APC Mouse IgG1κ P3.6.2.8.1 eBiosciences 17-4714-41 
PE Mouse IgG1κ P3.6.2.8.1 eBiosciences 12-4714-81 
PerCPCy5.5 Mouse IgG2ακ eBM2a eBiosciences 46-4724-80 
APCeFluor780 Mouse IgG1κ P3.6.2.8.1 eBiosciences 46-4714-80 
BV421 Mouse IgG1κ MOPC-21 Biolegend 400157 
 
 
 
 
 
 
 
 
 
 
 
Table 8.6: Antibodies used for flow cytometry. 
Tables show list of all antibodies used in flow cytometry and clones and 
sources, where a shows antibodies and b the isotype controls. 
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(Bataller and Brenner, 2005) (Belvin and Anderson) 
(Kousoulis et al., 2012) (Boylston, 2012) (von 
Behring E Fau - Kitasato and Kitasato, 1991) 
(Marrack P Fau - Kappler and Kappler) (Sadegh-
Nasseri, 2016) (Abbey and O'Neill, 2008) (Takaba 
and Takayanagi, 2017) (Boyd et al., 2009) 
(Romagnani, 2000) (Gray Pw Fau - Goeddel and 
Goeddel, 1982) (Nedwin Ge Fau - Naylor et al., 
1985) (Linterman et al., 2009) (Corthay, 2009) 
(Catalfamo and Henkart, 2003) (Gulzar and 
Copeland, 2004) (Flajnik, 2002) (Nemazee, 2006) 
(Newport, 2003) (Elgueta et al., 2009) (Deenick et al., 2005) (McIntyre et al., 
1993) (Pinheiro et al., 2011) (Fabbri et al., 2003) (Ricken et al., 2014) (Elias and 
Bengelsdorf, 1952) (Attili et al., 1986) (Xia et al., 2006) 
(Kamihira et al., 2005) (Trinchieri and Sher, 2007) 
(Inamura et al., 2006) (Cossarizza et al., 2017) 
(Groom and Luster, 2011b) (Begum et al., 2013) 
(Emmerich et al., 2012) (Al-Harthy and Kumagi, 
2012) (Wahlstrom et al., 2016) (Chaiyadet et al., 
2015b)  (Jentsch-Ullrich et al., 2005) (Grubman et 
al., 1994) (Alpini et al., 2002) (Mitsdoerffer et al., 
2010) (Lebman and Coffman, 1988b) (Dienz et al., 
2009) (Lupardus and Garcia, 2008, Luc et al., 2012, 
Wada et al., 2008, Nelson and Roy, 2015) 
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